<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002493</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>178</s160></s100><s200><s210>1</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 1Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Asp Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Lys Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>2</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 2Gly Thr Ile Phe Ser Ile Asn Arg Met Asp1               5                   10</s400><s200><s210>3</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 3Leu Ile Thr Ser Asp Gly Thr Pro Ala1               5</s400><s200><s210>4</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 4Ser Ser Gly Val Tyr Asn Tyr1               5</s400><s200><s210>5</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 5Gly Thr Ile Phe Ser1               5</s400><s200><s210>6</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 6Leu Ile Thr Ser Asp Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys Gly1               5                   10                  15</s400><s200><s210>7</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 7Ser Ser Gly Val Tyr Asn Tyr1               5</s400><s200><s210>8</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 8Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Asp Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>9</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 9Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Asp Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>10</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 10Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Asp Gly Thr Pro Ala Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>11</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 11Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Asp Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>12</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 12Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Asp Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>13</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 13Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Asp Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>14</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 14Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Lys Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>15</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 15Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Lys Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Lys Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>16</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 16Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Thr Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Lys Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>17</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 17Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Asp Arg Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Lys Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>18</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 18Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>19</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 19Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>20</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 20Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>21</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 21Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>22</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 22Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Ser Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>23</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 23Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>24</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 24Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>25</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 25Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn            20                  25                  30Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys His                85                  90                  95Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>26</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 26Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>27</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 27Gly Lys Ile Phe Ser Gly Asn Asp Met Gly1               5                   10</s400><s200><s210>28</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 28Ile Ile Thr Ser Gly Gly Ile Thr Asp1               5</s400><s200><s210>29</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 29Arg Asp Arg Thr Ile Trp1               5</s400><s200><s210>30</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 30Gly Lys Ile Phe Ser1               5</s400><s200><s210>31</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 31Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys Gly1               5                   10                  15</s400><s200><s210>32</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 32Arg Asp Arg Thr Ile Trp1               5</s400><s200><s210>33</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 33Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>34</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 34Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>35</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 35Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Met Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>36</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 36Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>37</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 37Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Ala            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>38</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 38Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Glu            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>39</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 39Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Phe            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>40</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 40Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Gly            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>41</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 41Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly His            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>42</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 42Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Ile            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>43</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 43Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Leu            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>44</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 44Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Gln            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>45</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 45Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Arg            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>46</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 46Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Ser            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>47</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 47Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Thr            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>48</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 48Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Val            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>49</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 49Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Tyr            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>50</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 50Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Glu Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>51</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 51Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>52</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 52Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30His Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>53</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 53Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Ile Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>54</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 54Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Leu Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>55</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 55Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Gln Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>56</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 56Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Arg Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>57</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 57Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>58</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 58Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Tyr Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>59</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 59Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Glu Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>60</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 60Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Phe Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>61</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 61Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95His Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>62</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 62Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Ile Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>63</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 63Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Leu Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>64</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 64Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Gln Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>65</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 65Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Arg Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>66</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 66Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Val Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>67</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 67Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Tyr Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Gln Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>68</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 68Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Arg            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>69</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 69Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30His Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Met Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>70</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 70Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Arg            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Val Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>71</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 71Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Arg            20                  25                  30Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Ile Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>72</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 72Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30His Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Val Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>73</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 73Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30His Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ala Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Ile Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>74</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 74Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly Asn            20                  25                  30His Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Val Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr Val            100                 105                 110Ser Ser</s400><s200><s210>75</s210><s211>290</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 75Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu1               5                   10                  15Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr            20                  25                  30Gly Ser Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu        35                  40                  45Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile    50                  55                  60Ile Gln Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser65                  70                  75                  80Tyr Arg Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn                85                  90                  95Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr            100                 105                 110Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val        115                 120                 125Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val    130                 135                 140Asp Pro Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr145                 150                 155                 160Pro Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser                165                 170                 175Gly Lys Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn            180                 185                 190Val Thr Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr        195                 200                 205Cys Thr Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu    210                 215                 220Val Ile Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr His225                 230                 235                 240Leu Val Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly Val Ala Leu Thr                245                 250                 255Phe Ile Phe Arg Leu Arg Lys Gly Arg Met Met Asp Val Lys Lys Cys            260                 265                 270Gly Ile Gln Asp Thr Asn Ser Lys Lys Gln Ser Asp Thr His Leu Glu        275                 280                 285Glu Thr    290</s400><s200><s210>76</s210><s211>176</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 76Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu1               5                   10                  15Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val Asp Pro            20                  25                  30Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr Pro Lys        35                  40                  45Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser Gly Lys    50                  55                  60Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn Val Thr65                  70                  75                  80Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr Cys Thr                85                  90                  95Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu Val Ile            100                 105                 110Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr His Leu Val        115                 120                 125Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly Val Ala Leu Thr Phe Ile    130                 135                 140Phe Arg Leu Arg Lys Gly Arg Met Met Asp Val Lys Lys Cys Gly Ile145                 150                 155                 160Gln Asp Thr Asn Ser Lys Lys Gln Ser Asp Thr His Leu Glu Glu Thr                165                 170                 175</s400><s200><s210>77</s210><s211>178</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 77Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu1               5                   10                  15Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr            20                  25                  30Gly Ser Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu        35                  40                  45Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile    50                  55                  60Ile Gln Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser65                  70                  75                  80Tyr Arg Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn                85                  90                  95Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr            100                 105                 110Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val        115                 120                 125Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val    130                 135                 140Asp Pro Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr145                 150                 155                 160Pro Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser                165                 170                 175Gly Asp</s400><s200><s210>78</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 78His His His His His His1               5</s400><s200><s210>79</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 79Tyr Pro Tyr Asp Val Pro Asp Tyr Gly Ser1               5                   10</s400><s200><s210>80</s210><s211>19</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 80Ala Ala Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Gly Ser His His His1               5                   10                  15His His His</s400><s200><s210>81</s210><s211>165</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 81Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met1               5                   10                  15Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu Lys Asp            20                  25                  30Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln        35                  40                  45Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe    50                  55                  60Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu65                  70                  75                  80Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu                85                  90                  95Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys            100                 105                 110Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu        115                 120                 125Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg    130                 135                 140Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser145                 150                 155                 160Leu Arg Ser Lys Glu                165</s400><s200><s210>82</s210><s211>165</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 82Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met1               5                   10                  15Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp            20                  25                  30Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln        35                  40                  45Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe    50                  55                  60Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu65                  70                  75                  80Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu                85                  90                  95Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys            100                 105                 110Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu        115                 120                 125Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg    130                 135                 140Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser145                 150                 155                 160Leu Arg Ser Lys Glu                165</s400><s200><s210>83</s210><s211>166</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 83Cys Asp Leu Pro Glu Thr His Ser Leu Asp Asn Arg Arg Thr Leu Met1               5                   10                  15Leu Leu Ala Gln Met Ser Arg Ile Ser Pro Ser Ser Cys Leu Met Asp            20                  25                  30Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe        35                  40                  45Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu Leu Ile Gln Gln Ile    50                  55                  60Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp65                  70                  75                  80Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu                85                  90                  95Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met            100                 105                 110Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr        115                 120                 125Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val    130                 135                 140Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu145                 150                 155                 160Arg Leu Arg Arg Lys Glu                165</s400><s200><s210>84</s210><s211>166</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 84Met Ser Tyr Asn Leu Leu Gly Phe Leu Gln Arg Ser Ser Asn Phe Gln1               5                   10                  15Cys Gln Lys Leu Leu Trp Gln Leu Asn Gly Arg Leu Glu Tyr Cys Leu            20                  25                  30Lys Asp Arg Met Asn Phe Asp Ile Pro Glu Glu Ile Lys Gln Leu Gln        35                  40                  45Gln Phe Gln Lys Glu Asp Ala Ala Leu Thr Ile Tyr Glu Met Leu Gln    50                  55                  60Asn Ile Phe Ala Ile Phe Arg Gln Asp Ser Ser Ser Thr Gly Trp Asn65                  70                  75                  80Glu Thr Ile Val Glu Asn Leu Leu Ala Asn Val Tyr His Gln Ile Asn                85                  90                  95His Leu Lys Thr Val Leu Glu Glu Lys Leu Glu Lys Glu Asp Phe Thr            100                 105                 110Arg Gly Lys Leu Met Ser Ser Leu His Leu Lys Arg Tyr Tyr Gly Arg        115                 120                 125Ile Leu His Tyr Leu Lys Ala Lys Glu Tyr Ser His Cys Ala Trp Thr    130                 135                 140Ile Val Arg Val Glu Ile Leu Arg Asn Phe Tyr Phe Ile Asn Arg Leu145                 150                 155                 160Thr Gly Tyr Leu Arg Asn                165</s400><s200><s210>85</s210><s211>166</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 85Met Lys Tyr Thr Ser Tyr Ile Leu Ala Phe Gln Leu Cys Ile Val Leu1               5                   10                  15Gly Ser Leu Gly Cys Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu            20                  25                  30Asn Leu Lys Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn        35                  40                  45Gly Thr Leu Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp    50                  55                  60Arg Lys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe65                  70                  75                  80Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile                85                  90                  95Lys Glu Asp Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys Lys Arg            100                 105                 110Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu Asn Val        115                 120                 125Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu Leu Ser    130                 135                 140Pro Ala Ala Lys Thr Gly Lys Arg Lys Arg Ser Gln Met Leu Phe Arg145                 150                 155                 160Gly Arg Arg Ala Ser Gln                165</s400><s200><s210>86</s210><s211>143</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 86Gln Asp Pro Tyr Val Lys Glu Ala Glu Asn Leu Lys Lys Tyr Phe Asn1               5                   10                  15Ala Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu Gly Ile            20                  25                  30Leu Lys Asn Trp Lys Glu Glu Ser Asp Arg Lys Ile Met Gln Ser Gln        35                  40                  45Ile Val Ser Phe Tyr Phe Lys Leu Phe Lys Asn Phe Lys Asp Asp Gln    50                  55                  60Ser Ile Gln Lys Ser Val Glu Thr Ile Lys Glu Asp Met Asn Val Lys65                  70                  75                  80Phe Phe Asn Ser Asn Lys Lys Lys Arg Asp Asp Phe Glu Lys Leu Thr                85                  90                  95Asn Tyr Ser Val Thr Asp Leu Asn Val Gln Arg Lys Ala Ile His Glu            100                 105                 110Leu Ile Gln Val Met Ala Glu Leu Ser Pro Ala Ala Lys Thr Gly Lys        115                 120                 125Arg Lys Arg Ser Gln Met Leu Phe Arg Gly Arg Arg Ala Ser Gln    130                 135                 140</s400><s200><s210>87</s210><s211>167</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 87Met Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu1               5                   10                  15Ile Leu Leu Ala Gln Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Lys            20                  25                  30Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln        35                  40                  45Phe Gln Lys Ala Gln Ala Ile Ser Val Leu His Glu Met Ile Gln Gln    50                  55                  60Thr Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu65                  70                  75                  80Ser Leu Leu Glu Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp                85                  90                  95Leu Glu Ala Cys Val Ile Gln Glu Val Gly Val Glu Glu Thr Pro Leu            100                 105                 110Met Asn Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Gln Arg Ile        115                 120                 125Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val    130                 135                 140Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln145                 150                 155                 160Glu Arg Leu Arg Arg Lys Glu                165</s400><s200><s210>88</s210><s211>166</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 88Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu Ile1               5                   10                  15Leu Leu Ala Gln Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Lys Asp            20                  25                  30Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe        35                  40                  45Gln Lys Ala Gln Ala Ile Ser Val Leu His Glu Met Ile Gln Gln Thr    50                  55                  60Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Ser65                  70                  75                  80Leu Leu Glu Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu                85                  90                  95Glu Ala Cys Val Ile Gln Glu Val Gly Val Glu Glu Thr Pro Leu Met            100                 105                 110Asn Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Gln Arg Ile Thr        115                 120                 125Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val    130                 135                 140Arg Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu145                 150                 155                 160Arg Leu Arg Arg Lys Glu                165</s400><s200><s210>89</s210><s211>166</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 89Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Thr Leu Met1               5                   10                  15Leu Leu Ala Gln Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Lys Asp            20                  25                  30Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe        35                  40                  45Gln Lys Ala Gln Ala Ile Ser Val Leu His Glu Met Ile Gln Gln Thr    50                  55                  60Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Ser65                  70                  75                  80Leu Leu Glu Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu                85                  90                  95Glu Ala Cys Val Ile Gln Glu Val Gly Val Glu Glu Thr Pro Leu Met            100                 105                 110Asn Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Gln Arg Ile Thr        115                 120                 125Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val    130                 135                 140Arg Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu145                 150                 155                 160Arg Leu Arg Arg Lys Glu                165</s400><s200><s210>90</s210><s211>166</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 90Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu Ile1               5                   10                  15Leu Leu Ala Gln Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Lys Asp            20                  25                  30Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe        35                  40                  45Gln Lys Ala Gln Ala Ile Ser Val Leu His Glu Met Ile Gln Gln Thr    50                  55                  60Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Ser65                  70                  75                  80Leu Leu Glu Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu                85                  90                  95Glu Ala Cys Val Ile Gln Glu Val Gly Val Glu Glu Thr Pro Leu Met            100                 105                 110Asn Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr        115                 120                 125Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val    130                 135                 140Arg Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu145                 150                 155                 160Arg Leu Arg Arg Lys Glu                165</s400><s200><s210>91</s210><s211>167</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 91Met Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu1               5                   10                  15Ile Leu Leu Ala Gln Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Lys            20                  25                  30Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln        35                  40                  45Phe Gln Lys Ala Gln Ala Ile Ser Val Leu His Glu Met Ile Gln Gln    50                  55                  60Thr Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu65                  70                  75                  80Ser Leu Leu Glu Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp                85                  90                  95Leu Glu Ala Cys Val Ile Gln Glu Val Gly Val Glu Glu Thr Pro Leu            100                 105                 110Met Asn Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile        115                 120                 125Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val    130                 135                 140Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln145                 150                 155                 160Glu Arg Leu Arg Arg Lys Glu                165</s400><s200><s210>92</s210><s211>167</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 92Met Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu1               5                   10                  15Ile Leu Leu Ala Gln Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Lys            20                  25                  30Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln        35                  40                  45Phe Gln Lys Ala Gln Ala Ile Ser Val Leu His Glu Met Ile Gln Gln    50                  55                  60Thr Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu65                  70                  75                  80Ser Leu Leu Glu Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp                85                  90                  95Leu Glu Ala Cys Val Ile Gln Glu Val Gly Val Glu Glu Thr Pro Leu            100                 105                 110Met Asn Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile        115                 120                 125Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val    130                 135                 140Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu Cys Thr Asn Leu Gln145                 150                 155                 160Glu Arg Leu Arg Arg Lys Glu                165</s400><s200><s210>93</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 93Glu Glu Phe Gly Asn Gln1               5</s400><s200><s210>94</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 94Glu Glu Phe Asp Gly Asn Gln1               5</s400><s200><s210>95</s210><s211>165</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 95Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His His Glu Val Val Lys1               5                   10                  15Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu            20                  25                  30Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys        35                  40                  45Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu    50                  55                  60Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile65                  70                  75                  80Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser Phe                85                  90                  95Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg            100                 105                 110Gln Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe        115                 120                 125Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser    130                 135                 140Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys Arg Cys145                 150                 155                 160Asp Lys Pro Arg Arg                165</s400><s200><s210>96</s210><s211>165</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 96Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His His Glu Val Val Lys1               5                   10                  15Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu            20                  25                  30Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys        35                  40                  45Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu    50                  55                  60Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile65                  70                  75                  80Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser Phe                85                  90                  95Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg            100                 105                 110Gln Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe        115                 120                 125Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser    130                 135                 140Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys Arg Ser145                 150                 155                 160Leu Thr Arg Lys Asp                165</s400><s200><s210>97</s210><s211>157</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 97Val Arg Ser Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val1               5                   10                  15Val Ala Asn Pro Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg            20                  25                  30Ala Asn Ala Leu Leu Ala Asn Gly Val Glu Leu Arg Asp Asn Gln Leu        35                  40                  45Val Val Pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser Gln Val Leu Phe    50                  55                  60Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile65                  70                  75                  80Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala                85                  90                  95Ile Lys Ser Pro Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys            100                 105                 110Pro Trp Tyr Glu Pro Ile Tyr Leu Gly Gly Val Phe Gln Leu Glu Lys        115                 120                 125Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp Tyr Leu Asp Phe    130                 135                 140Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu145                 150                 155</s400><s200><s210>98</s210><s211>171</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 98Leu Pro Gly Val Gly Leu Thr Pro Ser Ala Ala Gln Thr Ala Arg Gln1               5                   10                  15His Pro Lys Met His Leu Ala His Ser Asn Leu Lys Pro Ala Ala His            20                  25                  30Leu Ile Gly Asp Pro Ser Lys Gln Asn Ser Leu Leu Trp Arg Ala Asn        35                  40                  45Thr Asp Arg Ala Phe Leu Gln Asp Gly Phe Ser Leu Ser Asn Asn Ser    50                  55                  60Leu Leu Val Pro Thr Ser Gly Ile Tyr Phe Val Tyr Ser Gln Val Val65                  70                  75                  80Phe Ser Gly Lys Ala Tyr Ser Pro Lys Ala Thr Ser Ser Pro Leu Tyr                85                  90                  95Leu Ala His Glu Val Gln Leu Phe Ser Ser Gln Tyr Pro Phe His Val            100                 105                 110Pro Leu Leu Ser Ser Gln Lys Met Val Tyr Pro Gly Leu Gln Glu Pro        115                 120                 125Trp Leu His Ser Met Tyr His Gly Ala Ala Phe Gln Leu Thr Gln Gly    130                 135                 140Asp Gln Leu Ser Thr His Thr Asp Gly Ile Pro His Leu Val Leu Ser145                 150                 155                 160Pro Ser Thr Val Phe Phe Gly Ala Phe Ala Leu                165                 170</s400><s200><s210>99</s210><s211>281</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 99Met Ala Met Met Glu Val Gln Gly Gly Pro Ser Leu Gly Gln Thr Cys1               5                   10                  15Val Leu Ile Val Ile Phe Thr Val Leu Leu Gln Ser Leu Cys Val Ala            20                  25                  30Val Thr Tyr Val Tyr Phe Thr Asn Glu Leu Lys Gln Met Gln Asp Lys        35                  40                  45Tyr Ser Lys Ser Gly Ile Ala Cys Phe Leu Lys Glu Asp Asp Ser Tyr    50                  55                  60Trp Asp Pro Asn Asp Glu Glu Ser Met Asn Ser Pro Cys Trp Gln Val65                  70                  75                  80Lys Trp Gln Leu Arg Gln Leu Val Arg Lys Met Ile Leu Arg Thr Ser                85                  90                  95Glu Glu Thr Ile Ser Thr Val Gln Glu Lys Gln Gln Asn Ile Ser Pro            100                 105                 110Leu Val Arg Glu Arg Gly Pro Gln Arg Val Ala Ala His Ile Thr Gly        115                 120                 125Thr Arg Gly Arg Ser Asn Thr Leu Ser Ser Pro Asn Ser Lys Asn Glu    130                 135                 140Lys Ala Leu Gly Arg Lys Ile Asn Ser Trp Glu Ser Ser Arg Ser Gly145                 150                 155                 160His Ser Phe Leu Ser Asn Leu His Leu Arg Asn Gly Glu Leu Val Ile                165                 170                 175His Glu Lys Gly Phe Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe            180                 185                 190Gln Glu Glu Ile Lys Glu Asn Thr Lys Asn Asp Lys Gln Met Val Gln        195                 200                 205Tyr Ile Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Leu Leu Met Lys    210                 215                 220Ser Ala Arg Asn Ser Cys Trp Ser Lys Asp Ala Glu Tyr Gly Leu Tyr225                 230                 235                 240Ser Ile Tyr Gln Gly Gly Ile Phe Glu Leu Lys Glu Asn Asp Arg Ile                245                 250                 255Phe Val Ser Val Thr Asn Glu His Leu Ile Asp Met Asp His Glu Ala            260                 265                 270Ser Phe Phe Gly Ala Phe Leu Val Gly        275                 280</s400><s200><s210>100</s210><s211>153</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 100Ala Pro Val Arg Ser Leu Asn Cys Thr Leu Arg Asp Ser Gln Gln Lys1               5                   10                  15Ser Leu Val Met Ser Gly Pro Tyr Glu Leu Lys Ala Leu His Leu Gln            20                  25                  30Gly Gln Asp Met Glu Gln Gln Val Val Phe Ser Met Ser Phe Val Gln        35                  40                  45Gly Glu Glu Ser Asn Asp Lys Ile Pro Val Ala Leu Gly Leu Lys Glu    50                  55                  60Lys Asn Leu Tyr Leu Ser Cys Val Leu Lys Asp Asp Lys Pro Thr Leu65                  70                  75                  80Gln Leu Glu Ser Val Asp Pro Lys Asn Tyr Pro Lys Lys Lys Met Glu                85                  90                  95Lys Arg Phe Val Phe Asn Lys Ile Glu Ile Asn Asn Lys Leu Glu Phe            100                 105                 110Glu Ser Ala Gln Phe Pro Asn Trp Tyr Ile Ser Thr Ser Gln Ala Glu        115                 120                 125Asn Met Pro Val Phe Leu Gly Gly Thr Lys Gly Gly Gln Asp Ile Thr    130                 135                 140Asp Phe Thr Met Gln Phe Val Ser Ser145                 150</s400><s200><s210>101</s210><s211>133</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 101Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His1               5                   10                  15Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys            20                  25                  30Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys        35                  40                  45Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys    50                  55                  60Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu65                  70                  75                  80Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu                85                  90                  95Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala            100                 105                 110Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile        115                 120                 125Ile Ser Thr Leu Thr    130</s400><s200><s210>102</s210><s211>129</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 102His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile Lys Thr Leu Asn Ser1               5                   10                  15Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu Leu Thr Val Thr Asp Ile            20                  25                  30Phe Ala Ala Ser Lys Asn Thr Thr Glu Lys Glu Thr Phe Cys Arg Ala        35                  40                  45Ala Thr Val Leu Arg Gln Phe Tyr Ser His His Glu Lys Asp Thr Arg    50                  55                  60Cys Leu Gly Ala Thr Ala Gln Gln Phe His Arg His Lys Gln Leu Ile65                  70                  75                  80Arg Phe Leu Lys Arg Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly Leu                85                  90                  95Asn Ser Cys Pro Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn Phe            100                 105                 110Leu Glu Arg Leu Lys Thr Ile Met Arg Glu Lys Tyr Ser Lys Cys Ser        115                 120                 125Ser</s400><s200><s210>103</s210><s211>185</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 103Ala Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His1               5                   10                  15Arg Gln Pro Leu Thr Ser Ser Glu Arg Ile Asp Lys Gln Ile Arg Tyr            20                  25                  30Ile Leu Asp Gly Ile Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys Ser        35                  40                  45Asn Met Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn    50                  55                  60Leu Pro Lys Met Ala Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe Asn65                  70                  75                  80Glu Glu Thr Cys Leu Val Lys Ile Ile Thr Gly Leu Leu Glu Phe Glu                85                  90                  95Val Tyr Leu Glu Tyr Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu Gln            100                 105                 110Ala Arg Ala Val Gln Met Ser Thr Lys Val Leu Ile Gln Phe Leu Gln        115                 120                 125Lys Lys Ala Lys Asn Leu Asp Ala Ile Thr Thr Pro Asp Pro Thr Thr    130                 135                 140Asn Ala Ser Leu Thr Thr Lys Leu Gln Ala Gln Asn Gln Trp Leu Gln145                 150                 155                 160Asp Met Thr Thr His Leu Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln                165                 170                 175Ser Ser Leu Arg Ala Leu Arg Gln Met            180                 185</s400><s200><s210>104</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 104Ser Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Glu Leu Ile Glu1               5                   10                  15Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly            20                  25                  30Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala        35                  40                  45Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr    50                  55                  60Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln65                  70                  75                  80Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe                85                  90                  95Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Arg            100                 105                 110Phe Asn</s400><s200><s210>105</s210><s211>194</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 105Met Ala Ala Glu Pro Val Glu Asp Asn Cys Ile Asn Phe Val Ala Met1               5                   10                  15Lys Phe Ile Asp Asn Thr Leu Tyr Phe Ile Ala Glu Asp Asp Glu Asn            20                  25                  30Leu Glu Ser Asp Tyr Phe Gly Lys Leu Glu Ser Lys Leu Ser Val Ile        35                  40                  45Arg Asn Leu Asn Asp Gln Val Leu Phe Ile Asp Gln Gly Asn Arg Pro    50                  55                  60Leu Phe Glu Asp Met Thr Asp Ser Asp Cys Arg Asp Asn Ala Pro Arg65                  70                  75                  80Thr Ile Phe Ile Ile Ser Met Tyr Lys Asp Ser Gln Pro Arg Gly Met                85                  90                  95Ala Val Thr Ile Ser Val Lys Cys Glu Lys Ile Ser Thr Leu Ser Cys            100                 105                 110Glu Asn Lys Ile Ile Ser Phe Lys Glu Met Asn Pro Pro Asp Asn Ile        115                 120                 125Lys Asp Thr Lys Ser Asp Ile Ile Phe Phe Gln Arg Ser Val Pro Gly    130                 135                 140His Asp Asn Lys Met Gln Phe Glu Ser Ser Ser Tyr Glu Gly Tyr Phe145                 150                 155                 160Leu Ala Cys Glu Lys Glu Arg Asp Leu Phe Lys Leu Ile Leu Lys Lys                165                 170                 175Glu Asp Glu Leu Gly Asp Arg Ser Ile Met Phe Thr Val Gln Asn Glu            180                 185                 190Asp Leu</s400><s200><s210>106</s210><s211>270</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 106Met Lys Pro Lys Met Lys Tyr Ser Thr Asn Lys Ile Ser Thr Ala Lys1               5                   10                  15Trp Lys Asn Thr Ala Ser Lys Ala Leu Cys Phe Lys Leu Gly Lys Ser            20                  25                  30Gln Gln Lys Ala Lys Glu Val Cys Pro Met Tyr Phe Met Lys Leu Arg        35                  40                  45Ser Gly Leu Met Ile Lys Lys Glu Ala Cys Tyr Phe Arg Arg Glu Thr    50                  55                  60Thr Lys Arg Pro Ser Leu Lys Thr Gly Arg Lys His Lys Arg His Leu65                  70                  75                  80Val Leu Ala Ala Cys Gln Gln Gln Ser Thr Val Glu Cys Phe Ala Phe                85                  90                  95Gly Ile Ser Gly Val Gln Lys Tyr Thr Arg Ala Leu His Asp Ser Ser            100                 105                 110Ile Thr Gly Ile Ser Pro Ile Thr Glu Tyr Leu Ala Ser Leu Ser Thr        115                 120                 125Tyr Asn Asp Gln Ser Ile Thr Phe Ala Leu Glu Asp Glu Ser Tyr Glu    130                 135                 140Ile Tyr Val Glu Asp Leu Lys Lys Asp Glu Lys Lys Asp Lys Val Leu145                 150                 155                 160Leu Ser Tyr Tyr Glu Ser Gln His Pro Ser Asn Glu Ser Gly Asp Gly                165                 170                 175Val Asp Gly Lys Met Leu Met Val Thr Leu Ser Pro Thr Lys Asp Phe            180                 185                 190Trp Leu His Ala Asn Asn Lys Glu His Ser Val Glu Leu His Lys Cys        195                 200                 205Glu Lys Pro Leu Pro Asp Gln Ala Phe Phe Val Leu His Asn Met His    210                 215                 220Ser Asn Cys Val Ser Phe Glu Cys Lys Thr Asp Pro Gly Val Phe Ile225                 230                 235                 240Gly Val Lys Asp Asn His Leu Ala Leu Ile Lys Val Asp Ser Ser Glu                245                 250                 255Asn Leu Cys Thr Glu Asn Ile Leu Phe Lys Leu Ser Glu Thr            260                 265                 270</s400><s200><s210>107</s210><s211>193</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 107Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu1               5                   10                  15Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu            20                  25                  30Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu        35                  40                  45Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu    50                  55                  60Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg65                  70                  75                  80Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu                85                  90                  95Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser            100                 105                 110Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly        115                 120                 125Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu    130                 135                 140Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile145                 150                 155                 160Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu                165                 170                 175Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp            180                 185                 190Arg</s400><s200><s210>108</s210><s211>166</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial polymer</s223></s220></s200><s400> 108Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu1               5                   10                  15Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His            20                  25                  30Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe        35                  40                  45Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp    50                  55                  60Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu65                  70                  75                  80Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp                85                  90                  95Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu            100                 105                 110Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala        115                 120                 125Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val    130                 135                 140Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala145                 150                 155                 160Cys Arg Thr Gly Asp Arg                165</s400><s200><s210>109</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 109Gly Gly Gly Gly Ser1               5</s400><s200><s210>110</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1               5                   10</s400><s200><s210>111</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 111Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1               5                   10                  15</s400><s200><s210>112</s210><s211>20</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 112Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser            20</s400><s200><s210>113</s210><s211>25</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 113Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser            20                  25</s400><s200><s210>114</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 114Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser            20                  25                  30</s400><s200><s210>115</s210><s211>35</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 115Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser        35</s400><s200><s210>116</s210><s211>40</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 116Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser        35                  40</s400><s200><s210>117</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 117Gly Gly Ser Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1               5                   10                  15</s400><s200><s210>118</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 118Gly Gly Gly Gly Gly Gly Gly Gly1               5</s400><s200><s210>119</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 119Gly Gly Gly Gly Gly Gly1               5</s400><s200><s210>120</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 120Glu Ala Ala Ala Lys1               5</s400><s200><s210>121</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 121Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1               5                   10</s400><s200><s210>122</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 122Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1               5                   10                  15</s400><s200><s210>123</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 123Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Ala1               5                   10</s400><s200><s210>124</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 124Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1               5                   10                  15Ala</s400><s200><s210>125</s210><s211>22</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 125Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1               5                   10                  15Glu Ala Ala Ala Lys Ala            20</s400><s200><s210>126</s210><s211>27</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 126Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1               5                   10                  15Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Ala            20                  25</s400><s200><s210>127</s210><s211>46</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 127Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys1               5                   10                  15Glu Ala Ala Ala Lys Ala Leu Glu Ala Glu Ala Ala Ala Lys Glu Ala            20                  25                  30Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Ala        35                  40                  45</s400><s200><s210>128</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 128Pro Ala Pro Ala Pro1               5</s400><s200><s210>129</s210><s211>18</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 129Lys Glu Ser Gly Ser Val Ser Ser Glu Gln Leu Ala Gln Phe Arg Ser1               5                   10                  15Leu Asp</s400><s200><s210>130</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 130Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr1               5                   10</s400><s200><s210>131</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 131Gly Ser Ala Gly Ser Ala Ala Gly Ser Gly Glu Phe1               5                   10</s400><s200><s210>132</s210><s211>3</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 132Gly Gly Ser1</s400><s200><s210>133</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 133Gly Gly Ser Gly Gly Ser1               5</s400><s200><s210>134</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 134Gly Gly Ser Gly Gly Ser Gly Gly Ser1               5</s400><s200><s210>135</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 135Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser1               5                   10</s400><s200><s210>136</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 136Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser1               5                   10                  15</s400><s200><s210>137</s210><s211>18</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 137Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser</s400><s200><s210>138</s210><s211>21</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 138Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser            20</s400><s200><s210>139</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 139Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser            20</s400><s200><s210>140</s210><s211>27</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 140Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser            20                  25</s400><s200><s210>141</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 141Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser            20                  25                  30</s400><s200><s210>142</s210><s211>33</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 142Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            20                  25                  30Ser</s400><s200><s210>143</s210><s211>36</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 143Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            20                  25                  30Ser Gly Gly Ser        35</s400><s200><s210>144</s210><s211>39</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 144Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            20                  25                  30Ser Gly Gly Ser Gly Gly Ser        35</s400><s200><s210>145</s210><s211>42</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 145Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            20                  25                  30Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser        35                  40</s400><s200><s210>146</s210><s211>45</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 146Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            20                  25                  30Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser        35                  40                  45</s400><s200><s210>147</s210><s211>48</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 147Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            20                  25                  30Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser        35                  40                  45</s400><s200><s210>148</s210><s211>51</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 148Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            20                  25                  30Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser        35                  40                  45Gly Gly Ser    50</s400><s200><s210>149</s210><s211>54</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 149Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            20                  25                  30Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser        35                  40                  45Gly Gly Ser Gly Gly Ser    50</s400><s200><s210>150</s210><s211>57</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 150Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            20                  25                  30Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser        35                  40                  45Gly Gly Ser Gly Gly Ser Gly Gly Ser    50                  55</s400><s200><s210>151</s210><s211>60</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 151Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly1               5                   10                  15Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            20                  25                  30Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser        35                  40                  45Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser    50                  55                  60</s400><s200><s210>152</s210><s211>45</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 152Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser        35                  40                  45</s400><s200><s210>153</s210><s211>50</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 153Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser    50</s400><s200><s210>154</s210><s211>55</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 154Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser    50                  55</s400><s200><s210>155</s210><s211>60</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 155Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser    50                  55                  60</s400><s200><s210>156</s210><s211>65</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 156Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly    50                  55                  60Ser65</s400><s200><s210>157</s210><s211>70</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 157Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly    50                  55                  60Ser Gly Gly Gly Gly Ser65                  70</s400><s200><s210>158</s210><s211>75</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 158Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly    50                  55                  60Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser65                  70                  75</s400><s200><s210>159</s210><s211>80</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 159Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly    50                  55                  60Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser65                  70                  75                  80</s400><s200><s210>160</s210><s211>85</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 160Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly    50                  55                  60Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser65                  70                  75                  80Gly Gly Gly Gly Ser                85</s400><s200><s210>161</s210><s211>90</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 161Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly    50                  55                  60Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser65                  70                  75                  80Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                85                  90</s400><s200><s210>162</s210><s211>95</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 162Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly    50                  55                  60Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser65                  70                  75                  80Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                85                  90                  95</s400><s200><s210>163</s210><s211>100</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 163Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            20                  25                  30Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        35                  40                  45Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly    50                  55                  60Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser65                  70                  75                  80Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly                85                  90                  95Gly Gly Gly Ser            100</s400><s200><s210>164</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 164Gly Gly Gly Ser Glu1               5</s400><s200><s210>165</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 165Gly Ser Glu Ser Gly1               5</s400><s200><s210>166</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 166Gly Ser Glu Gly Ser1               5</s400><s200><s210>167</s210><s211>35</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 167Gly Glu Gly Gly Ser Gly Glu Gly Ser Ser Gly Glu Gly Ser Ser Ser1               5                   10                  15Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu            20                  25                  30Gly Gly Ser        35</s400><s200><s210>168</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 168Cys Pro Pro Cys1</s400><s200><s210>169</s210><s211>508</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 169Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr Gly Ser1               5                   10                  15Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu Asp Leu            20                  25                  30Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile Ile Gln        35                  40                  45Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser Tyr Arg    50                  55                  60Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn Ala Ala65                  70                  75                  80Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr Arg Cys                85                  90                  95Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val Lys Val            100                 105                 110Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val Asp Pro        115                 120                 125Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr Pro Lys    130                 135                 140Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser Gly Lys145                 150                 155                 160Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn Val Thr                165                 170                 175Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr Cys Thr            180                 185                 190Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu Val Ile        195                 200                 205Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Ser Gly Gly Ser    210                 215                 220Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly225                 230                 235                 240Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly                245                 250                 255Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser            260                 265                 270Gly Gly Ser Gly Gly Ser Gly Gly Ser Asp Lys Thr His Thr Cys Pro        275                 280                 285Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe    290                 295                 300Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val305                 310                 315                 320Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe                325                 330                 335Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro            340                 345                 350Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr        355                 360                 365Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Gln Val    370                 375                 380Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala385                 390                 395                 400Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg                405                 410                 415Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly            420                 425                 430Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro        435                 440                 445Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser    450                 455                 460Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln465                 470                 475                 480Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His                485                 490                 495Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys            500                 505</s400><s200><s210>170</s210><s211>733</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Sequence</s223></s220></s200><s400> 170Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr Gly Ser1               5                   10                  15Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu Asp Leu            20                  25                  30Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile Ile Gln        35                  40                  45Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser Tyr Arg    50                  55                  60Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn Ala Ala65                  70                  75                  80Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr Arg Cys                85                  90                  95Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val Lys Val            100                 105                 110Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val Asp Pro        115                 120                 125Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr Pro Lys    130                 135                 140Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser Gly Lys145                 150                 155                 160Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn Val Thr                165                 170                 175Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr Cys Thr            180                 185                 190Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu Val Ile        195                 200                 205Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Ser Gly Gly Ser    210                 215                 220Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly225                 230                 235                 240Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly                245                 250                 255Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser            260                 265                 270Gly Gly Ser Gly Gly Ser Gly Gly Ser Asp Lys Thr His Thr Cys Pro        275                 280                 285Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe    290                 295                 300Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val305                 310                 315                 320Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe                325                 330                 335Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro            340                 345                 350Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr        355                 360                 365Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Gln Val    370                 375                 380Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala385                 390                 395                 400Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg                405                 410                 415Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly            420                 425                 430Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro        435                 440                 445Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser    450                 455                 460Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln465                 470                 475                 480Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His                485                 490                 495Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly Ser Gly            500                 505                 510Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly        515                 520                 525Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser    530                 535                 540Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly545                 550                 555                 560Gly Ser Gly Gly Ser Gly Gly Ser Cys Asp Leu Pro Gln Thr His Ser                565                 570                 575Leu Gly Ser Arg Arg Thr Leu Met Leu Leu Ala Gln Met Arg Lys Ile            580                 585                 590Ser Leu Phe Ser Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln        595                 600                 605Glu Glu Phe Gly Asn Gln Phe Gln Lys Ala Glu Thr Ile Pro Val Leu    610                 615                 620His Glu Met Ile Gln Gln Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser625                 630                 635                 640Ser Ala Ala Trp Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu                645                 650                 655Tyr Gln Gln Leu Asn Asp Leu Glu Ala Cys Val Ile Gln Gly Val Gly            660                 665                 670Val Glu Glu Thr Pro Leu Met Lys Glu Asp Ser Ile Leu Ala Val Arg        675                 680                 685Lys Tyr Phe Gln Arg Ile Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser    690                 695                 700Pro Cys Ala Trp Glu Val Val Arg Ala Glu Ile Met Ala Ser Phe Ser705                 710                 715                 720Leu Ser Thr Asn Leu Gln Glu Ser Leu Arg Ser Lys Glu                725                 730</s400><s200><s210>171</s210><s211>376</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic polymer.</s223></s220></s200><s400> 171Met Glu Phe Gly Leu Ser Trp Leu Phe Leu Val Ala Ile Leu Lys Gly1               5                   10                  15Val Gln Cys Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln            20                  25                  30Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe        35                  40                  45Ser Ile Asn Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg    50                  55                  60Glu Leu Val Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp65                  70                  75                  80Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr                85                  90                  95Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr            100                 105                 110Tyr Cys His Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr        115                 120                 125Leu Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly    130                 135                 140Gly Ser Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala145                 150                 155                 160Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro                165                 170                 175Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val            180                 185                 190Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val        195                 200                 205Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln    210                 215                 220Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln225                 230                 235                 240Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala                245                 250                 255Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro            260                 265                 270Arg Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr        275                 280                 285Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser    290                 295                 300Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr305                 310                 315                 320Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val                325                 330                 335Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe            340                 345                 350Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys        355                 360                 365Ser Leu Ser Leu Ser Pro Gly Lys    370                 375</s400><s200><s210>172</s210><s211>375</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic polymer.</s223></s220></s200><s400> 172Met Glu Phe Gly Leu Ser Trp Leu Phe Leu Val Ala Ile Leu Lys Gly1               5                   10                  15Val Gln Cys Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln            20                  25                  30Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe        35                  40                  45Ser Gly Asn His Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg    50                  55                  60Glu Leu Val Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp65                  70                  75                  80Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr                85                  90                  95Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr            100                 105                 110Tyr Cys Asn Val Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu        115                 120                 125Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly    130                 135                 140Ser Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro145                 150                 155                 160Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys                165                 170                 175Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val            180                 185                 190Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp        195                 200                 205Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr    210                 215                 220Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp225                 230                 235                 240Trp Leu Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu                245                 250                 255Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg            260                 265                 270Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys        275                 280                 285Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp    290                 295                 300Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys305                 310                 315                 320Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser                325                 330                 335Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser            340                 345                 350Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser        355                 360                 365Leu Ser Leu Ser Pro Gly Lys    370                 375</s400><s200><s210>173</s210><s211>551</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic polymer.</s223></s220></s200><s400> 173Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly1               5                   10                  15Val His Ser Asp Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln            20                  25                  30Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe        35                  40                  45Ser Ile Asn Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg    50                  55                  60Glu Leu Val Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp65                  70                  75                  80Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr                85                  90                  95Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr            100                 105                 110Tyr Cys His Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr        115                 120                 125Leu Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly    130                 135                 140Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly145                 150                 155                 160Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser                165                 170                 175Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly            180                 185                 190Gly Ser Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro        195                 200                 205Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser    210                 215                 220Ile Asn Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu225                 230                 235                 240Leu Val Ala Leu Ile Thr Ser Gly Gly Thr Pro Ala Tyr Ala Asp Ser                245                 250                 255Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val            260                 265                 270Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr        275                 280                 285Cys His Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu    290                 295                 300Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly305                 310                 315                 320Ser Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro                325                 330                 335Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys            340                 345                 350Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val        355                 360                 365Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp    370                 375                 380Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr385                 390                 395                 400Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp                405                 410                 415Trp Leu Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu            420                 425                 430Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg        435                 440                 445Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys    450                 455                 460Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp465                 470                 475                 480Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys                485                 490                 495Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser            500                 505                 510Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser        515                 520                 525Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser    530                 535                 540Leu Ser Leu Ser Pro Gly Lys545                 550</s400><s200><s210>174</s210><s211>549</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic polymer.</s223></s220></s200><s400> 174Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly1               5                   10                  15Val His Ser Asp Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln            20                  25                  30Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe        35                  40                  45Ser Gly Asn His Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg    50                  55                  60Glu Leu Val Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp65                  70                  75                  80Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr                85                  90                  95Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr            100                 105                 110Tyr Cys Asn Val Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu        115                 120                 125Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly    130                 135                 140Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser145                 150                 155                 160Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly                165                 170                 175Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            180                 185                 190Ser Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly        195                 200                 205Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Lys Ile Phe Ser Gly    210                 215                 220Asn His Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu225                 230                 235                 240Val Gly Ile Ile Thr Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ser Val                245                 250                 255Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr            260                 265                 270Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys        275                 280                 285Asn Val Arg Asp Arg Thr Ile Trp Trp Gly Gln Gly Thr Leu Val Thr    290                 295                 300Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly305                 310                 315                 320Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala                325                 330                 335Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr            340                 345                 350Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val        355                 360                 365Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val    370                 375                 380Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser385                 390                 395                 400Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu                405                 410                 415Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala            420                 425                 430Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro        435                 440                 445Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln    450                 455                 460Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala465                 470                 475                 480Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr                485                 490                 495Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu            500                 505                 510Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser        515                 520                 525Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser    530                 535                 540Leu Ser Pro Gly Lys545</s400><s200><s210>175</s210><s211>246</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic polymer.</s223></s220></s200><s400> 175Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala1               5                   10                  15Ser Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu            20                  25                  30Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp        35                  40                  45Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp    50                  55                  60Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly65                  70                  75                  80Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn                85                  90                  95Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp            100                 105                 110Leu Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro        115                 120                 125Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu    130                 135                 140Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn145                 150                 155                 160Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile                165                 170                 175Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr            180                 185                 190Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys        195                 200                 205Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys    210                 215                 220Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu225                 230                 235                 240Ser Leu Ser Pro Gly Lys                245</s400><s200><s210>176</s210><s211>442</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic polymer.</s223></s220></s200><s400> 176Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala1               5                   10                  15Ser Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu            20                  25                  30Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp        35                  40                  45Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp    50                  55                  60Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly65                  70                  75                  80Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn                85                  90                  95Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp            100                 105                 110Leu Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro        115                 120                 125Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu    130                 135                 140Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn145                 150                 155                 160Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile                165                 170                 175Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr            180                 185                 190Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys        195                 200                 205Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys    210                 215                 220Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu225                 230                 235                 240Ser Leu Ser Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly                245                 250                 255Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            260                 265                 270Ser Gly Gly Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser        275                 280                 285Arg Arg Thr Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe    290                 295                 300Ser Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe305                 310                 315                 320Gly Asn Gln Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met                325                 330                 335Ile Gln Gln Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala            340                 345                 350Trp Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln        355                 360                 365Leu Asn Asp Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu    370                 375                 380Thr Pro Leu Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe385                 390                 395                 400Gln Arg Ile Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala                405                 410                 415Trp Glu Val Val Arg Ala Glu Ile Met Ala Ser Phe Ser Leu Ser Thr            420                 425                 430Asn Leu Gln Glu Ser Leu Arg Ser Lys Glu        435                 440</s400><s200><s210>177</s210><s211>442</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic polymer.</s223></s220></s200><s400> 177Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala1               5                   10                  15Ser Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu            20                  25                  30Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp        35                  40                  45Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp    50                  55                  60Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly65                  70                  75                  80Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn                85                  90                  95Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp            100                 105                 110Leu Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro        115                 120                 125Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu    130                 135                 140Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn145                 150                 155                 160Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile                165                 170                 175Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr            180                 185                 190Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys        195                 200                 205Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys    210                 215                 220Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu225                 230                 235                 240Ser Leu Ser Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly                245                 250                 255Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            260                 265                 270Ser Gly Gly Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser        275                 280                 285Arg Arg Thr Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe    290                 295                 300Ser Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe305                 310                 315                 320Gly Asn Gln Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met                325                 330                 335Ile Gln Gln Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala            340                 345                 350Trp Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln        355                 360                 365Leu Asn Asp Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu    370                 375                 380Thr Pro Leu Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe385                 390                 395                 400Gln Arg Ile Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala                405                 410                 415Trp Glu Val Val Arg Gly Glu Ile Met Arg Ser Phe Ser Leu Ser Thr            420                 425                 430Asn Leu Gln Glu Ser Leu Arg Ser Lys Glu        435                 440</s400><s200><s210>178</s210><s211>442</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic polymer.</s223></s220></s200><s400> 178Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala1               5                   10                  15Ser Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu            20                  25                  30Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp        35                  40                  45Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp    50                  55                  60Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly65                  70                  75                  80Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn                85                  90                  95Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp            100                 105                 110Leu Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro        115                 120                 125Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu    130                 135                 140Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn145                 150                 155                 160Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile                165                 170                 175Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr            180                 185                 190Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys        195                 200                 205Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys    210                 215                 220Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu225                 230                 235                 240Ser Leu Ser Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly                245                 250                 255Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly            260                 265                 270Ser Gly Gly Ser Cys Asp Leu Pro Glu Thr His Ser Leu Asp Asn Arg        275                 280                 285Arg Thr Leu Met Leu Leu Ala Gln Met Ser Arg Ile Ser Pro Ser Ser    290                 295                 300Cys Leu Met Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp305                 310                 315                 320Gly Asn Gln Phe Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu Leu                325                 330                 335Ile Gln Gln Ile Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala            340                 345                 350Trp Asp Glu Asp Leu Leu Asp Lys Phe Ser Thr Glu Leu Tyr Gln Gln        355                 360                 365Leu Asn Asp Leu Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu    370                 375                 380Thr Pro Leu Met Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe385                 390                 395                 400Arg Arg Ile Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala                405                 410                 415Trp Glu Val Val Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr            420                 425                 430Asn Leu Gln Glu Arg Leu Arg Arg Lys Glu        435                 440</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002494A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002494</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17772323</doc-number><date>20201030</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><priority-claims><priority-claim sequence="01" kind="national"><country>CN</country><doc-number>201911044297.0</doc-number><date>20191030</date></priority-claim><priority-claim sequence="02" kind="national"><country>CN</country><doc-number>202010765530.0</doc-number><date>20200731</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>28</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>85</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2827</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>85</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>33</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>92</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>565</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>569</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>52</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e79">PD-L1 BINDING MOLECULE</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>SANYOU BIOPHARMACEUTICALS CO., LTD.</orgname><address><city>Shanghai</city><country>CN</country></address></addressbook><residence><country>CN</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Kong</last-name><first-name>Chao</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Lang</last-name><first-name>Guojun</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Wu</last-name><first-name>Qi</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Liu</last-name><first-name>Chanjuan</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>Yan</last-name><first-name>Run</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>Yan</last-name><first-name>Xintian</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>Tan</last-name><first-name>Lunmei</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/CN2020/125301</doc-number><date>20201030</date></document-id><us-371c12-date><date>20220427</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present application provides an isolated PD-L1 binding molecule, specifically, an isolated PD-L1 single-domain antibody or an antigen-binding fragment thereof. The present invention also provides a nucleic acid encoding the isolated PD-L1 binding molecule, an expression vector or host cell comprising the nucleic acid, and a pharmaceutical composition or kit comprising the PD-L1 binding molecule.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="58.08mm" wi="148.76mm" file="US20230002494A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="228.35mm" wi="164.59mm" file="US20230002494A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="192.62mm" wi="122.77mm" file="US20230002494A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="246.55mm" wi="165.78mm" file="US20230002494A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="219.63mm" wi="145.12mm" file="US20230002494A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="229.79mm" wi="154.94mm" file="US20230002494A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="246.46mm" wi="159.94mm" file="US20230002494A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="111.84mm" wi="152.15mm" file="US20230002494A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="189.57mm" wi="161.29mm" file="US20230002494A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="253.75mm" wi="92.37mm" orientation="landscape" file="US20230002494A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">CLAIM OF PRIORITY</heading><p id="p-0002" num="0001">The present application claims the benefits of Chinese invention patent application No. 201911044297.0 filed on Oct. 30, 2019 and Chinese invention patent application No. 202010765530.0 filed on Jul. 31, 2020, the content of which is fully incorporated herein by reference.</p><heading id="h-0002" level="1">TECHNICAL FIELD</heading><p id="p-0003" num="0002">The present application belongs to the technical field of biology, and in general, relates to antibodies. More specifically, the present application relates to a binding molecule (e.g., a single-domain antibody) that specifically recognizes PD-L1, a method for preparing same and the use thereof.</p><heading id="h-0003" level="1">BACKGROUND OF THE INVENTION</heading><p id="p-0004" num="0003">Immune checkpoints are regulatory molecules that play an inhibitory role in the immune system, including CTLA-4, PD-1, LAG-3, TIM-3, etc. At present, there are a plurality of antibody drugs on the basis of the two immune checkpoints CTLA-4 and PD-1 on the market. PD-1 (programmed death 1), an important immunosuppressive molecule, was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunoregulation targeting PD-1 is of great significance in the anti-tumor, anti-infection, anti-autoimmune diseases and survival of organ transplantation.</p><p id="p-0005" num="0004">The main ligands of PD-1 are PD-L1 and PD-L2, of which PD-L1 plays an important role in mediating tumor cell escape and is highly expressed in tumor cells and some antigen-presenting cells, with the expression level capable of being induced by various cytokines such as IFN-&#x3b3; and TGF-&#x3b2;. In a tumor microenvironment, the upregulation of PD-L1 expression can directly inhibit the anti-tumor response of T cells and mediate the immune escape of tumor cells via a PD-1 signaling pathway.</p><p id="p-0006" num="0005">A single-domain antibody (referred to as sdAb for short) is an antibody comprising a single variable domain of heavy chain of an antibody. Similar to an IgG antibody, the single-domain antibody can selectively bind to a specific antigen, but has a molecular weight much smaller than that of the IgG antibody. At present, the first single-domain antibody is engineered from a heavy chain antibody found in camelids (Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E B, Bendahman N, Hamers R (1993) Naturally Occurring Antibodies Devoid of Light Chains. Nature 363(6428):446-448); and the heavy chain antibody found in camelids is also referred to as a VHH fragment. At present, most of the research on single-domain antibodies are based on heavy chain variable domains.</p><p id="p-0007" num="0006">Single-domain antibodies have many advantages. For example, they have quite high solubility, good thermal stability and good tissue penetration. Due to the presence of an intramolecular disulfide bond, some single-domain antibodies can also be resistant to the degradation by papains, etc. In addition, single-domain antibodies can be produced, in a quite high expression level, in a plurality of expression hosts such as yeast, plant and mammalian cells, which endows them with very great cost effectiveness (Harmsen M M, De Haard H J (2007) Properties, Production, and Applications of Camelid Single-domain Antibody Fragments. Appl Microbiol Biotechnol 77(1):13-22). Single-domain antibodies have good application prospects in various biotechnology and medical fields due to their numerous advantages. At present, the first single-domain antibody drug of Ablynx has been approved for marketing.</p><p id="p-0008" num="0007">Up to now, there are not too many antibody drugs targeting PD-L1 on the market. Therefore, there is still a need to develop new binding molecules (e.g., single-domain antibodies) that specifically recognize PD-L1 for cancer immunotherapy, making them to have lower toxicity, lower side effects and better clinical efficacy.</p><heading id="h-0004" level="1">BRIEF SUMMARY OF THE INVENTION</heading><p id="p-0009" num="0008">The objective of the present invention is to provide a new PD-L1 binding molecule, specifically, to provide a new single-domain antibody that specifically recognizes PD-L1. Compared with the existing PD-L1 binding molecules, the PD-L1 binding molecule of the present invention has lower toxicity and side effects and better clinical efficacy, and can treat cancers more effectively.</p><p id="p-0010" num="0009">In general, the present invention provides a binding molecule that specifically recognizes PD-L1, specifically, a single-domain antibody that specifically recognizes PD-L1. The single-domain antibody is also referred to hereinafter as a PD-L1 single-domain antibody, a PD-L1 antibody in a nanobody format, a PD-L1 nanobody or a VHH antibody of PD-L1, and the above-mentioned terms can be used interchangeably. The present application also provides a method for constructing and screening the PD-L1 binding molecule, a nucleic acid molecule encoding the PD-L1 binding molecule, a vector and a host cell for expressing the PD-L1 binding molecule, and a composition or a kit comprising the PD-L1 binding molecule. The PD-L1 binding molecule of the present application can treat various cancers by modulating the immune system, and can thus be used to prepare an agent for treating cancers.</p><p id="p-0011" num="0010">Specifically, the present invention provides a PD-L1 antibody in a nanobody format and a humanized modified or an affinity-matured molecule derived therefrom. While the advantages of the PD-L1 antibody, such as high affinity and low molecular weight are maintained, immunogenicity modification is performed thereon to improve the druggability, making same to have great therapeutic advantages.</p><p id="p-0012" num="0011">In some aspects, the present invention provides an isolated PD-L1 binding molecule, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0013" num="0012">(i) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1;</p><p id="p-0014" num="0013">a CDR1 comprising an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 1; or</p><p id="p-0015" num="0014">a CDR1 comprising an amino acid sequence which differs from SEQ ID NO: 1 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0016" num="0015">(ii) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2;</p><p id="p-0017" num="0016">a CDR2 comprising an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 2; or</p><p id="p-0018" num="0017">a CDR2 comprising an amino acid sequence which differs from SEQ ID NO: 2 by no more than 2 (e.g., 0, 1, and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0019" num="0018">and</p><p id="p-0020" num="0019">(iii) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3 or 12;</p><p id="p-0021" num="0020">a CDR3 comprising an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 3 or 12; or</p><p id="p-0022" num="0021">a CDR3 comprising an amino acid sequence which differs from SEQ ID NO: 3 or 12 by no more than 2 (e.g., 0, 1, and 2) amino acid additions, deletions and/or substitutions.</p><p id="p-0023" num="0022">In some embodiments, the PD-L1 binding molecule comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0024" num="0023">(i) a CDR1 as shown in formula RTDSNIX<sub>1</sub>GMH, wherein X<sub>1 </sub>is H, F or N;</p><p id="p-0025" num="0024">(ii) a CDR2 as shown in formula TIFIDX<sub>2</sub>NTX<sub>3</sub>, wherein X<sub>2 </sub>is G, L or A, and X<sub>3 </sub>is I or L; and</p><p id="p-0026" num="0025">(iii) a CDR3 as shown in formula DVSGYGRX<sub>4</sub>, wherein X<sub>4 </sub>is A or Y.</p><p id="p-0027" num="0026">In some embodiments, the PD-L1 binding molecule comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0028" num="0027">(i) a CDR1 comprising or consisting of SEQ ID NO: 1;</p><p id="p-0029" num="0028">(ii) a CDR2 comprising or consisting of SEQ ID NO: 2; and</p><p id="p-0030" num="0029">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0031" num="0030">In some embodiments, the PD-L1 binding molecule comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0032" num="0031">(i) a CDR1 comprising or consisting of SEQ ID NO: 4;</p><p id="p-0033" num="0032">(ii) a CDR2 comprising or consisting of SEQ ID NO: 5; and</p><p id="p-0034" num="0033">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0035" num="0034">In some embodiments, the PD-L1 binding molecule comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0036" num="0035">(i) a CDR1 comprising or consisting of SEQ ID NO: 6;</p><p id="p-0037" num="0036">(ii) a CDR2 comprising or consisting of SEQ ID NO: 7; and</p><p id="p-0038" num="0037">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0039" num="0038">In some embodiments, the PD-L1 binding molecule comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0040" num="0039">(i) a CDR1 comprising or consisting of SEQ ID NO: 1;</p><p id="p-0041" num="0040">(ii) a CDR2 comprising or consisting of SEQ ID NO: 8; and</p><p id="p-0042" num="0041">(iii) a CDR3 comprising or consisting of SEQ ID NO: 9.</p><p id="p-0043" num="0042">In some embodiments, the PD-L1 binding molecule comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0044" num="0043">(i) a CDR1 comprising or consisting of SEQ ID NO: 10;</p><p id="p-0045" num="0044">(ii) a CDR2 comprising or consisting of SEQ ID NO: 11; and</p><p id="p-0046" num="0045">(iii) a CDR3 comprising or consisting of SEQ ID NO: 12.</p><p id="p-0047" num="0046">In some embodiments, the PD-L1 binding molecule comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0048" num="0047">(i) a CDR1 comprising or consisting of SEQ ID NO: 13;</p><p id="p-0049" num="0048">(ii) a CDR2 comprising or consisting of SEQ ID NO: 5; and</p><p id="p-0050" num="0049">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0051" num="0050">In some embodiments, the PD-L1 binding molecule comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0052" num="0051">(i) a CDR1 comprising or consisting of SEQ ID NO: 14;</p><p id="p-0053" num="0052">(ii) a CDR2 comprising or consisting of SEQ ID NO: 15; and</p><p id="p-0054" num="0053">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0055" num="0054">In some embodiments, the PD-L1 binding molecule comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0056" num="0055">(i) a CDR1 comprising or consisting of SEQ ID NO: 16;</p><p id="p-0057" num="0056">(ii) a CDR2 comprising or consisting of SEQ ID NO: 17; and</p><p id="p-0058" num="0057">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0059" num="0058">In some embodiments, the PD-L1 binding molecule comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0060" num="0059">(i) a CDR1 comprising or consisting of SEQ ID NO: 18;</p><p id="p-0061" num="0060">(ii) a CDR2 comprising or consisting of SEQ ID NO: 19; and</p><p id="p-0062" num="0061">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0063" num="0062">In some embodiments, the PD-L1 binding molecule comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0064" num="0063">(i) a CDR1 comprising or consisting of SEQ ID NO: 20;</p><p id="p-0065" num="0064">(ii) a CDR2 comprising or consisting of SEQ ID NO: 5; and</p><p id="p-0066" num="0065">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0067" num="0066">In some aspects, the present invention provides an isolated PD-L1 binding molecule, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0068" num="0067">(i) a CDR1 comprising or consisting of SEQ ID NO: 21;</p><p id="p-0069" num="0068">(ii) a CDR2 comprising or consisting of SEQ ID NO: 22; and</p><p id="p-0070" num="0069">(iii) a aCDR3 comprising or consisting of SEQ ID NO: 23.</p><p id="p-0071" num="0070">In some aspects, the present invention provides an isolated PD-L1 binding molecule, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0072" num="0071">(i) a CDR1 comprising or consisting of SEQ ID NO: 24;</p><p id="p-0073" num="0072">(ii) a CDR2 comprising or consisting of SEQ ID NO: 25; and</p><p id="p-0074" num="0073">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0075" num="0074">In some aspects, the present invention provides an isolated PD-L1 binding molecule, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0076" num="0075">(i) a CDR1 comprising or consisting of SEQ ID NO: 26;</p><p id="p-0077" num="0076">(ii) a CDR2 comprising or consisting of SEQ ID NO: 27; and</p><p id="p-0078" num="0077">(iii) a CDR3 comprising or consisting of SEQ ID NO: 23.</p><p id="p-0079" num="0078">In some aspects, the present invention provides an isolated PD-L1 binding molecule, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0080" num="0079">(i) a CDR1 comprising or consisting of SEQ ID NO: 28;</p><p id="p-0081" num="0080">(ii) a CDR2 comprising or consisting of SEQ ID NO: 29; and</p><p id="p-0082" num="0081">(iii) a CDR3 comprising or consisting of SEQ ID NO: 23.</p><p id="p-0083" num="0082">In some aspects, the present invention provides an isolated PD-L1 binding molecule, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0084" num="0083">(i) a CDR1 comprising or consisting of SEQ ID NO: 30;</p><p id="p-0085" num="0084">(ii) a CDR2 comprising or consisting of SEQ ID NO: 31; and</p><p id="p-0086" num="0085">(iii) a CDR3 comprising or consisting of SEQ ID NO: 23.</p><p id="p-0087" num="0086">In some aspects, the present invention provides an isolated PD-L1 binding molecule, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises 3 CDRs in a heavy chain variable region amino acid sequence of any one of SEQ ID NOs: 36-52.</p><p id="p-0088" num="0087">In some embodiments, in the isolated PD-L1 binding molecule of the present invention, the heavy chain variable region further comprises an FR region comprising FR1, FR2, FR3 and FR4, and the FR1, FR2, FR3 and FR4 and CDR1, CDR2 and CDR3 are arranged alternately on the heavy chain variable region to form a structure of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 from N-terminus to C-terminus.</p><p id="p-0089" num="0088">In a preferred embodiment, in the isolated PD-L1 binding molecule of the present invention, the FR region comprises:</p><p id="p-0090" num="0089">(a) an FR1 comprising the amino acid sequence of SEQ ID NO: 53;</p><p id="p-0091" num="0090">an FR1 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 53; or</p><p id="p-0092" num="0091">an FR1 comprising an amino acid sequence which differs from SEQ ID NO: 53 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0093" num="0092">(b) an FR2 comprising the amino acid sequence of SEQ ID NO: 54;</p><p id="p-0094" num="0093">an FR2 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 54; or</p><p id="p-0095" num="0094">an FR2 comprising an amino acid sequence which differs from SEQ ID NO: 54 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0096" num="0095">(c) an FR3 comprising the amino acid sequence of SEQ ID NO: 55;</p><p id="p-0097" num="0096">an FR3 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 55; or</p><p id="p-0098" num="0097">an FR3 comprising an amino acid sequence which differs from SEQ ID NO: 55 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions; and</p><p id="p-0099" num="0098">(d) an FR4 comprising the amino acid sequence as shown in SEQ ID NO: 56;</p><p id="p-0100" num="0099">an FR4 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 56; or</p><p id="p-0101" num="0100">an FR4 comprising an amino acid sequence which differs from SEQ ID NO: 56 by no more than 2 (e.g., 0, 1, and 2) amino acid additions, deletions and/or substitutions.</p><p id="p-0102" num="0101">In a preferred embodiment, in the isolated PD-L1 binding molecule of the present invention, the FR region comprises:</p><p id="p-0103" num="0102">(a) an FR1 comprising the amino acid sequence of SEQ ID NO: 57;</p><p id="p-0104" num="0103">an FR1 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 57; or</p><p id="p-0105" num="0104">an FR1 comprising an amino acid sequence which differs from SEQ ID NO: 57 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0106" num="0105">(b) an FR2 comprising the amino acid sequence as shown in SEQ ID NO: 58;</p><p id="p-0107" num="0106">an FR2 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 58; or</p><p id="p-0108" num="0107">an FR2 comprising an amino acid sequence which differs from SEQ ID NO: 58 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0109" num="0108">(c) an FR3 comprising the amino acid sequence of SEQ ID NO: 59;</p><p id="p-0110" num="0109">an FR3 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 59; or</p><p id="p-0111" num="0110">an FR3 comprising an amino acid sequence which differs from SEQ ID NO: 59 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions of amino acids;</p><p id="p-0112" num="0111">and</p><p id="p-0113" num="0112">(d) an FR4 comprising the amino acid sequence of SEQ ID NO: 60;</p><p id="p-0114" num="0113">an FR4 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 60; or</p><p id="p-0115" num="0114">an FR4 comprising an amino acid sequence which differs from SEQ ID NO: 60 by no more than 2 (e.g., 0, 1, and 2) amino acid additions, deletions and/or substitutions.</p><p id="p-0116" num="0115">In a preferred embodiment, in the isolated PD-L1 binding molecule of the present invention, the FR region comprises:</p><p id="p-0117" num="0116">(a) an FR1 comprising the amino acid sequence of SEQ ID NO: 61;</p><p id="p-0118" num="0117">an FR1 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 61; or</p><p id="p-0119" num="0118">an FR1 comprising an amino acid sequence which differs from SEQ ID NO: 61 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0120" num="0119">(b) an FR2 comprising the amino acid sequence of SEQ ID NO: 58;</p><p id="p-0121" num="0120">an FR2 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 58; or</p><p id="p-0122" num="0121">an FR2 comprising an amino acid sequence which differs from SEQ ID NO: 58 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0123" num="0122">(c) an FR3 comprising the amino acid sequence of SEQ ID NO: 59;</p><p id="p-0124" num="0123">an FR3 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 59; or</p><p id="p-0125" num="0124">an FR3 comprising an amino acid sequence which differs from SEQ ID NO: 59 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0126" num="0125">and</p><p id="p-0127" num="0126">(d) an FR4 comprising the amino acid sequence of SEQ ID NO: 60;</p><p id="p-0128" num="0127">an FR4 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 60; or</p><p id="p-0129" num="0128">an FR4 comprising an amino acid sequence which differs from SEQ ID NO: 60 by no more than 2 (e.g., 0, 1, and 2) amino acid additions, deletions and/or substitutions of amino acids.</p><p id="p-0130" num="0129">In some embodiments, in the isolated PD-L1 binding molecule of the present invention, the heavy chain variable region comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 36-52.</p><p id="p-0131" num="0130">In some embodiments, in the isolated PD-L1 binding molecule of the present invention, the heavy chain variable region comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to an amino acid sequence as shown in any one of SEQ ID NOs: 36-52 and retaining the ability to specifically bind to PD-L1.</p><p id="p-0132" num="0131">In some embodiments, in the isolated PD-L1 binding molecule of the present invention, the heavy chain variable region comprises an amino acid sequence having one or more amino acid additions, deletions and/or substitutions (e.g., conservative substitutions) compared to an amino acid sequence of any one of SEQ ID NOs: 36-52 and retaining the ability to specifically bind to PD-L1.</p><p id="p-0133" num="0132">In a preferred embodiment, the one or more additions, deletions and/or substitutions (e.g., conservative substitutions) of amino acids are no more than five, preferably no more than three.</p><p id="p-0134" num="0133">In some aspects, the isolated PD-L1 binding molecule of the present invention is a camelized antibody, a humanized antibody, an affinity-matured antibody or a druggability-modified molecule.</p><p id="p-0135" num="0134">In some aspects, the isolated PD-L1 binding molecule of the present invention is a single-domain antibody or an antigen-binding fragment thereof. Therefore, the present invention also provides an isolated PD-L1 single-domain antibody in a nanobody format.</p><p id="p-0136" num="0135">In some aspects, the heavy chain variable region of the isolated PD-L1 binding molecule of the present invention can be fused to an additional molecule, and the additional molecule is selected from an Fc domain of an immunoglobulin (e.g., IgG), an antibody, an antigen-binding fragment of the antibody, an antibody-drug conjugate, an antibody-like molecule, an antigen-binding fragment of the antibody-like molecule or a fluorescent protein.</p><p id="p-0137" num="0136">In some embodiments, the PD-L1 binding molecule is fused to an Fc domain of human IgG (e.g., human IgG1 or human IgG4).</p><p id="p-0138" num="0137">In some aspects, the present invention provides an isolated nucleic acid molecule, comprising a nucleotide sequence encoding the isolated PD-L1 binding molecule of the present invention.</p><p id="p-0139" num="0138">In some aspects, the present invention provides a vector, wherein the vector comprises a nucleic acid molecule comprising a nucleotide sequence encoding the isolated PD-L1 binding molecule of the present invention.</p><p id="p-0140" num="0139">In some aspects, the present invention provides a host cell, wherein the host cell comprises a nucleic acid molecule comprising a nucleotide sequence encoding the isolated PD-L1 binding molecule of the present invention or comprises the vector of the present invention.</p><p id="p-0141" num="0140">In some aspects, the present invention provides a pharmaceutical composition, wherein the pharmaceutical composition comprises the PD-L1 binding molecule of the present invention and a pharmaceutically acceptable carrier.</p><p id="p-0142" num="0141">In some embodiments, the pharmaceutical composition comprises the PD-L1 single-domain antibody or the antigen-binding fragment thereof of the present invention and a pharmaceutically acceptable carrier.</p><p id="p-0143" num="0142">In some aspects, the present invention provides a method for preparing the PD-L1 binding molecule of the present invention, wherein the method comprises the following steps:</p><p id="p-0144" num="0143">(1) expressing the nucleotide sequence encoding the isolated PD-L1 binding molecule of the present invention in a suitable host cell to produce the PD-L1 binding molecule; and</p><p id="p-0145" num="0144">(2) isolating the PD-L1 binding molecule from the host cell.</p><p id="p-0146" num="0145">In some aspects, the present invention relates to a method for modulating an immune response in a subject, comprising administering the PD-L1 binding molecule as disclosed herein to the subject, such that the immune response in the subject is modulated.</p><p id="p-0147" num="0146">In some embodiments, the subject is a human or a mammal suffering from a disease associated with PD-L1. Specifically, the subject may suffer from diseases including but not limited to the following: renal cell carcinoma, non-small cell lung cancer, bladder cancer, urothelial carcinoma, microsatellite unstable solid tumor, etc.</p><p id="p-0148" num="0147">In some aspects, the present invention relates to a method for treating or preventing a disease associated with PD-L1, comprising administering an effective amount of the PD-L1 binding molecule as disclosed herein, or administering the PD-L1 single-domain antibody or the antigen-binding fragment thereof as disclosed herein, or administering an effective amount of a pharmaceutical composition comprising the PD-L1 binding molecule as disclosed herein, or administering an effective amount of a pharmaceutical composition comprising the PD-L1 single-domain antibody or the antigen-binding fragment thereof as disclosed herein, to a patient suffering from the disease associated with PD-L1 or a subject with a propensity to suffer from the disease associated with PD-L1.</p><p id="p-0149" num="0148">In some aspects, the present invention relates to a method for treating any disease or condition that can be improved, slowed, inhibited or prevented by eliminating, inhibiting or reducing PD-L1 activity.</p><p id="p-0150" num="0149">In some other aspects, the method of the present invention further relates to a method for treating or preventing tumors by combination therapy, the method comprising administering an effective amount of the PD-L1 binding molecule, the PD-L1 single-domain antibody or the antigen-binding fragment thereof described herein and one or more other drugs to a subject.</p><p id="p-0151" num="0150">In some embodiments, the method disclosed herein further comprises administering in combination an effective amount of a second drug to a subject, wherein the PD-L1 binding molecule or the PD-L1 single-domain antibody or the antigen-binding fragment thereof disclosed herein is a first drug. In one embodiment, the second drug is a chemotherapeutic agent, a radiotherapeutic agent, or a biomacromolecular drug for the treatment of a disease associated with PD-L1. In one embodiment, the biomacromolecular drug is, for example, various monoclonal antibody drugs (e.g., rituximab, cetuximab and trastuzumab) that attack tumor cells by T cell recognition. As used herein, the expression &#x201c;a second drug&#x201d; does not mean that it refers to the only drug other than the first drug. Thus, the second drug need not be one drug, but may constitute or contain more than one such drug.</p><p id="p-0152" num="0151">In some embodiments, the subject, patient or individual is a mammal, such as a mouse or a human, preferably a human.</p><p id="p-0153" num="0152">In some aspects, the present invention relates to the use of the PD-L1 binding molecule as disclosed herein in the preparation of a drug for treating or preventing a disease associated with PD-L1.</p><p id="p-0154" num="0153">In some aspects, the present invention relates to the use of the PD-L1 single-domain antibody or the antigen-binding fragment thereof as disclosed herein in the preparation of a drug for treating or preventing a disease associated with PD-L1.</p><p id="p-0155" num="0154">In some embodiments, the disease associated with PD-L1 is selected from, but is not limited to renal cell carcinoma, non-small cell lung cancer, bladder cancer, urothelial carcinoma, microsatellite unstable solid tumor, etc.</p><p id="p-0156" num="0155">In some aspects, the present invention relates to a kit or a device and a related method of using the PD-L1 binding molecule, the PD-L1 single-domain antibody or the antigen-binding fragment thereof as disclosed herein, and the pharmaceutical composition as disclosed herein, which can be used for treating a disease associated with PD-L1, such as cancers. To this end, the present invention preferably provides an article that can be used for treating such conditions, which comprises a container comprising the PD-L1 binding molecule, the PD-L1 single-domain antibody or the antigen-binding fragment thereof as disclosed herein, and an explanatory material of using the PD-L1 single-domain antibody or the antigen-binding fragment thereof as disclosed herein to treat, improve or prevent a disease associated with PD-L1 or progression or relapse thereof.</p><p id="p-0157" num="0156">The present invention also encompasses any combinations of any embodiments described herein. Any embodiments or any combinations thereof described herein are applicable to any and all PD-L1 binding molecules, PD-L1 single-domain antibodies or antigen-binding fragments thereof, methods and uses thereof of the present invention described herein.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0005" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0158" num="0157"><figref idref="DRAWINGS">FIG. <b>1</b></figref> shows the results of screening for binding affinity of VHH antibody lysate samples that bind to PD-L1.</p><p id="p-0159" num="0158"><figref idref="DRAWINGS">FIG. <b>2</b></figref> shows the screening results of blocking assay of anti-PD-L1 candidate antibody molecules.</p><p id="p-0160" num="0159"><figref idref="DRAWINGS">FIG. <b>3</b></figref> shows the verification results of cell binding assay of candidate antibody molecules: (A) isotype control, (B) NB22D-21, (C) NB22gb-10, and (D) positive control KN035.</p><p id="p-0161" num="0160"><figref idref="DRAWINGS">FIG. <b>4</b></figref> shows the verification results of specific binding reaction assay of the NB22D-21 molecule.</p><p id="p-0162" num="0161"><figref idref="DRAWINGS">FIG. <b>5</b></figref> shows the verification results of mixed lymphocyte reaction assay of the NB22D-21 molecule.</p><p id="p-0163" num="0162"><figref idref="DRAWINGS">FIG. <b>6</b></figref> shows the verification results of binding assay of the NB22D-21 molecule and the humanized modified derivative molecules thereof.</p><p id="p-0164" num="0163"><figref idref="DRAWINGS">FIG. <b>7</b></figref> shows the results of human-mouse cross reaction assay of the NB22D-21 molecule and the humanized modified derivative molecules thereof.</p><p id="p-0165" num="0164"><figref idref="DRAWINGS">FIG. <b>8</b></figref> shows the results of the peak plots in flow cytometry of human-mouse cross reaction assay of the humanized modified derivative molecule NB22D-21-huVH1: (A) control molecule KN035, and (B) NB22D-21-huVH1.</p><p id="p-0166" num="0165"><figref idref="DRAWINGS">FIG. <b>9</b></figref> shows the results of blocking activity on binding of the NB22D-21 molecule and the humanized modified molecules thereof.</p><p id="p-0167" num="0166"><figref idref="DRAWINGS">FIG. <b>10</b></figref> shows the results of affinity assay of the affinity-matured molecules on PD-L1-CHO.</p><p id="p-0168" num="0167"><figref idref="DRAWINGS">FIG. <b>11</b></figref> shows the binding of PD-1 to PD-L1-CHO cells blocked by the affinity-matured molecules.</p><p id="p-0169" num="0168"><figref idref="DRAWINGS">FIG. <b>12</b></figref> shows the affinity assay of the second affinity-matured molecules binding to human PD-L1-CHO cells.</p><p id="p-0170" num="0169"><figref idref="DRAWINGS">FIG. <b>13</b></figref> shows the blocking activity assay of the second affinity-matured molecules in PD-1 binding to human PD-L1-CHO cells.</p><p id="p-0171" num="0170"><figref idref="DRAWINGS">FIG. <b>14</b></figref> shows the binding assay of the second affinity-matured molecules to mouse PD-L1 cells.</p><p id="p-0172" num="0171"><figref idref="DRAWINGS">FIG. <b>15</b></figref> shows the blocking activity of druggability-modified molecules in PD-L1-CHO, wherein the isotype control is human IgG1.</p><p id="p-0173" num="0172"><figref idref="DRAWINGS">FIG. <b>16</b></figref> shows the effect of druggability-modified molecules on the secretion of IFN-&#x3b3; (A) and IL-2 (B) in the mixed lymphocyte reaction.</p><p id="p-0174" num="0173"><figref idref="DRAWINGS">FIG. <b>17</b></figref> shows the sequence alignment of candidate antibody molecules, wherein the CDR sequences are marked with boxes.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0006" level="1">OVERVIEW OF THE SEQUENCE LISTING</heading><p id="p-0175" num="0174">The present application is accompanied by a Sequence Listing containing numerous nucleotide and amino acid sequences. Tables A, B and C below provide an overview of the sequences included.</p><p id="p-0176" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="441pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;A</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Heavy&#x2003;chain&#x2003;variable&#x2003;region&#x2003;CDR&#x2003;sequences&#x2003;of&#x2003;antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="56pt" align="left"/><colspec colname="5" colwidth="35pt" align="left"/><colspec colname="6" colwidth="49pt" align="left"/><colspec colname="7" colwidth="28pt" align="left"/><colspec colname="8" colwidth="84pt" align="left"/><tbody valign="top"><row><entry/><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/></row><row><entry/><entry/><entry>ID</entry><entry/><entry>ID</entry><entry/><entry>ID</entry><entry/></row><row><entry>Description</entry><entry>Clone&#x2003;name</entry><entry>NO:</entry><entry>CDR1</entry><entry>NO:</entry><entry>CDR2</entry><entry>NO:</entry><entry>CDR3</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row><row><entry>Positive&#x2003;control</entry><entry>KN035</entry><entry>32</entry><entry>GFTFSRRCKA</entry><entry>33</entry><entry>KILTTSGSTY</entry><entry>34</entry><entry>DSFEDPTCTLVTSSGAFQY</entry></row><row><entry> </entry></row><row><entry>Alpaca&#x2003;screening</entry><entry>NB22D-21</entry><entry>&#x2003;1</entry><entry>RTDSNINGMH</entry><entry>&#x2003;2</entry><entry>TIFIDGNTI</entry><entry>&#x2003;3</entry><entry>DVSGYGRA</entry></row><row><entry> </entry></row><row><entry>Humanization</entry><entry>NB22D-21-huVH2</entry><entry>&#x2003;1</entry><entry>RTDSNINGMH</entry><entry>&#x2003;2</entry><entry>TIFIDGNTI</entry><entry>&#x2003;3</entry><entry>DVSGYGRA</entry></row><row><entry> </entry></row><row><entry>Humanization</entry><entry>NB22D-21-huVH1</entry><entry>&#x2003;1</entry><entry>RTDSNINGMH</entry><entry>&#x2003;2</entry><entry>TIFIDGNTI</entry><entry>&#x2003;3</entry><entry>DVSGYGRA</entry></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>SY01-201</entry><entry>&#x2003;4</entry><entry>RTDSNIHGMH</entry><entry>&#x2003;5</entry><entry>TIFIDLNTI</entry><entry>&#x2003;3</entry><entry>DVSGYGRA</entry></row><row><entry>maturation</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>SY01-208</entry><entry>&#x2003;6</entry><entry>RTDSNIFGMH</entry><entry>&#x2003;7</entry><entry>TIFIDANTI</entry><entry>&#x2003;3</entry><entry>DVSGYGRA</entry></row><row><entry>maturation</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>SY01-NB-004</entry><entry>&#x2003;1</entry><entry>RTDSNINGMH</entry><entry>&#x2003;8</entry><entry>TIFIDGNTI</entry><entry>&#x2003;9</entry><entry>DVSGYGRY</entry></row><row><entry>maturation</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>SY01-NB-027-M</entry><entry>10</entry><entry>RTDSNINSMH</entry><entry>11</entry><entry>TWFIDGNTI</entry><entry>12</entry><entry>DEWMYGRA</entry></row><row><entry>maturation</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Druggability</entry><entry>NB22D-21-4</entry><entry>13</entry><entry>RTDRNINTMH</entry><entry>&#x2003;5</entry><entry>TIFIDLNTI</entry><entry>&#x2003;3</entry><entry>DVSGYGRA</entry></row><row><entry>modification</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Druggability</entry><entry>NB22D-21-8</entry><entry>14</entry><entry>RTYSNIYGMH</entry><entry>15</entry><entry>TIFIGSNTI</entry><entry>&#x2003;3</entry><entry>DVSGYGRA</entry></row><row><entry>modification</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Druggability</entry><entry>NB22D-21-17</entry><entry>16</entry><entry>RTGSNIYGMH</entry><entry>17</entry><entry>TIFIDWNTI</entry><entry>&#x2003;3</entry><entry>DVSGYGRA</entry></row><row><entry>modification</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Druggability</entry><entry>NB22D-21-24</entry><entry>18</entry><entry>RTFSNIFGMH</entry><entry>19</entry><entry>TIFITGNTI</entry><entry>&#x2003;3</entry><entry>DVSGYGRA</entry></row><row><entry>modification</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Druggability</entry><entry>NB22D-21-47</entry><entry>20</entry><entry>RTLSNIRGMH</entry><entry>5</entry><entry>TIFIDLNTI</entry><entry>&#x2003;3</entry><entry>DVSGYGRA</entry></row><row><entry>modification</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>NB22D-21-45-106</entry><entry>21</entry><entry>RRWSNIHGMH</entry><entry>22</entry><entry>SRFITGNTI</entry><entry>23</entry><entry>DVRGYGRA</entry></row><row><entry>maturation</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>NB22D-21-123</entry><entry>24</entry><entry>PTASNIHGMH</entry><entry>25</entry><entry>MIFITGLTI</entry><entry>&#x2003;3</entry><entry>DVSGYGRA</entry></row><row><entry>maturation</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>NB22D-21-154</entry><entry>26</entry><entry>RTASNAMGMH</entry><entry>2?</entry><entry>MIFRDGNTI</entry><entry>23</entry><entry>DVRGYGRA</entry></row><row><entry>maturation</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>NB22D-21-94</entry><entry>28</entry><entry>RTAGNIHGMH</entry><entry>29</entry><entry>SIFITGNTI</entry><entry>23</entry><entry>DVRGYGRA</entry></row><row><entry>maturation</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>NB22D-21-109</entry><entry>30</entry><entry>RTAGYIHGMH</entry><entry>31</entry><entry>MIFGWGNTI</entry><entry>23</entry><entry>DVRGYGRA</entry></row><row><entry>maturation</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0177" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="399pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE B</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>VH sequences of antibodies, with the CDRs marked with boxes</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="280pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>SEQ</entry><entry/></row><row><entry/><entry/><entry>ID</entry><entry/></row><row><entry>Description</entry><entry>Clone</entry><entry>NO:</entry><entry>VH region</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>Positive control</entry><entry>KN035</entry><entry>35</entry><entry><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="11.77mm" wi="96.35mm" file="US20230002494A1-20230105-C00001.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Alpaca screening</entry><entry>NB22D-21</entry><entry>36</entry><entry><chemistry id="CHEM-US-00002" num="00002"><img id="EMI-C00002" he="11.94mm" wi="94.91mm" file="US20230002494A1-20230105-C00002.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Humanization</entry><entry>NB22D-21- huVH2</entry><entry>37</entry><entry><chemistry id="CHEM-US-00003" num="00003"><img id="EMI-C00003" he="11.85mm" wi="96.35mm" file="US20230002494A1-20230105-C00003.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Humanization</entry><entry>NB22D-21- huVH1</entry><entry>38</entry><entry><chemistry id="CHEM-US-00004" num="00004"><img id="EMI-C00004" he="11.85mm" wi="96.35mm" file="US20230002494A1-20230105-C00004.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Affinity maturation</entry><entry>SY01-201</entry><entry>39</entry><entry><chemistry id="CHEM-US-00005" num="00005"><img id="EMI-C00005" he="11.94mm" wi="96.35mm" file="US20230002494A1-20230105-C00005.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Affinity maturation</entry><entry>SY01-208</entry><entry>40</entry><entry><chemistry id="CHEM-US-00006" num="00006"><img id="EMI-C00006" he="11.85mm" wi="96.35mm" file="US20230002494A1-20230105-C00006.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Affinity maturation</entry><entry>SY01- NB-004</entry><entry>41</entry><entry><chemistry id="CHEM-US-00007" num="00007"><img id="EMI-C00007" he="11.77mm" wi="96.35mm" file="US20230002494A1-20230105-C00007.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Affinity maturation</entry><entry>SY01-NB- 027-M</entry><entry>42</entry><entry><chemistry id="CHEM-US-00008" num="00008"><img id="EMI-C00008" he="11.77mm" wi="94.91mm" file="US20230002494A1-20230105-C00008.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Druggability modification</entry><entry>SY01- D21-4</entry><entry>43</entry><entry><chemistry id="CHEM-US-00009" num="00009"><img id="EMI-C00009" he="11.77mm" wi="96.35mm" file="US20230002494A1-20230105-C00009.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Druggability modification</entry><entry>SY01- D21-8</entry><entry>44</entry><entry><chemistry id="CHEM-US-00010" num="00010"><img id="EMI-C00010" he="11.77mm" wi="96.35mm" file="US20230002494A1-20230105-C00010.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Druggability modification</entry><entry>SY01- D21-17</entry><entry>45</entry><entry><chemistry id="CHEM-US-00011" num="00011"><img id="EMI-C00011" he="11.94mm" wi="96.35mm" file="US20230002494A1-20230105-C00011.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Druggability modification</entry><entry>SY01- D21-24</entry><entry>46</entry><entry><chemistry id="CHEM-US-00012" num="00012"><img id="EMI-C00012" he="11.94mm" wi="97.87mm" file="US20230002494A1-20230105-C00012.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Druggability modification</entry><entry>SY01- D21-47</entry><entry>47</entry><entry><chemistry id="CHEM-US-00013" num="00013"><img id="EMI-C00013" he="11.94mm" wi="96.35mm" file="US20230002494A1-20230105-C00013.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Affinity maturation</entry><entry>NB22D- 21-45-106</entry><entry>48</entry><entry><chemistry id="CHEM-US-00014" num="00014"><img id="EMI-C00014" he="12.02mm" wi="94.91mm" file="US20230002494A1-20230105-C00014.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Affinity maturation</entry><entry>NB22D- 21-123</entry><entry>49</entry><entry><chemistry id="CHEM-US-00015" num="00015"><img id="EMI-C00015" he="11.85mm" wi="96.35mm" file="US20230002494A1-20230105-C00015.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Affinity maturation</entry><entry>NB22D- 21-154</entry><entry>50</entry><entry><chemistry id="CHEM-US-00016" num="00016"><img id="EMI-C00016" he="12.02mm" wi="93.39mm" file="US20230002494A1-20230105-C00016.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Affinity maturation</entry><entry>NB22D- 21-94</entry><entry>51</entry><entry><chemistry id="CHEM-US-00017" num="00017"><img id="EMI-C00017" he="11.94mm" wi="96.35mm" file="US20230002494A1-20230105-C00017.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry> </entry></row><row><entry>Affinity maturation</entry><entry>NB22D- 21-109</entry><entry>52</entry><entry><chemistry id="CHEM-US-00018" num="00018"><img id="EMI-C00018" he="12.02mm" wi="93.39mm" file="US20230002494A1-20230105-C00018.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry namest="1" nameend="4" align="left" id="FOO-00001">Notes:</entry></row><row><entry namest="1" nameend="4" align="left" id="FOO-00002">the CDR1-3 sequences are marked with boxes.</entry></row></tbody></tgroup></table></tables></p><p id="p-0178" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="441pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;C</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>FR&#x2003;sequences&#x2003;of&#x2003;antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="10"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="28pt" align="left"/><colspec colname="4" colwidth="63pt" align="left"/><colspec colname="5" colwidth="28pt" align="left"/><colspec colname="6" colwidth="42pt" align="left"/><colspec colname="7" colwidth="28pt" align="left"/><colspec colname="8" colwidth="84pt" align="left"/><colspec colname="9" colwidth="21pt" align="left"/><colspec colname="10" colwidth="35pt" align="left"/><tbody valign="top"><row><entry/><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/></row><row><entry/><entry>Clone</entry><entry>ID</entry><entry/><entry>ID</entry><entry/><entry>ID</entry><entry/><entry>ID</entry><entry/></row><row><entry>Description</entry><entry>name</entry><entry>NO:</entry><entry>FR1</entry><entry>NO:</entry><entry>FR2</entry><entry>NO:</entry><entry>FR3</entry><entry>NO:</entry><entry>FR4</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row><row><entry>Positive</entry><entry>KN03S</entry><entry>62</entry><entry>QVQLVESGGGLV</entry><entry>63</entry><entry>WFRQAPGK</entry><entry>64</entry><entry>LADSVKGRFTISRDNSKN</entry><entry>65</entry><entry>WGQGTL</entry></row><row><entry>control</entry><entry/><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>ERERVA</entry><entry/><entry>TVYLQMNSLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Alpaca</entry><entry>NB22D-21</entry><entry>53</entry><entry>EVQVQESGGGLV</entry><entry>54</entry><entry>WYRQAPGK</entry><entry>55</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>56</entry><entry>WGQGTQ</entry></row><row><entry>screening</entry><entry/><entry/><entry>QAGGSLRLSCAHS</entry><entry/><entry>QRDWVG</entry><entry/><entry>TLYLQMNTLKPEDTAVYF</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>CAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Humanization</entry><entry>NB22D-21-</entry><entry>57</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry/><entry>huVH2</entry><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Humanization</entry><entry>NB22D-21-</entry><entry>61</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry/><entry>huVH1</entry><entry/><entry>QPGGSLRLSCAHS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>SY01-201</entry><entry>61</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>maturation</entry><entry/><entry/><entry>QPGGSLRLSCAHS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>SY01-208</entry><entry>61</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>maturation</entry><entry/><entry/><entry>QPGGSLRLSCAHS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>SYO1-NB-</entry><entry>61</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>maturation</entry><entry>004</entry><entry/><entry>QPGGSLRLSCAHS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>SY01-NB-</entry><entry>61</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>maturation</entry><entry>027-M</entry><entry/><entry>QPGGSLRLSCAHS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Druggability</entry><entry>NB22D-21-</entry><entry>57</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>modification</entry><entry>4</entry><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Druggability</entry><entry>Nb220-21-</entry><entry>57</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>modification</entry><entry>8</entry><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Druggability</entry><entry>NB22D-21-</entry><entry>57</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>modification</entry><entry>17</entry><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Druggability</entry><entry>NB22D-21-</entry><entry>57</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>modification</entry><entry>24</entry><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Druggability</entry><entry>NB22D-21-</entry><entry>57</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>modification</entry><entry>47</entry><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>NB22D-21-</entry><entry>57</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>maturation</entry><entry>45-106</entry><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>NB22D-21-</entry><entry>57</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>maturation</entry><entry>123</entry><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>NB22D-21-</entry><entry>57</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>maturation</entry><entry>154</entry><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>NB22D-21-</entry><entry>57</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>69</entry><entry>WGQGTT</entry></row><row><entry>maturation</entry><entry>94</entry><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Affinity</entry><entry>NB22D-21-</entry><entry>57</entry><entry>EVQLVESGGGLV</entry><entry>58</entry><entry>WYRQAPGK</entry><entry>59</entry><entry>VTDSVKGRFTISRDNAKN</entry><entry>60</entry><entry>WGQGTT</entry></row><row><entry>maturation</entry><entry>109</entry><entry/><entry>QPGGSLRLSCAAS</entry><entry/><entry>GREWVG</entry><entry/><entry>TLYLQMNTLRAEDTAVY</entry><entry/><entry>VTVSS</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>YCAA</entry></row><row><entry namest="1" nameend="10" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0007" level="1">DETAILED DESCRIPTION OF EMBODIMENTS</heading><p id="p-0179" num="0175">It is to be understood by a person skilled in the art that the present invention is not limited to the specific methodology, embodiments and reagents described herein, because these are exemplary illustrations. It is also to be understood that the terminology used herein is merely for description of specific embodiments, and is not intended to limit the scope of the present invention which is defined only by the appended claims.</p><p id="p-0180" num="0176">Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which the present invention pertains.</p><p id="p-0181" num="0177">In addition, unless the context requires otherwise, terms in the singular form shall include the plural form, and terms in the plural form shall include the singular form. More specifically, as used in the present specification and in the appended claims, the singular forms &#x201c;a/an&#x201d; and &#x201c;the&#x201d; include plural referents unless the context clearly dictates otherwise. Therefore, for example, reference to &#x201c;an antibody&#x201d; includes multiple antibodies.</p><heading id="h-0008" level="1">I. Definitions</heading><p id="p-0182" num="0178">To better understand the present invention, definitions and explanations of related terms are provided below.</p><p id="p-0183" num="0179">The term &#x201c;about&#x201d; when used in connection with a numerical value is meant to encompass numerical values within a range having a lower limit that is 5% smaller than the specified numerical value and an upper limit that is 5% larger than the specified numerical value.</p><p id="p-0184" num="0180">The term &#x201c;antibody&#x201d; herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) and antibody fragments so long as they exhibit the desired antigen-binding activity. A complete antibody generally will comprise at least two full-length heavy chains and two full-length light chains, but in some instances may include fewer chains, for example, naturally-occurring antibodies in camelids may comprise only heavy chains.</p><p id="p-0185" num="0181">As used herein, the term &#x201c;antigen-binding moiety&#x201d; refers to a moiety that specifically binds to a target antigen. The term includes antibodies and other natural molecules (e.g., receptors and ligands) or synthetic molecules (e.g. DARPins) capable of specifically binding to a target antigen. In one preferred embodiment, the antigen-binding moiety of the antibody of the present invention is an antibody fragment.</p><p id="p-0186" num="0182">The terms &#x201c;full-length antibody&#x201d;, &#x201c;intact antibody&#x201d;, and &#x201c;complete antibody&#x201d; are used herein interchangeably to refer to an antibody having a structure substantially similar to that of a natural antibody or having heavy chains that contain an Fc region.</p><p id="p-0187" num="0183">As used herein, the term &#x201c;monoclonal antibody&#x201d; or &#x201c;monoclonal antibody composition&#x201d; refers to a preparation of an antibody molecule having a single amino acid composition, not to the method by which it is produced. Monoclonal antibodies or antigen-binding fragments thereof can be produced, for example, by hybridoma techniques, recombinant techniques, phage display techniques, synthetic techniques such as CDR grafting, or combinations of such or other techniques known in the art.</p><p id="p-0188" num="0184">As used herein, the term &#x201c;PD-1&#x201d; refers to a programmed cell death protein, which belongs to an immunoglobulin superfamily and functions as a co-inhibitory receptor to negatively modulate the immune system. PD-1 is a member of the CD28/CTLA-4 family, and has two known ligands including PD-L1 and PD-L2. Alternative names or synonyms for PD-1 include PDCD1, PD1, CD279, SLEB2, etc. A representative amino acid sequence of human PD-1 is disclosed under the NCBI accession number: NP_005009.2, and a representative nucleic acid sequence encoding the human PD-1 is shown under the NCBI accession number: NM 005018.3.</p><p id="p-0189" num="0185">As used herein, the term &#x201c;PD-L1&#x201d; refers to programmed cell death ligand 1 (PD-L1, see, for example, Freeman et al. (2000) J. Exp. Med. 192: 1027). Alternative names or synonyms for PD-L1 include PDCD1L1, PDL1, B7H1, CD274, B7-H, etc. A representative amino acid sequence of human PD-L1 is disclosed under the NCBI accession number: NP_054862.1, and a representative nucleic acid sequence encoding the human PD-L1 is shown under the NCBI accession number: NM 014143.4. PD-L1 is expressed in placenta, spleen, lymph nodes, thymus, heart and fetal liver, and is also found in many tumor or cancer cells. PD-L1 binds to its receptor PD-1 or B7-1 which is expressed on activated T cells, B cells and myeloid cells. The binding of PD-L1 to its receptor induces signal transduction to inhibit TCR-mediated activation of cytokine production and T cell proliferation. Accordingly, PD-L1 plays a major role in suppressing the immune system during particular events such as pregnancy, autoimmune diseases and tissue allografts, and is considered to allow tumor or cancer cells to bypass the immune checkpoints and evade the immune response.</p><p id="p-0190" num="0186">As used herein, the terms &#x201c;binding&#x201d; and &#x201c;specific binding&#x201d; refer to the binding of an antibody or an antigen-binding moiety to an epitope in an in vitro assay, preferably in a bio-optical interferometry (ForteBio) with a purified wild-type antigen.</p><p id="p-0191" num="0187">In certain embodiments, an antibody or an antigen-binding moiety is said to specifically bind an antigen when it preferentially recognizes its target antigen in a complex mixture of proteins and/or macromolecules.</p><p id="p-0192" num="0188">Antibodies are divided into the following &#x201c;classes&#x201d;: IgA, IgD, IgE, IgG and IgM, depending on the amino acid sequence of the heavy chain constant region thereof, and several of these classes may be further divided into subclasses, such as IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. The heavy chain constant regions corresponding to different classes of antibodies are called [image] &#x3b4;, &#x3b5;, &#x3b3; and &#x3bc;, respectively. The light chain constant regions (CLs) that can be found in all five antibody classes are called &#x3ba; and &#x3bb;. Within full-length light and heavy chains, the variable and constant regions are typically linked by the &#x201c;J&#x201d; region of about 12 or more amino acids, and the heavy chain also includes the &#x201c;D&#x201d; region of about 10 or more amino acids. See, for example, Fundamental Immunology, Ch. 7 (Paul, W. ed., 2nd edition, Raven Press, N.Y. (1989)) (which is incorporated herein by reference in its entirety for all purposes). The variable regions of each light/heavy chain pair typically form antigen-binding sites.</p><p id="p-0193" num="0189">The term &#x201c;variable region&#x201d; or &#x201c;variable domain&#x201d; refers to an antibody heavy or light chain domain that is involved in the binding of an antibody to an antigen. The heavy and light chain variable domains of a natural antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three complementarity determining regions (CDRs) (see, for example, Kindt et al., Kuby Immunology, 6<sup>th </sup>ed., W.H. Freeman and Co., page 91 (2007)). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, an antibody that binds to a particular antigen may be isolated using a VH or VL domain from the antibody that binds to the antigen to screen a library of complementary VL or VH domains, respectively. See, for example, Portolano, et al., J. Immunol. 150: 880-887 (1993); Clarkson, et al., Nature 352: 624-628 (1991). The FRs and CDRs in the present disclosure are divided according to the AbM standard, but it must be pointed out that the CDRs in the present disclosure are not limited to the division method of AbM, and can further be divided according to any other conventional division methods in the art, such as Chothia, Martin, Kabat, AHo and IMGT.</p><p id="p-0194" num="0190">The variable regions typically exhibit the same general structure as the relatively conserved framework regions (FRs) linked by three hypervariable regions which also called complementarity determining regions or CDRs. Generally, the CDRs from both chains of each pair are aligned by the framework regions, which CDRs allow the antibody to bind to a specific epitope. Two light and heavy chain variable regions typically comprise, from N-terminus to C-terminus, the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.</p><p id="p-0195" num="0191">An &#x201c;antibody fragment&#x201d; refers to a molecule other than a complete antibody that comprises a portion of the complete antibody, which portion binds to the antigen to which the complete antibody binds.</p><p id="p-0196" num="0192">&#x201c;Affinity&#x201d; refers to the strength of the sum of all non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and a binding partner thereof (e.g., an antigen). Unless otherwise specified, &#x201c;binding affinity&#x201d; when used herein refers to an intrinsic binding affinity that reflects 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of molecule X for the partner thereof, Y, can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those known in the art and described herein.</p><p id="p-0197" num="0193">As used herein, the term &#x201c;EC<sub>50</sub>&#x201d;, also referred to as &#x201c;half maximal effective concentration&#x201d;, refers to the concentration of a drug, antibody or toxic agent which induces a response at 50% between the baseline and the maximum after a specific exposure time. In the context of the present application, the unit of EC<sub>50 </sub>is &#x201c;nM&#x201d;.</p><p id="p-0198" num="0194">A &#x201c;human antibody&#x201d; refers to an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by human or human cells or derived from a non-human source using human antibody repertoire or other human antibody coding sequences. This definition of a human antibody explicitly excludes a humanized antibody comprising non-human antigen-binding residues.</p><p id="p-0199" num="0195">A &#x201c;human consensus framework&#x201d; refers to a framework representing the most frequently occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is a selection from a subtype of variable domain sequences. Generally, the subtype of the sequences is the subtype as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5<sup>th </sup>edition, NIH Publication 91-3242, Bethesda Md. (1991), vol. 1-3. In one embodiment, for VL, the subtype is the subtype &#x3ba; I as described in Kabat et al. (supra). In one embodiment, for VH, the subtype is the subtype III as described in Kabat et al. (supra).</p><p id="p-0200" num="0196">A &#x201c;humanized&#x201d; antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In some embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A &#x201c;humanized form&#x201d; of an antibody (e.g., a non-human antibody) refers to an antibody that has undergone humanization.</p><p id="p-0201" num="0197">The term &#x201c;conservative substitution&#x201d; refers to substitution of an amino acid by another amino acid within the same class, for example, substitution of an acidic amino acid by another acidic amino acid, substitution of a basic amino acid by another basic amino acid, or substitution of a neutral amino acid by another neutral amino acid. Exemplary substitutions are shown in Table D below:</p><p id="p-0202" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE D</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Exemplary substitutions</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="105pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><tbody valign="top"><row><entry>Original</entry><entry/><entry>Conservative</entry></row><row><entry>residue</entry><entry>Exemplary substitution</entry><entry>substitution</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>Ala (A)</entry><entry>Val; Leu; He</entry><entry>Val</entry></row><row><entry>Arg (R)</entry><entry>Lys; Gln; Asn</entry><entry>Lys</entry></row><row><entry>Asn (N)</entry><entry>Gln; His; Asp, Lys; Arg</entry><entry>Gln</entry></row><row><entry>Asp (D)</entry><entry>Glu; Asn</entry><entry>Glu</entry></row><row><entry>Cys (C)</entry><entry>Ser; Ala</entry><entry>Ser</entry></row><row><entry>Gln (Q)</entry><entry>Asn; Glu</entry><entry>Asn</entry></row><row><entry>Glu (E)</entry><entry>Asp; Gln</entry><entry>Asp</entry></row><row><entry>Gly (G)</entry><entry>Ala</entry><entry>Ala</entry></row><row><entry>His (H)</entry><entry>Asn; Gln; Lys; Arg</entry><entry>Arg</entry></row><row><entry>Ile (I)</entry><entry>Leu; Val; Met; Ala; Phe; Norleucine</entry><entry>Leu</entry></row><row><entry>Leu (L)</entry><entry>Norleucine; Ile; Val; Met; Ala; Phe</entry><entry>Ile</entry></row><row><entry>Lys (K)</entry><entry>Arg; Gln; Asn</entry><entry>Arg</entry></row><row><entry>Met (M)</entry><entry>Leu; Phe; Ile</entry><entry>Leu</entry></row><row><entry>Phe (F)</entry><entry>Trp; Leu; Val; Ile; Ala; Tyr</entry><entry>Tyr</entry></row><row><entry>Pro (P)</entry><entry>Ala</entry><entry>Ala</entry></row><row><entry>Ser (S)</entry><entry>Thr</entry><entry>Thr</entry></row><row><entry>Thr (T)</entry><entry>Val; Ser</entry><entry>Ser</entry></row><row><entry>Trp (W)</entry><entry>Tyr; Phe</entry><entry>Tyr</entry></row><row><entry>Tyr (Y)</entry><entry>Trp; Phe; Thr; Ser</entry><entry>Phe</entry></row><row><entry>Val (V)</entry><entry>Ile; Leu; Met; Phe; Ala; Norleucine</entry><entry>Leu</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0203" num="0198">Amino acids can be grouped according to the properties of common side chains:</p><p id="p-0204" num="0199">(1) hydrophobic: Norleucine, Met, Ala, Val, Leu, and Be;</p><p id="p-0205" num="0200">(2) neutral hydrophilic: Cys, Ser, Thr, Asn, and Gln;</p><p id="p-0206" num="0201">(3) acidic: Asp and Glu;</p><p id="p-0207" num="0202">(4) basic: His, Lys, and Arg;</p><p id="p-0208" num="0203">(5) residues that influence chain orientation: Gly and Pro;</p><p id="p-0209" num="0204">(6) aromatic: Trp, Tyr, and Phe.</p><p id="p-0210" num="0205">Non-conservative substitutions will entail exchanging a member of one of these classes for another class.</p><p id="p-0211" num="0206">One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized antibody). Generally, the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity and reduced immunogenicity) relative to a parent antibody, and/or will have specific biological properties that are substantially retained by the parent antibody. An exemplary substitutional variant is an affinity-matured antibody, which can be conveniently produced by, for example, using phage-based affinity maturation techniques such as those described herein. In short, one or more HVR residues are mutated, and the variant antibodies are displayed on phages and screened for a particular biological activity (e.g., binding affinity).</p><p id="p-0212" num="0207">The &#x201c;percent (%) amino acid sequence identity&#x201d; with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment of sequences for the purpose of determining percent amino acid sequence identity can be achieved by using a variety of methods in the art, for instance, using publicly available computer software, such as BLAST, BLAST-2, ALIGN or MEGALIGN (DNASTAR) software. A person skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. When percentages of sequence identity are referred to in the present application, these percentages are calculated with respect to the full length of the longer sequence, unless otherwise specified. This calculation with respect to the full length of the longer sequence applies to both nucleic acid sequences and polypeptide sequences.</p><p id="p-0213" num="0208">The terms &#x201c;effective amount&#x201d; and &#x201c;therapeutically effective amount&#x201d; refer to the amount or dose of the antibody of the present invention or the antigen-binding fragment, which upon administration to a patient in a single or multiple doses, produces the desired effect in a subject being treated, including the improvement in the condition of the subject (e.g., the improvement in one or more symptoms) and/or the delay in the progression of symptoms. The &#x201c;effective amount&#x201d; and &#x201c;therapeutically effective amount&#x201d; can also refer to an amount sufficient to reduce PD-L1 signaling.</p><p id="p-0214" num="0209">The effective amount can be readily determined by the attending physician as a person skilled in the art with consideration of a variety of factors, such as the species of the mammal; the size, age and general health thereof; the specific disease involved; the extent or severity of the disease; the response of an individual patient; the specific antibody administered; the mode of administration; the bioavailability characteristics of the formulation administered; the selected dosing regimen; and use of any concomitant therapy.</p><p id="p-0215" num="0210">The term &#x201c;blocking&#x201d; used herein indicates reducing PD-L1 signaling in the presence of the antibody of the present invention. Blocking of PD-L1-mediated signaling means that the PD-L1 signaling level in the presence of the PD-L1 single-domain antibody of the present invention is lower than the control PD-L1 level (namely, the PD-L1 signaling level in the absence of the antibody), with the reduction range greater than or equal to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100%. The PD-L1 signaling level can be measured by using a variety of standard techniques, such as, by way of non-limiting examples, luciferase reporter assays which measure the activation of the downstream gene and/or the activation in response to PD-L1. It is understood by a person skilled in the art that the PD-L1 signaling level can be measured by using a variety of assays, including, for example, commercially available kits.</p><p id="p-0216" num="0211">The terms &#x201c;host cell&#x201d;, &#x201c;host cell line&#x201d;, and &#x201c;host cell culture&#x201d; are used interchangeably and refer to the cell into which exogenous nucleic acid is introduced, including the progeny of such cell. The host cell includes a &#x201c;transformant&#x201d; and a &#x201c;transformed cell&#x201d;, which includes a primary transformed cell and the progeny derived therefrom regardless of the number of passages. The progeny may be not completely identical to the parent cell in terms of nucleic acid content, but may contain mutations. The mutant progeny that has the same function or biological activity screened or selected in the original transformed cell is included herein.</p><p id="p-0217" num="0212">The term &#x201c;vector&#x201d; when used herein denotes a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure and the vector incorporated into the genome of a host cell into which it has been introduced. Some vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as &#x201c;expression vectors&#x201d;.</p><p id="p-0218" num="0213">An &#x201c;individual&#x201d; or &#x201c;subject&#x201d; includes mammals. Mammals include, but are not limited to, domesticated animals (e.g., cattles, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, alpacas, and rodents (e.g., mice and rats). In some embodiments, the individual or subject is a human.</p><heading id="h-0009" level="1">II. PD-L1 Single-Domain Antibodies or Antigen-Binding Fragments Thereof</heading><p id="p-0219" num="0214">The isolated PD-L1 binding molecule of the present invention can be a single-domain antibody or an antigen-binding fragment thereof. In other words, the present invention provides an isolated PD-L1 single-domain antibody or an antigen-binding fragment thereof, which is capable of specifically binding to PD-L1.</p><p id="p-0220" num="0215">Therefore, the present invention also provides the following embodiments:</p><p id="p-0221" num="0216">1. An isolated PD-L1 single-domain antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0222" num="0217">(i) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1;</p><p id="p-0223" num="0218">a CDR1 comprising an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 1; or</p><p id="p-0224" num="0219">a CDR1 comprising an amino acid sequence which differs from SEQ ID NO: 1 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0225" num="0220">(ii) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2;</p><p id="p-0226" num="0221">a CDR2 comprising an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 2; or</p><p id="p-0227" num="0222">a CDR2 comprising an amino acid sequence which differs from SEQ ID NO: 2 by no more than 2 (e.g., 0, 1, and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0228" num="0223">and</p><p id="p-0229" num="0224">(iii) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3 or 12;</p><p id="p-0230" num="0225">a CDR3 comprising an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 3 or 12; or</p><p id="p-0231" num="0226">a CDR3 comprising an amino acid sequence which differs from SEQ ID NO: 3 or 12 by no more than 2 (e.g., 0, 1, and 2) amino acid additions, deletions and/or substitutions.</p><p id="p-0232" num="0227">2. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 1, wherein the heavy chain variable region comprises:</p><p id="p-0233" num="0228">(i) a CDR1 as shown in formula RTDSNIX<sub>1</sub>GMH, wherein X<sub>1 </sub>is H, F or N;</p><p id="p-0234" num="0229">(ii) a CDR2 as shown in formula TIFIDX<sub>2</sub>NTX<sub>3</sub>, wherein X<sub>2 </sub>is G, L or A, and X<sub>3 </sub>is I or L; and</p><p id="p-0235" num="0230">(iii) a CDR3 as shown in formula DVSGYGRX<sub>4</sub>, wherein X<sub>4 </sub>is A or Y.</p><p id="p-0236" num="0231">3. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 1, wherein the heavy chain variable region comprises:</p><p id="p-0237" num="0232">(i) a CDR1 comprising or consisting of SEQ ID NO: 1;</p><p id="p-0238" num="0233">(ii) a CDR2 comprising or consisting of SEQ ID NO: 2; and</p><p id="p-0239" num="0234">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0240" num="0235">4. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 1, wherein the heavy chain variable region comprises:</p><p id="p-0241" num="0236">(i) a CDR1 comprising or consisting of SEQ ID NO: 4;</p><p id="p-0242" num="0237">(ii) a CDR2 comprising or consisting of SEQ ID NO: 5; and</p><p id="p-0243" num="0238">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0244" num="0239">5. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 1, wherein the heavy chain variable region comprises:</p><p id="p-0245" num="0240">(i) a CDR1 comprising or consisting of SEQ ID NO: 6;</p><p id="p-0246" num="0241">(ii) a CDR2 comprising or consisting of SEQ ID NO: 7; and</p><p id="p-0247" num="0242">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0248" num="0243">6. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 1, wherein the heavy chain variable region comprises:</p><p id="p-0249" num="0244">(i) a CDR1 comprising or consisting of SEQ ID NO: 1;</p><p id="p-0250" num="0245">(ii) a CDR2 comprising or consisting of SEQ ID NO: 8; and</p><p id="p-0251" num="0246">(iii) a CDR3 comprising or consisting of SEQ ID NO: 9.</p><p id="p-0252" num="0247">7. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 1, wherein the heavy chain variable region comprises:</p><p id="p-0253" num="0248">(i) a CDR1 comprising or consisting of SEQ ID NO: 10;</p><p id="p-0254" num="0249">(ii) a CDR2 comprising or consisting of SEQ ID NO: 11; and</p><p id="p-0255" num="0250">(iii) a CDR3 comprising or consisting of SEQ ID NO: 12.</p><p id="p-0256" num="0251">8. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 1, wherein the heavy chain variable region comprises:</p><p id="p-0257" num="0252">(i) a CDR1 comprising or consisting of SEQ ID NO: 13;</p><p id="p-0258" num="0253">(ii) a CDR2 comprising or consisting of SEQ ID NO: 5; and</p><p id="p-0259" num="0254">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0260" num="0255">9. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 1, wherein the heavy chain variable region comprises:</p><p id="p-0261" num="0256">(i) a CDR1 comprising or consisting of SEQ ID NO: 14;</p><p id="p-0262" num="0257">(ii) a CDR2 comprising or consisting of SEQ ID NO: 15; and</p><p id="p-0263" num="0258">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0264" num="0259">10. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 1, wherein the heavy chain variable region comprises:</p><p id="p-0265" num="0260">(i) a CDR1 comprising or consisting of SEQ ID NO: 16;</p><p id="p-0266" num="0261">(ii) a CDR2 comprising or consisting of SEQ ID NO: 17; and</p><p id="p-0267" num="0262">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0268" num="0263">11. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 1, wherein the heavy chain variable region comprises:</p><p id="p-0269" num="0264">(i) a CDR1 comprising or consisting of SEQ ID NO: 18;</p><p id="p-0270" num="0265">(ii) a CDR2 comprising or consisting of SEQ ID NO: 19; and</p><p id="p-0271" num="0266">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0272" num="0267">12. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 1, wherein the heavy chain variable region comprises:</p><p id="p-0273" num="0268">(i) a CDR1 comprising or consisting of SEQ ID NO: 20;</p><p id="p-0274" num="0269">(ii) a CDR2 comprising or consisting of SEQ ID NO: 5; and</p><p id="p-0275" num="0270">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0276" num="0271">13. An isolated PD-L1 single-domain antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0277" num="0272">(i) a CDR1 comprising or consisting of SEQ ID NO: 21;</p><p id="p-0278" num="0273">(ii) a CDR2 comprising or consisting of SEQ ID NO: 22; and</p><p id="p-0279" num="0274">(iii) a CDR3 comprising or consisting of SEQ ID NO: 23.</p><p id="p-0280" num="0275">14. An isolated PD-L1 single-domain antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0281" num="0276">(i) a CDR1 comprising or consisting of SEQ ID NO: 24;</p><p id="p-0282" num="0277">(ii) a CDR2 comprising or consisting of SEQ ID NO: 25; and</p><p id="p-0283" num="0278">(iii) a CDR3 comprising or consisting of SEQ ID NO: 3.</p><p id="p-0284" num="0279">15. An isolated PD-L1 single-domain antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0285" num="0280">(i) a CDR1 comprising or consisting of SEQ ID NO: 26;</p><p id="p-0286" num="0281">(ii) a CDR2 comprising or consisting of SEQ ID NO: 27; and</p><p id="p-0287" num="0282">(iii) a CDR3 comprising or consisting of SEQ ID NO: 23.</p><p id="p-0288" num="0283">16. An isolated PD-L1 single-domain antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0289" num="0284">(i) a CDR1 comprising or consisting of SEQ ID NO: 28;</p><p id="p-0290" num="0285">(ii) a CDR2 comprising or consisting of SEQ ID NO: 29; and</p><p id="p-0291" num="0286">(iii) a CDR3 comprising or consisting of SEQ ID NO: 23.</p><p id="p-0292" num="0287">17. An isolated PD-L1 single-domain antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:</p><p id="p-0293" num="0288">(i) a CDR1 comprising or consisting of SEQ ID NO: 30;</p><p id="p-0294" num="0289">(ii) a CDR2 comprising or consisting of SEQ ID NO: 31; and</p><p id="p-0295" num="0290">(iii) a CDR3 comprising or consisting of SEQ ID NO: 23.</p><p id="p-0296" num="0291">18. An isolated PD-L1 single-domain antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises 3 CDRs in a heavy chain variable region amino acid sequence of any one of SEQ ID NOs: 36-52.</p><p id="p-0297" num="0292">19. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-18, wherein the heavy chain variable region further comprises an FR region comprising FR1, FR2, FR3 and FR4, and the FR1, FR2, FR3 and FR4 and CDR1, CDR2 and CDR3 are arranged alternately on the heavy chain variable region to form a structure of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 from N-terminus to C-terminus.</p><p id="p-0298" num="0293">20. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 19, wherein the FR region comprises:</p><p id="p-0299" num="0294">(a) an FR1 comprising the amino acid sequence of SEQ ID NO: 53;</p><p id="p-0300" num="0295">an FR1 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 53; or</p><p id="p-0301" num="0296">an FR1 comprising an amino acid sequence which differs from SEQ ID NO: 53 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0302" num="0297">(b) an FR2 comprising the amino acid sequence of SEQ ID NO: 54;</p><p id="p-0303" num="0298">an FR2 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 54; or</p><p id="p-0304" num="0299">an FR2 comprising an amino acid sequence which differs from SEQ ID NO: 54 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0305" num="0300">(c) an FR3 comprising the amino acid sequence of SEQ ID NO: 55;</p><p id="p-0306" num="0301">an FR3 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 55; or</p><p id="p-0307" num="0302">an FR3 comprising an amino acid sequence which differs from SEQ ID NO: 55 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions; and</p><p id="p-0308" num="0303">(d) an FR4 comprising the amino acid sequence as shown in SEQ ID NO: 56;</p><p id="p-0309" num="0304">an FR4 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 56; or</p><p id="p-0310" num="0305">an FR4 comprising an amino acid sequence which differs from SEQ ID NO: 56 by no more than 2 (e.g., 0, 1, and 2) amino acid additions, deletions and/or substitutions.</p><p id="p-0311" num="0306">21. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 19, wherein the FR region comprises:</p><p id="p-0312" num="0307">(a) an FR1 comprising the amino acid sequence of SEQ ID NO: 57;</p><p id="p-0313" num="0308">an FR1 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 57; or</p><p id="p-0314" num="0309">an FR1 comprising an amino acid sequence which differs from SEQ ID NO: 57 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0315" num="0310">(b) an FR2 comprising the amino acid sequence of SEQ ID NO: 58;</p><p id="p-0316" num="0311">an FR2 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 58; or</p><p id="p-0317" num="0312">an FR2 comprising an amino acid sequence which differs from SEQ ID NO: 58 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0318" num="0313">(c) an FR3 comprising the amino acid sequence of SEQ ID NO: 59;</p><p id="p-0319" num="0314">an FR3 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 59; or</p><p id="p-0320" num="0315">an FR3 comprising an amino acid sequence which differs from SEQ ID NO: 59 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0321" num="0316">and</p><p id="p-0322" num="0317">(d) an FR4 comprising the amino acid sequence of SEQ ID NO: 60;</p><p id="p-0323" num="0318">an FR4 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 60; or</p><p id="p-0324" num="0319">an FR4 comprising an amino acid sequence which differs from SEQ ID NO: 60 by no more than 2 (e.g., 0, 1, and 2) amino acid additions, deletions and/or substitutions.</p><p id="p-0325" num="0320">22. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 19, wherein the FR region comprises:</p><p id="p-0326" num="0321">(a) an FR1 comprising the amino acid sequence of SEQ ID NO: 61;</p><p id="p-0327" num="0322">an FR1 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 61; or</p><p id="p-0328" num="0323">an FR1 comprising an amino acid sequence which differs from SEQ ID NO: 61 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0329" num="0324">(b) an FR2 comprising the amino acid sequence of SEQ ID NO: 58;</p><p id="p-0330" num="0325">an FR2 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 58; or</p><p id="p-0331" num="0326">an FR2 comprising an amino acid sequence which differs from SEQ ID NO: 58 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0332" num="0327">(c) an FR3 comprising the amino acid sequence of SEQ ID NO: 59;</p><p id="p-0333" num="0328">an FR3 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 59; or</p><p id="p-0334" num="0329">an FR3 comprising an amino acid sequence which differs from SEQ ID NO: 59 by no more than 2 (e.g., 0, 1 and 2) amino acid additions, deletions and/or substitutions;</p><p id="p-0335" num="0330">and</p><p id="p-0336" num="0331">(d) an FR4 comprising the amino acid sequence of SEQ ID NO: 60;</p><p id="p-0337" num="0332">an FR4 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 60; or</p><p id="p-0338" num="0333">an FR4 comprising an amino acid sequence which differs from SEQ ID NO: 60 by no more than 2 (e.g., 0, 1, and 2) amino acid additions, deletions and/or substitutions.</p><p id="p-0339" num="0334">23. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-22, wherein the heavy chain variable region comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 36-52.</p><p id="p-0340" num="0335">24. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-22, wherein the heavy chain variable region comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to an amino acid sequence of any one of SEQ ID NOs: 36-52 and retaining the ability to specifically bind to PD-L1.</p><p id="p-0341" num="0336">25. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-22, wherein the heavy chain variable region comprises an amino acid sequence having one or more additions, deletions and/or substitutions (e.g., conservative substitutions) of amino acids compared to an amino acid sequence of any one of SEQ ID NOs: 36-52 and retaining the ability to specifically bind to PD-L1, wherein the one or more amino acid additions, deletions and/or substitutions (e.g., conservative substitutions) are no more than five, preferably no more than three.</p><p id="p-0342" num="0337">26. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-25, wherein the PD-L1 binding molecule is a camelized antibody, a humanized antibody, an affinity-matured antibody or a druggability-modified molecule.</p><p id="p-0343" num="0338">27. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-26, wherein the heavy chain variable region is fused to an additional molecule, and the additional molecule is selected from an Fc domain of an immunoglobulin (e.g., IgG), an antibody, an antigen-binding fragment of the antibody, an antibody-drug conjugate, an antibody-like molecule, an antigen-binding fragment of the antibody-like molecule or a fluorescent protein.</p><p id="p-0344" num="0339">28. The isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to embodiment 27, wherein the heavy chain variable region is fused to an Fc domain of human IgG (e.g., human IgG1 or human IgG4).</p><p id="p-0345" num="0340">29. An isolated nucleic acid molecule, comprising a nucleotide sequence encoding the isolated PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-28.</p><p id="p-0346" num="0341">30. A vector, comprising the nucleic acid molecule according to embodiment 29.</p><p id="p-0347" num="0342">31. A host cell, comprising the vector according to embodiment 30.</p><p id="p-0348" num="0343">32. A pharmaceutical composition, comprising an effective amount of the PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-28 and a pharmaceutically acceptable carrier.</p><p id="p-0349" num="0344">33. A method for preparing the PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-28, wherein the method comprises the following steps:</p><p id="p-0350" num="0345">expressing the nucleotide sequence encoding the PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-28 in a host cell to produce the PD-L1 single-domain antibody or the antigen-binding fragment thereof; and</p><p id="p-0351" num="0346">isolating the PD-L1 single-domain antibody or the antigen-binding fragment thereof from the host cell.</p><p id="p-0352" num="0347">34. A method for preventing or treating a disease associated with PD-L1 in a subject, the method comprising administering a therapeutically effective amount of the PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-28, or administering an effective amount of a pharmaceutical composition comprising the PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-27 to the subject.</p><p id="p-0353" num="0348">35. A method for modulating an immune response in a subject, comprising administering a therapeutically effective amount of the PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-28, or administering an effective amount of a pharmaceutical composition comprising the PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-28 to the subject, such that the immune response in the subject is modulated.</p><p id="p-0354" num="0349">36. The method according to embodiment 34 or 35, wherein the subject is a mammal, preferably a mouse or a human, more preferably a human.</p><p id="p-0355" num="0350">37. The method according to embodiment 36, wherein the disease associated with PD-L1 is selected from renal cell carcinoma, non-small cell lung cancer, bladder cancer, urothelial carcinoma, and microsatellite unstable solid tumor.</p><p id="p-0356" num="0351">38. The method according to embodiment 34 or 35, wherein the method further comprises administering in combination an effective amount of a second drug to a subject, wherein the second drug is a chemotherapeutic agent, a radiotherapeutic agent, or a biomacromolecular drug for the treatment of a disease associated with PD-L1.</p><p id="p-0357" num="0352">39. The method according to embodiment 38, wherein the biomacromolecular drug is, for example, various monoclonal antibody drugs (e.g., rituximab, cetuximab and trastuzumab) that attack tumor cells by T cell recognition.</p><p id="p-0358" num="0353">40. A kit for preventing or treating a disease associated with PD-L1 in a subject, comprising a container, wherein the container comprises at least one PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-29.</p><p id="p-0359" num="0354">41. The PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-29, for use in preventing or treating a disease associated with PD-L1 in a subject.</p><p id="p-0360" num="0355">42. The PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-29, for use in modulating an immune response in a subject.</p><p id="p-0361" num="0356">43. Use of the PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-29 in the preparation of a pharmaceutical composition for modulating an immune response in a subject.</p><p id="p-0362" num="0357">44. Use of the PD-L1 single-domain antibody or the antigen-binding fragment thereof according to any one of embodiments 1-29 in the preparation of a pharmaceutical composition for preventing or treating a disease associated with PD-L1 in a subject.</p><p id="p-0363" num="0358">45. The use according to embodiment 43 or 44, wherein the subject is a mammal, preferably a mouse or a human, more preferably a human.</p><p id="p-0364" num="0359">46. The use according to embodiment 45, wherein the disease associated with PD-L1 is selected from renal cell carcinoma, non-small cell lung cancer, bladder cancer, urothelial carcinoma, and microsatellite unstable solid tumor.</p><heading id="h-0010" level="1">EXAMPLE</heading><p id="p-0365" num="0360">The present invention, thus generally described, will be understood more readily by reference to the following Examples, which are provided by way of illustration and are not intended to be limiting of the present invention.</p><p id="p-0366" num="0361">It is to be understood by a person skilled in the art that the reagents, plasmids, cells, etc., used in the following examples, unless otherwise noted, are all commercially available products.</p><heading id="h-0011" level="1">Example 1 Construction of Cell Lines Stably Expressing PD-L1</heading><p id="p-0367" num="0362">In this example, the present inventors construct CHO-s cells expressing human PD-L1, monkey PD-L1 and mouse PD-L1, respectively, and prepare a control antibody from Roche.</p><p id="p-0368" num="0363">1.1 Preparation of a Control Antibody</p><p id="p-0369" num="0364">The light chain and heavy chain gene sequences of the control antibody Atezolizumab (Roche) are subjected to complete gene synthesis (gene synthesis supplier: General Biol). The control antibody is expressed by using the ExpiCHO transient transfection and expression system (purchased from Thermo Fisher); the culture medium is the ExpiCHO&#x2122; Expression Medium (Gibco, A29100-01); and the transfection kit is the ExpiFectamine&#x2122; CHO Transfection Kit (Gibco, A29129).</p><p id="p-0370" num="0365">The specific method is as follows: the ExpiCHO expression plasmids for the light chain and heavy chain genes of the Atezolizumab antibody are constructed by molecular cloning. One day prior to transfection, ExpiCHO cells (purchased from Gibco A29127) are passaged, and on the day of transfection, 25 &#x3bc;g of the constructed plasmids (a plasmid mixture containing a light chain coding gene and a heavy chain coding gene in a mass ratio of 2:1) are mixed with a transfection reagent, then added dropwise to 25 ml of ExpiCHO cell cultures, fully mixed and incubated at 37&#xb0; C. for 18-22 hours. Then a feed culture medium is added according to the instruction in the kit, and after feeding, the cells are cultured at 32&#xb0; C. On day 5 after transfection, a second feed culture medium is added, and the cells are cultured at 32&#xb0; C. for 10-12 days. Then the expressed cell suspension is centrifuged at a high speed to obtain a supernatant. The obtained supernatant is filtered through a 0.22 &#x3bc;m membrane filter and then purified by an affinity purification method using a Protein A/G affinity chromatography column. 100 mM glycine salt (pH 3.0) is used to elute the protein of interest followed by neutralization to pH 7.0 with 1 M Tris-HCl. A small amount of samples are taken, then identified by SDS-PAGE. The rest of the products are aliquoted and cryopreserved.</p><p id="p-0371" num="0366">The method for preparing the control antibody KN035 (see SEQ ID NO: 35 in the sequence listing for the amino acid sequence) is as follows:</p><p id="p-0372" num="0367">the complete gene sequences of the control antibody KN035 are subjected to complete gene synthesis, and the ExpiCHO expression plasmids for the genes of the KN035 antibody are constructed by molecular cloning. One day prior to transfection, ExpiCHO cells (purchased from Gibco A29127) are passaged. In a 25 ml cell culture, 25 &#x3bc;g of the constructed plasmids are mixed with a transfection reagent, and then transfected according to the above-mentioned method for preparing the control antibody-KN035.</p><p id="p-0373" num="0368">1.2 Construction of Stable Cell Lines</p><p id="p-0374" num="0369">The recombinant vectors (plasmids) expressing the full-length proteins of human PD-L1 (gi number: NP_054862.1), mouse PD-L1 (gi number: NP_068693) and rhesus monkey PD-L1 (gi number: AB033163.1) are constructed, respectively. The constructed plasmids are introduced into CHO-s cells (purchased from Thermo Fisher) and A375 melanoma cell line (ATCC, CRL-1619) by an electroporation method. The CHO-s cell line with high expression of PD-L1 proteins of the above-mentioned three species and the A375 cell line with high expression of human PD-L1 (PD-L1-A375) are obtained by screening, respectively.</p><p id="p-0375" num="0370">1.2.1 Construction of Plasmids Expressing Human PD-1 and PD-L1 Proteins</p><p id="p-0376" num="0371">The expression vectors containing the full-length protein gene sequences of human PD-L1, mouse PD-L1 and rhesus monkey PD-L1 are synthesized by gene synthesis techniques, respectively. After ligation, the expression vectors are introduced into <i>Escherichia coli</i>. The <i>Escherichia coli </i>monoclones are picked, and then sequenced to obtain the correct plasmid clones which are subjected to plasmid extraction and resequencing.</p><p id="p-0377" num="0372">1.2.2 Construction of the CHO-s Cell Line Expressing PD-1 and PD-L1 Proteins</p><p id="p-0378" num="0373">1.2.2.1 Electroporation</p><p id="p-0379" num="0374">CHO-s cells are cultured and maintained in a CD-CHO serum-free culture medium (Gibco, 10743029). One day prior to electroporation, the cells are passaged to 5&#xd7;10<sup>6</sup>/mL, and the next day, the constructed plasmids are introduced into the CHO-s cells by using an electroporation kit (Invitrogen, Neon&#x2122; Kit, MPK10096) and an electroporation apparatus (Invitrogen, Neon&#x2122; Transfection System, MP922947). The electroporated cells are added to 3 mL of CD-CHO culture medium and placed in a carbon dioxide incubator at 37&#xb0; C. for 48 hours.</p><p id="p-0380" num="0375">1.2.2.2 Cell Plating and Culture</p><p id="p-0381" num="0376">The electroporated CHO-s cells are plated at 2000 cells/well in a 96-well cell culture plate, and L-Methionine sulfoximine (MSX) (Millipore, GSS-1015-F) is added at a final concentration of 30 &#x3bc;M/Ml. The culture volume is kept at 100 &#x3bc;L/well with 1&#xd7;GS supplement (Sigma, 58672C). The cells are placed in a carbon dioxide incubator at 37&#xb0; C. for 10 days, and then 50 &#x3bc;L of culture medium containing 30 &#x3bc;M MSX and 1&#xd7;GS supplement is added.</p><p id="p-0382" num="0377">1.2.2.3 Clone Identification and Cell Amplification and Culture</p><p id="p-0383" num="0378">The grown clones are picked and transferred to a 24-well cell culture plate. The cell lines are identified by an FACS method, and clones with high expression level are selected for amplification, culture and cryopreservation. The related FACS identification methods are as follows:</p><p id="p-0384" num="0379">1) firstly, collecting 2&#xd7;10<sup>5 </sup>of untransfected CHO-s cells and each transfected monoclonal CHO-s cells, centrifuging the collected cells at 300 g to remove the supernatant, and resuspending the cells in a 96-well round-bottom plate with 200 &#x3bc;L of the formulated FACS buffer (1&#xd7;PBS+2% FBS);</p><p id="p-0385" num="0380">2) centrifuging the 96-well round-bottom plate at 300 g for 5 min, and removing the supernatant;</p><p id="p-0386" num="0381">3) adding anti-PD-L1 antibody diluents or negative control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0387" num="0382">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L of FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0388" num="0383">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0389" num="0384">6) adding a PE-labeled anti-human IgG Fc flow cytometry antibody (Abcam, ab98596), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0390" num="0385">7) centrifuging the mixture at 300 g to remove the supernatant, adding an FACS buffer and resuspending the cells; and</p><p id="p-0391" num="0386">8) repeating step 7) twice, adding an FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102).</p><p id="p-0392" num="0387">1.2.3 Preparation of the A375 Cell Line Expressing PD-L1</p><p id="p-0393" num="0388">The PD-L1 high-expressing A375 cell line (PD-L1-A375) is prepared by using the same method as that of 1.2.2.1 for electroporation of CHO-s cells, and is used for the construction of the animal tumor model of the A375 cell line.</p><heading id="h-0012" level="1">Example 2 Animal Immunization and Serum Titer Detection</heading><p id="p-0394" num="0389">2.1 Animal Immunization</p><p id="p-0395" num="0390">A PD-L1 (NP_054862.1) ectodomain protein (Sino Biological Co., Ltd., 10084-H05H) is purchased to immunize 2 alpacas (Nanchang Dajia Technology Co., Ltd). Each alpaca is immunized with 500m of ectodomain protein each time, once every 2 weeks, for a total of 4 times.</p><p id="p-0396" num="0391">2.2 Serum Titer Detection</p><p id="p-0397" num="0392">After the completion of the alpaca immunization, the alpaca serum is taken for immune titer detection.</p><p id="p-0398" num="0393">Immune titer determination is performed to determine the binding ability of immune serum to recombinant protein PD-L1 (Sino Biological Co., Ltd., 10084-H05H) by an ELISA method, and to determine the immune effect according to the titer of the bound antibodies.</p><p id="p-0399" num="0394">The specific method is as follows:</p><p id="p-0400" num="0395">2.2.1 Antigen coating: one day prior to the immune titer determination, the recombinant antigen protein PD-L1 is diluted with PBS to a final concentration of 2 &#x3bc;g/mL, thereby obtaining a diluent. 30 &#x3bc;l of the obtained diluent is added to each well of the ELISA plate and coated overnight at 4&#xb0; C. On the day of the immune titer determination, the plate is rinsed three times with PBS, then blocked with PBST containing 5% skimmed milk for two hours at room temperature, and subsequently rinsed three times with PBS.</p><p id="p-0401" num="0396">2.2.2 Serum dilution: in a different plate for dilution, the unimmunized negative serum and the immunized serum are diluted with PBS, with 200-fold dilution for the first well and a 3-fold gradient dilution for the following 7 wells.</p><p id="p-0402" num="0397">2.2.3 Antibody binding: the diluted serum is added to the first ELISA plate, incubated at 37&#xb0; C. for 1 h, and washed twice with PBS. Subsequently, a secondary antibody (goat anti-camelid IgG antibody) (purchased from Nanjing Genscript Biotech Corporation) is added at 1:5000 dilution and incubated for 1 h.</p><p id="p-0403" num="0398">2.2.4 Color development and reading: after the above-mentioned incubation, the plate is washed with PBS 3 times, a color developing solution is added and color development is performed for 5 minutes. A stopping solution is added, and then the plate is read at OD450 by a microplate reader (Molecular Devices, SpecterMax 190). The results are shown in Table 1.</p><p id="p-0404" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Results of ELISA color development experiment at different</entry></row><row><entry>dilution ratios</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="56pt" align="center"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Negative</entry><entry/><entry/></row><row><entry/><entry>Dilution ratio</entry><entry>serum</entry><entry>NSY004</entry><entry>NSY005</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><tbody valign="top"><row><entry/><entry>1:2000</entry><entry>0.209</entry><entry>2.582</entry><entry>2.163</entry></row><row><entry/><entry>1:4000</entry><entry>0.133</entry><entry>2.286</entry><entry>2.216</entry></row><row><entry/><entry>1:8000</entry><entry>0.093</entry><entry>1.923</entry><entry>2.131</entry></row><row><entry/><entry>1:16000</entry><entry>0.052</entry><entry>1.817</entry><entry>1.868</entry></row><row><entry/><entry>1:32000</entry><entry>0.054</entry><entry>1.337</entry><entry>1.218</entry></row><row><entry/><entry>1:64000</entry><entry>0.048</entry><entry>1.048</entry><entry>0.792</entry></row><row><entry/><entry>1:128000</entry><entry>0.042</entry><entry>0.761</entry><entry>0.587</entry></row><row><entry/><entry>1:256000</entry><entry>0.048</entry><entry>0.404</entry><entry>0.473</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0405" num="0399">The two columns NSY004 and NSY005 are the results of ELISA titer detection of serum diluted at different times from two immunized alpacas, and the negative serum is the ELISA experiment result of the serum from an unimmunized alpaca. According to the results in Table 1, the two alpacas have the immune titers (IgG titers) of 256000 and show good immune effect, which can be used for the construction of the immune antibody library in the next step.</p><heading id="h-0013" level="1">Example 3 Construction and Preliminary Screening of Alpaca Immune Library</heading><p id="p-0406" num="0400">After the completion of the animal immunization, 50 mL of fresh alpaca blood is collected, and peripheral blood mononuclear cells (PBMC) are separated by a Ficoll-Paque density gradient separation solution (GE, 171440035) for the construction of a phage-displayed alpaca immune library of an anti-human PD-L1 antibodies.</p><p id="p-0407" num="0401">The specific method is as follows:</p><p id="p-0408" num="0402">the collected alpaca blood is diluted with PBS at a ratio of 1:1 (v/v). 15 ml of the Ficoll-Paque density gradient separation solution is taken and slowly added to a 50 ml centrifuge tube. The centrifuge tube is tilted and 30 mL of diluted alpaca blood is added slowly along the tube wall, so that the two layers of liquid maintain a clear separation interface. The solution is centrifuged at 4&#xb0; C. for 20 min, with an acceleration of 3 and a deceleration of 0. After centrifugation, the entire solution is divided into four layers, with the top layer being a plasma mixture, the bottom layer being red blood cells and granulocytes, the middle layer being Ficoll-Paque PLUS, and the junction of the top and middle layers being a white and narrow zone mainly composed of PBMCs, i.e., a PBMC cell layer. PBMC cells in the middle are carefully pipetted into a new 50 mL centrifuge tube with a pipette. The PBMC cells are rinsed twice with PBS and horizontally centrifuged at 4&#xb0; C., 1500 rpm for 10 min, and finally resuspended with 1.5 ml PBS and counted by a microscope.</p><p id="p-0409" num="0403">RNA is extracted from the isolated PBMC cells, and the extracted RNA is reversely transcribed into cDNA by a reverse transcription kit (TaKaRa, 6210A). As the molecular form of an alpaca antibody has no light chain and has a heavy chain without CH1, the molecular form thereof is different from that of a common antibody. Therefore, firstly, two fragments of different sizes are obtained by using common primers designed prior to the VH and in the CH2 by PCR, and the smaller fragment of interest is recovered by gel extraction. Subsequently, by aligning the amino acid sequences of all common VHH germlines, germline-specific primers containing NcoI and NotI restriction enzyme sites at both ends are designed to amplify all the VHH genes by using the product recovered as the template. Finally, the gene fragment of the antibody of interest is inserted into the vector for phage display by double digestion and ligation. It need to be pointed out that the C-terminus of the VHH gene on the expression vector is fused to the GIII gene in the phage expression vector. The ligation product is recovered by a recovery kit (Omega, D6492-02), and finally transformed into competent <i>Escherichia coli </i>SS320 by an electroporation apparatus (Bio-Rad, MicroPulser), and the transformed <i>Escherichia coli </i>SS320 is plated onto a 2-YT solid plate with ampicillin resistance. To calculate the library size, 10 &#x3bc;l of the bacterial culture from the library is taken for 10-fold gradient dilution, with 2 &#x3bc;l of the bacterial culture in each dilution gradient spotted on the plate, and the clones formed on the plate are used to calculate the total number of all the clones formed by electroporation, thereby obtaining the library size. The library size of this immune library is 1&#xd7;10<sup>9</sup>.</p><p id="p-0410" num="0404">Based on the size of this library, the bacteria in an amount 10 times the library size (about 20 OD) are added to a fresh 2-YT liquid culture medium, and the amount of the culture medium added is adjusted so that the initial OD value of the bacterial culture diluent is 0.05. Cultures are placed at 37&#xb0; C., 220 rpm and cultured to the log growth phase, and at this time, VSCM13 helper phages in an amount 50 times the number of the bacteria are added, fully mixed and allowed to stand for 30 min and then cultured at 37&#xb0; C., 220 rpm for 1 h. The obtained culture is centrifuged at 10000 rpm for 5 min and have the culture medium changed to a carbenicillin/kanamycin dual resistant 2-YT culture medium, and cultured at 30&#xb0; C., 220 rpm overnight. The next day, the resulting culture is centrifuged at 13000 g for 10 min, and the supernatant is precipitated by adding 20% PEG/NaCl solution to obtain phages representing the alpaca immune antibody library, which phages are used for anti-PD-L1 antibody screening following rinsing with PBS once.</p><p id="p-0411" num="0405">A recombinant PD-L1 protein, and two methods (magnetic bead panning and immunotube panning) are used in phage panning. The specific method is as follows.</p><p id="p-0412" num="0406">3.1 Magnetic Bead Panning</p><p id="p-0413" num="0407">Panning is performed based on the binding of a biotin-labeled recombinant PD-L1 protein to avidin-coupled magnetic beads (purchased from Thermo Fisher, Cat. No. 11205D). Firstly, the recombinant human PD-L1 protein is labeled with biotin (for the biotin labeling method, please make reference to the instruction of the biotin protein labeling kit (Roche), Cat. No. 11418165001), and the biotin-labeled PD-L1 protein is incubated with magnetic beads, so that the PD-L1 protein is bound to the magnetic beads. The magnetic beads conjugated with the PD-L1 antigen and the nanobody-displaying phage library are incubated at room temperature for 2 hours and washed 6-8 times with PBST. Then the non-specifically adsorbed phages are removed, and trypsin (Gibco) is added and mixed gently for 20 min, so as to elute the nanobody-displaying phages specifically binding to the human PD-L1 protein. The eluted phages are used to infect SS320 bacterial cells at log-phase (Lucigen, MC1061 F), and the phage-infected SS320 bacterial cells are plated onto a carbenicillin-resistant plate and cultured at 37&#xb0; C. overnight. The bacterial cells are collected the next day. The phages are prepared by infecting SS320 bacterial cells. For the preparation method, please make reference to the above-mentioned library phage preparation method. The resulting phages are used for a second round of panning, and elution is performed by using trypsin at the end of the second round of panning. The phages obtained from the second round of panning are used for a third round of panning, and elution is performed by using trypsin at the end of the third round of panning. The procedures are repeated as such and sequence analysis is performed on 10 clones randomly selected from each round of panning. The results show that for the monoclonal phages obtained after 3 rounds of panning, it is found by sequencing of monoclones that in different clones, the same gene sequences are repeated, which indicates the sequence enrichment.</p><p id="p-0414" num="0408">3.2 Immunotube Panning</p><p id="p-0415" num="0409">Immunotube panning is performed based on coating the antigen on the surface of an immunotube to screen for antibody-displaying phages that bind to the antigen of interest. One day prior to panning, the recombinant human PD-L1 protein is used to coat the immunotube. The immunotube conjugated with the PD-L1 antigen and the nanobody-displaying phage library are incubated at room temperature for 2 hours and washed 6-8 times with PBST. Then the non-specifically adsorbed phages are removed, and trypsin (Gibco) is added and mixed gently for 20 min, so as to elute the nanobody-displaying phages specifically binding to the human PD-L1 protein. The eluted phages are used to infect SS320 bacterial cells at log-phase (Lucigen, MC1061 F), and the phage-infected SS320 bacterial cells are plated onto a carbenicillin-resistant plate and cultured at 37&#xb0; C. overnight. The bacterial cells are collected the next day. The phages are prepared by infesting SS320 bacterial cells. For the preparation method, please make reference to the above-mentioned library phage preparation method. The resulting phages are used for a second round of panning. Elution is performed by using trypsin at the end of the second round of panning. The phages obtained from the second round of panning are used for a third round of panning, and elution is performed by using trypsin at the end of the third round of panning. The procedures are repeated as above. Sequencing is performed on 10 clones randomly selected from each round of panning, and then sequence analysis is performed thereon. The results show that after 3 rounds of panning, it is found by sequencing of monoclones that in different clones, the same gene sequences are repeated, which indicates the sequence enrichment.</p><p id="p-0416" num="0410">The phage libraries obtained by two different panning methods are screened for monoclones, and the positive clones in the third round of outputs from magnetic bead panning and immunotube panning are picked, respectively. The specific method is as follows:</p><p id="p-0417" num="0411">one day prior to screening, the recombinant human PD-L1 protein is coated on a 96-well ELISA plate, and the phage culture is incubated in the 96-well plate the next day. The positive clones against the recombinant human PD-L1 protein are screened by phage ELISA, and then all the positive clones are picked for sequencing analysis. Subsequently, a lysate is prepared with each clone having the unique sequence, and the preparation method is as follows: one day prior to preparation, the bacterial culture of the clone (50 mL) is inoculated at 1:100, and cultured with shaking in a 37&#xb0; C. constant-temperature shaker for 14 h. The culture medium is centrifuged at 10000 g for 5 min at room temperature. The bacteria are resuspended in 1 mL of Tris-HCl buffer containing benzonase nuclease at PH 9.0, lysed on ice for 30 min, and centrifuged at 10000 g for 10 min at 4&#xb0; C. The supernatant is collected to obtain a positive clone lysate.</p><p id="p-0418" num="0412">The prepared positive clone lysate is further verified by flow cytometry, and a candidate antibody that specifically recognizes human PD-L1 is screened out. The method for verifying by flow cytometry is as follows:</p><p id="p-0419" num="0413">1) firstly, collecting the cultured human PD-L1-CHO cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0420" num="0414">2) adding the PD-L1-CHO cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0421" num="0415">3) adding a gradient-diluted candidate antibody lysate and a control antibody diluent to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0422" num="0416">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L of FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0423" num="0417">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0424" num="0418">6) adding a PE-labeled flow cytometry antibody (Genscript Biotech Corporation), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0425" num="0419">7) centrifuging the mixture at 300 g to remove the supernatant, adding an FACS buffer and resuspending the cells; and</p><p id="p-0426" num="0420">8) repeating step 7) twice, adding an FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102).</p><p id="p-0427" num="0421"><figref idref="DRAWINGS">FIG. <b>1</b></figref> shows the results of screening for binding affinity of anti-PD-L1 VHH lysate samples.</p><p id="p-0428" num="0422"><figref idref="DRAWINGS">FIG. <b>1</b></figref> shows that the VHH molecules of the indicated clone numbers exhibit affinity for CHO cells expressing PD-L1. Since this detection experiment is only qualitative and semi-quantitative, it is impossible to confirm which VHH antibody molecule of the clone number has better affinity, and further experimental confirmation is required.</p><p id="p-0429" num="0423">The prepared positive clone lysate is further screened for blocking activity by flow cytometry, and a candidate antibody that specifically recognizes human PD-L1 and blocks the binding thereof to a PD-1 protein is screened out. The method for verifying the blocking activity by flow cytometry is as follows:</p><p id="p-0430" num="0424">1) firstly, collecting the cultured human PD-L1-CHO cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0431" num="0425">2) adding the PD-L1-CHO cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0432" num="0426">3) adding the candidate antibody lysates and the control antibody diluents with concentration gradients of 1:1, 1:5 and 1:25 (obtained by gradient dilution) to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0433" num="0427">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0434" num="0428">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0435" num="0429">6) adding 100 &#x3bc;L of PD-1-Fc protein diluent (1 &#x3bc;g/mL) to the corresponding wells, resuspending the cells and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0436" num="0430">7) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0437" num="0431">8) repeating step 7) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0438" num="0432">9) adding a PE-labeled anti-human IgG Fc flow cytometry antibody (Abcam), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0439" num="0433">10) centrifuging the mixture at 300 g to remove the supernatant, adding an FACS buffer and resuspending the cells; and 11) repeating step 10) twice, adding an FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102).</p><p id="p-0440" num="0434">The screening results of the blocking assay of anti-PD-L1 antibody candidates are shown in <figref idref="DRAWINGS">FIG. <b>2</b></figref>. By means of the preliminary screening by methods such as ELISA and FACS, it shows that the antibody lysate prepared from the screened antibody sequences contains antibodies that have the blocking activity against the binding of PD-L1 to PD1. The present inventors screen out 10 candidate molecules with good affinity and blocking activity.</p><heading id="h-0014" level="1">Example 4 Expression and Production of a Chimeric VHH-Fc Antibody</heading><p id="p-0441" num="0435">The positive VHH candidate antibodies obtained by screening is fused to the human IgG1 Fc fragment by molecular cloning. The C-terminus of the positive VHH gene sequence is linked to the N-terminus of the human IgG1 Fc fragment gene sequence to construct a fusion expression plasmid. The fusion expression plasmid is transformed into ExpiCHO cells to induce expression, thereby obtaining a VHH-Fc chimeric antibody protein.</p><p id="p-0442" num="0436">The antibody is expressed by using the ExpiCHO transient transfection and expression system; the culture medium is the medium of Gibco ExpiCHO Expression Medium, A29100-01; and the transfection kit is ExpiFectamine&#x2122; CHO Transfection Kit, A29129. The specific method is as follows: one day prior to transfection, ExpiCHO cells are passaged, and in a 25 ml culture, 25 &#x3bc;g of the constructed plasmids are mixed with the transfection reagent, then added dropwise to 25 ml of ExpiCHO cell cultures, fully mixed and expressed at 37&#xb0; C. for 18-22 hours. Then a feed culture medium is added according to the instruction in the kit, and after feeding, the cells are cultured at 32&#xb0; C. On day 5 after transfection, a second feed culture medium is added, and the cells are cultured at 32&#xb0; C. for 10-12 days. Then the expressed cell suspension is centrifuged at a high speed to obtain a supernatant. The obtained supernatant is filtered through 0.22 &#x3bc;m and then purified by using a Protein A/G affinity purification method. 100 mM glycine salt (pH 3.0) is used to elute the protein of interest followed by neutralization with 1 M Tris-HCl.</p><heading id="h-0015" level="1">Example 5 Verification of Affinity Activity of the Chimeric VHH-Fc Antibodies In Vitro</heading><p id="p-0443" num="0437">In order to evaluate the obtained VHH-Fc candidate antibodies, an FACS method is used to detect the binding activity thereof to the PD-L1 protein expressing cells. The specific method is as follows:</p><p id="p-0444" num="0438">1) collecting the cultured human PD-L1-CHO cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0445" num="0439">2) adding the PD-L1-CHO cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0446" num="0440">3) adding the gradient-diluted candidate antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0447" num="0441">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0448" num="0442">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0449" num="0443">6) adding a PE-labeled anti-human IgG Fc flow cytometry antibody (Abcam, ab98596), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0450" num="0444">7) centrifuging the mixture at 300 g to remove the supernatant, adding the FACS buffer and resuspending the cells; and</p><p id="p-0451" num="0445">8) repeating step 10) twice, adding the FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102).</p><p id="p-0452" num="0446">As shown in Table 2, by the FACS experiment, the present inventors screen out 2 nanobody candidates with high affinities (NB22D-21 and NB22gb-10), and the affinities thereof are higher than or similar to that of the control antibody.</p><p id="p-0453" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>EC50 of antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="70pt" align="center"/><colspec colname="2" colwidth="119pt" align="center"/><tbody valign="top"><row><entry/><entry>Clone number</entry><entry>EC50 (&#x3bc;g/mL)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>NB22D-21</entry><entry>0.39</entry></row><row><entry/><entry>NB22gb-10</entry><entry>0.39</entry></row><row><entry/><entry>KN035 (control)</entry><entry>0.39</entry></row><row><entry/><entry>Atezolizumab (control)</entry><entry>0.83</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0016" level="1">Example 6 Verification of Blocking Activity of the Chimeric VHH-Fc Antibodies Against PD-1</heading><p id="p-0454" num="0447">In order to evaluate the obtained VHH-Fc candidate antibodies, an FACS method is used to detect the blocking activity thereof against PD-1/PD-L1. The specific method is as follows:</p><p id="p-0455" num="0448">1) collecting the cultured human PD-L1-CHO cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0456" num="0449">2) adding the PD-L1-CHO cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0457" num="0450">3) adding the gradient-diluted candidate antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0458" num="0451">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0459" num="0452">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0460" num="0453">6) adding 100 &#x3bc;L of biotin-labeled PD-1-Fc protein diluent (1 &#x3bc;g/mL) to the corresponding wells, resuspending the cells and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0461" num="0454">7) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0462" num="0455">8) repeating step 7) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0463" num="0456">9) adding a PE-labeled streptavidin (eBioscience, 12-4317-87), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0464" num="0457">10) centrifuging the mixture at 300 g to remove the supernatant, adding an FACS buffer and resuspending the cells; and</p><p id="p-0465" num="0458">11) repeating step 10) twice, adding the FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102).</p><p id="p-0466" num="0459">As shown in Table 3, by the FACS experiment, the present inventors verify that the 2 nanobody candidates with clone numbers NB22D-21 and NB22gb-10 in Example 5 both have high blocking activities, and the blocking activities thereof are higher than or similar to that of the control antibody.</p><p id="p-0467" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>IC50 of antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="35pt" align="left"/><colspec colname="1" colwidth="70pt" align="center"/><colspec colname="2" colwidth="112pt" align="center"/><tbody valign="top"><row><entry/><entry>Clone number</entry><entry>IC50 (&#x3bc;g/mL)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>NB22D-21</entry><entry>0.41</entry></row><row><entry/><entry>NB22gb-10</entry><entry>0.54</entry></row><row><entry/><entry>KN035 (control)</entry><entry>0.39</entry></row><row><entry/><entry>Atezolizumab (control)</entry><entry>0.86</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0017" level="1">Example 7 Verification of Blocking Activity of the Chimeric VHH-Fc Antibodies Against CD80</heading><p id="p-0468" num="0460">In order to evaluate the obtained VHH-Fc candidate antibodies, an FACS method is used to detect the blocking activity thereof against CD80/PD-L1. The specific method is as follows:</p><p id="p-0469" num="0461">1) collecting the cultured human PD-L1-CHO cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0470" num="0462">2) adding the PD-L1-CHO cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0471" num="0463">3) adding the gradient-diluted candidate antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0472" num="0464">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0473" num="0465">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0474" num="0466">6) adding 100 &#x3bc;L of biotin-labeled CD80 protein diluent (1 &#x3bc;g/mL) to the corresponding wells, resuspending the cells and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0475" num="0467">7) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0476" num="0468">8) repeating step 7) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0477" num="0469">9) adding a PE-labeled streptavidin (eBioscience, 12-4317-87), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0478" num="0470">10) centrifuging the mixture at 300 g to remove the supernatant, adding the FACS buffer and resuspending the cells; and</p><p id="p-0479" num="0471">11) repeating step 10) twice, adding the FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102).</p><p id="p-0480" num="0472">As shown in Table 4, by the FACS experiment, the present inventors verify that the 2 nanobody candidate molecules with clone numbers NB22D-21 and NB22gb-10 in Example 5 both have high blocking activities, and the blocking activities thereof are higher than or similar to that of the control antibody.</p><p id="p-0481" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>IC50 of antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="35pt" align="left"/><colspec colname="1" colwidth="70pt" align="center"/><colspec colname="2" colwidth="112pt" align="center"/><tbody valign="top"><row><entry/><entry>Clone number</entry><entry>IC50 (&#x3bc;g/mL)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>NB22D-21</entry><entry>0.7081</entry></row><row><entry/><entry>NB22gb-10</entry><entry>0.7651</entry></row><row><entry/><entry>KN035 (control)</entry><entry>0.6307</entry></row><row><entry/><entry>Atezolizumab (control)</entry><entry>0.9077</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0018" level="1">Example 8 Binding Activity of the Chimeric VHH-Fc Antibodies on Tumor Cells</heading><p id="p-0482" num="0473">In order to evaluate the binding activity of the VHH-Fc candidate antibodies on human melanoma cell line A375 cells (ATCC, CRL-1619), an FACS method is used to detect the binding activity thereof to the PD-L1 protein on A375 cells. The specific method is as follows:</p><p id="p-0483" num="0474">1) detaching A375 cells with trypsin containing 0.25% EDTA, collecting the cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0484" num="0475">2) adding the A375 cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0485" num="0476">3) adding the gradient-diluted candidate antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0486" num="0477">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0487" num="0478">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0488" num="0479">6) adding 100 &#x3bc;L of diluents of each candidate antibody and the control antibody (1 &#x3bc;g/mL) to the corresponding wells, resuspending the cells and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0489" num="0480">7) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0490" num="0481">8) repeating step 7) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0491" num="0482">9) adding a PE-labeled anti-biotin flow cytometry antibody (Abcam), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0492" num="0483">10) centrifuging the mixture at 300 g to remove the supernatant, adding the FACS buffer and resuspending the cells; and</p><p id="p-0493" num="0484">11) repeating step 10) twice, adding an FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102) (the detection results are shown in <figref idref="DRAWINGS">FIG. <b>3</b></figref>).</p><p id="p-0494" num="0485"><figref idref="DRAWINGS">FIG. <b>3</b></figref> shows that the 2 nanobody candidates with clone numbers NB22D-21 and NB22gb-10 have comparable binding activity on human melanoma cell line A375 cells to that of the control antibody.</p><heading id="h-0019" level="1">Example 9 Verification of Binding Activity of the Chimeric VHH-Fc Antibodies to Mouse PD-L1 and Rhesus Monkey PD-L1</heading><p id="p-0495" num="0486">In order to evaluate the cross-reactivity of the VHH-Fc candidate antibodies to monkey PD-L1 and mouse PD-L1, an FACS method is used to detect the binding activity thereof to the mouse and rhesus monkey PD-L1 protein on cells. The specific method is as follows:</p><p id="p-0496" num="0487">1) collecting the cultured mouse PD-L1-CHO cells and monkey PD-L1-CHO cells, centrifuging the collected cells at 300 g to remove the culture medium, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0497" num="0488">2) adding the mouse PD-L1-CHO cells and the monkey PD-L1-CHO cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, respectively, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0498" num="0489">3) adding the gradient-diluted candidate antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0499" num="0490">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0500" num="0491">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0501" num="0492">6) adding 100 &#x3bc;L of biotin-labeled PD-1-Fc protein diluent (1 &#x3bc;g/mL) to the corresponding wells, resuspending the cells and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0502" num="0493">7) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0503" num="0494">8) repeating step 7) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0504" num="0495">96) adding a PE-labeled anti-biotin flow cytometry antibody (Abcam), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0505" num="0496">7) centrifuging the mixture at 300 g to remove the supernatant, adding the FACS buffer and resuspending the cells; and</p><p id="p-0506" num="0497">8) repeating step 7) twice, adding the FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102).</p><p id="p-0507" num="0498">The detection results of the human-mouse cross reactivity show that the nanobody candidate molecule with clone number NB22D-21 has a certain binding activity to mouse PD-L1.</p><p id="p-0508" num="0499">For the detection results of the human-monkey cross reactivity, Table 5 shows that the 2 nanobody candidates with clone numbers NB22D-21 and NB22gb-10 both have good activities in recognizing monkey PD-L1.</p><p id="p-0509" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 5</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>EC50 value</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="70pt" align="center"/><colspec colname="2" colwidth="119pt" align="center"/><tbody valign="top"><row><entry/><entry>Clone number</entry><entry>EC50 (&#x3bc;g/mL)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>NB22D-21</entry><entry>0.25</entry></row><row><entry/><entry>NB22gb-10</entry><entry>0.20</entry></row><row><entry/><entry>KN035 (control)</entry><entry>0.21</entry></row><row><entry/><entry>Atezolizumab (control)</entry><entry>0.33</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0020" level="1">Example 10 Specificity Detection of the Chimeric VHH-Fc Antibodies to PD-L1</heading><p id="p-0510" num="0500">In order to confirm the binding specificity of the candidate antibodies to a PD-L1 protein, an ELISA method is used to detect the binding activity thereof to other proteins of the B7 family. The specific method is as follows:</p><p id="p-0511" num="0501">one day prior to the experiment, 30 &#x3bc;L of protein diluents such as B7-H1 (i.e., PDL1), B7-H2, B7-H3, B7-H4 and B7-DC (the above-mentioned proteins are all purchased from Sino Biological Co., Ltd., with Cat. Nos. 10084-HNAH, 11559-H08H, 11188-H08H, 10738-H08H and 10292-H08H-B, respectively) are added to an ELISA plate at a final concentration of 2 &#x3bc;g/mL, and incubated at 4&#xb0; C. overnight; the next day, the ELISA plate is rinsed 3 times with PBST, then blocked with 150 &#x3bc;L of 5% PBSM, and incubated at room temperature for 2 hours; the ELISA plate is rinsed 3 times with PBST again, and then 30 &#x3bc;L of candidate antibody and control antibody diluents are added thereto, and the plate is incubated at room temperature for 1 hour; the plate is rinsed 3 times with PBST, and an anti-human IgG Fc-HRP second antibody diluted at 1:7000 is added thereto (30 &#x3bc;L/well), and the plate is incubated at room temperature for 30 minutes; the plate is rinsed 6 times with PBST, then TMB is added thereto for color development, and finally, 2M HCl is added to stop the reaction. The values are read at the wavelength of OD450 by using a microplate reader (Molecular Devices, SpecterMax 190), and the results are shown in Table 6 and <figref idref="DRAWINGS">FIG. <b>4</b></figref>.</p><p id="p-0512" num="0502">The results of the specificity assay are shown in Table 6 and <figref idref="DRAWINGS">FIG. <b>4</b></figref>.</p><p id="p-0513" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 6</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Binding specificity of candidate antibodies to the PD-L1 family</entry></row><row><entry>proteins</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><tbody valign="top"><row><entry>Clone/control</entry><entry>B7-H1</entry><entry>B7-H2</entry><entry>B7-H3</entry><entry>B7-H4</entry><entry>B7-DC</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>NB22D-21</entry><entry>+</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry></row><row><entry>NB22-gb-10</entry><entry>+</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry></row><row><entry>KN035</entry><entry>+</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry></row><row><entry>Atezolizumab</entry><entry>+</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry namest="1" nameend="6" align="left" id="FOO-00003">+: indicates the binding activity being detected.</entry></row><row><entry namest="1" nameend="6" align="left" id="FOO-00004">&#x2212;: indicates no binding activity being detected.</entry></row></tbody></tgroup></table></tables></p><p id="p-0514" num="0503">Table 6 and <figref idref="DRAWINGS">FIG. <b>4</b></figref> showed that the 2 nanobody candidates with clone numbers NB22D-21 and NB22gb-10 have no binding activities to B7 family proteins other than B7-H1, but only have the binding activity to B7-H1, and this binding specificity is consistent with that of the control antibodies.</p><heading id="h-0021" level="1">Example 11 Verification of the In Vitro Biological Activity of the Chimeric VHH-Fc Antibodies</heading><p id="p-0515" num="0504">In order to confirm the ability of the candidate antibody to stimulate T cell activation in vitro, the present inventors established a mixed lymphocyte reaction in vitro assay. The specific method is as follows: CD14-positive monocytes and CD4-positive T cells are sorted in vitro by using a</p><p id="p-0516" num="0505">Miltenyibiotec sorting kit (Miltenyibiotec, 130-050-201). The monocytes are induced into dendritic cells (DCs) by in vitro induction culture with 100 ng/mL IL-4 and 100 ng/mL GM-CSF for 7 days. Then the CD4-positive T cells and DCs are mixed at a cell number ratio of 10:1, and the gradient-diluted candidate antibody and the control antibody are added to the cells and cultured in a cell incubator at 37&#xb0; C. for 5 days. After 72 hours of culture, the cell supernatant is taken and diluted with PBS, so as to detect the secretion amount of IL-2 in the culture supernatant by using an IL-2 ELISA kit; and after 5 days of culture, the cell supernatant is taken and diluted with PBS, so as to detect the secretion amount of IFN-&#x3b3; in the culture supernatant by using an IFN-&#x3b3; ELISA kit.</p><p id="p-0517" num="0506">By detecting the secretion amount of IL-2, the present inventors obtain the verification results of mixed lymphocyte reaction assay of the candidate antibody, which results are shown in <figref idref="DRAWINGS">FIG. <b>5</b></figref>. <figref idref="DRAWINGS">FIG. <b>5</b></figref> shows that the nanobody candidate of the present invention can activate the T cell immune response.</p><heading id="h-0022" level="1">Example 12 Humanization of the Candidate Antibody</heading><p id="p-0518" num="0507">In order to reduce the potential immunogenicity of the candidate, the present inventors perform humanization conversion on the candidate antibodies. Structural Modeling is performed by using a homology modeling method with Discovery Studio and Schrodinger Antibody Modeling, respectively, and 5-10 optimal structural solutions are selected. The homology modeling method is generally used to perform modeling on a Loop region, and if the CDR amino acid sequence alignment results show that the identity is lower than 50%, the de novo modeling method is used to build a CDR3 structural model. PDB BLAST is used to retrieve 10 antibody crystal structure models with the highest sequence identity (the structure resolution is higher than 2.5 angstroms); the models are compared with that from the automatic modeling, and the optimal structural model is selected. The present inventors preform antibody humanization modification on the NB22D-21 molecule, thus obtaining two humanized molecules, the numbers of which are NB22D-21-huVH1 and NB22D-21-huVH2, respectively.</p><heading id="h-0023" level="1">Example 13 Binding of the Humanized Candidate Antibodies to the Human PD-L1-CHO Cells</heading><p id="p-0519" num="0508">In order to detect the effect of antibody humanization on the binding activity to the human PD-L1 antigen, the present inventors use FACS to detect the parental antibody and the humanized antibodies thereof, as follows:</p><p id="p-0520" num="0509">1) collecting the cultured human PD-L1-CHO cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0521" num="0510">2) adding the PD-L1-CHO cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0522" num="0511">3) adding the gradient-diluted parental antibody and humanized antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0523" num="0512">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0524" num="0513">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0525" num="0514">6) adding a PE-labeled anti-human IgG Fc flow cytometry antibody (Abcam, ab98596), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0526" num="0515">7) centrifuging the mixture at 300 g to remove the supernatant, adding the FACS buffer and resuspending the cells; and</p><p id="p-0527" num="0516">8) repeating step 7) twice, adding the FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102) (the results are shown in <figref idref="DRAWINGS">FIG. <b>6</b></figref>).</p><p id="p-0528" num="0517"><figref idref="DRAWINGS">FIG. <b>6</b></figref> shows that the humanized antibodies (i.e., NB22D-21-huVH1 and NB22D-21-huVH2) bind to human PD-L1 with the similar affinity as that of the parental antibody (i.e., NB22D-21).</p><heading id="h-0024" level="1">Example 14 Binding of the Humanized Antibodies to Mouse PD-L1-CHO Cells</heading><p id="p-0529" num="0518">In order to detect the effect of the humanization on the cross reactivity to the mouse PD-L1 antigen, the present inventors use FACS to detect the candidate antibodies.</p><p id="p-0530" num="0519">1) collecting the cultured mouse PD-L1-CHO cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0531" num="0520">2) adding the mouse PD-L1-CHO cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0532" num="0521">3) adding the gradient-diluted parental antibody and humanized antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0533" num="0522">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0534" num="0523">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0535" num="0524">6) adding a PE-labeled anti-human IgG Fc flow cytometry antibody (Abcam, ab98596), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0536" num="0525">7) centrifuging the mixture at 300 g to remove the supernatant, adding the FACS buffer and resuspending the cells; and</p><p id="p-0537" num="0526">8) repeating step 7) twice, adding the FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102) (see <figref idref="DRAWINGS">FIG. <b>7</b></figref> and <figref idref="DRAWINGS">FIG. <b>8</b></figref> for results).</p><p id="p-0538" num="0527"><figref idref="DRAWINGS">FIG. <b>7</b></figref> shows that among the humanized antibodies, NB22D-21-huVH1 binds to mouse PD-L1 with better affinity than that of the parent molecule (i.e., NB22D-21).</p><p id="p-0539" num="0528">Specifically, it is shown in <figref idref="DRAWINGS">FIG. <b>7</b></figref> that compared with the parental antibody NB22D-21 and the control antibody KN035, the humanized antibody NB22D-21-huVH1 has a very good binding activity to the mouse PD-L1 protein; the peak plots in flow cytometry of KN035 and NB22D-21-huVH1 are selected (as shown in <figref idref="DRAWINGS">FIG. <b>8</b></figref>), and it shows that when 20m/mL of KN035 and NB22D-21-huVH1 are used to bind to mouse PD-L1-overexpressing cells, respectively, KN035 cannot recognize mouse PD-L1 on the surface of the CHO cells (<figref idref="DRAWINGS">FIG. <b>8</b>A</figref>), while NB22D-21-huVH1 can recognize mouse PD-L1 on the surface of the CHO cells well (<figref idref="DRAWINGS">FIG. <b>8</b>B</figref>) (note: the dividing line of each figure is the position of the set fluorescence intensity threshold).</p><heading id="h-0025" level="1">Example 15 Verification of the Blocking Activity of the Humanized Antibodies Against PD-1</heading><p id="p-0540" num="0529">In order to evaluate the humanized antibodies, an FACS method is used to detect the blocking activity thereof against PD-1/PD-L1. The specific method is as follows:</p><p id="p-0541" num="0530">1) collecting the cultured human PD-L1-CHO cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0542" num="0531">2) adding the PD-L1-CHO cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0543" num="0532">3) adding the gradient-diluted parental antibody and humanized antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0544" num="0533">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0545" num="0534">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0546" num="0535">6) adding 100 &#x3bc;L of biotin-labeled PD-1-Fc protein diluents (1 &#x3bc;g/mL) to the corresponding wells, resuspending the cells and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0547" num="0536">7) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0548" num="0537">8) repeating step 7) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0549" num="0538">9) adding a PE-labeled streptavidin (eBioscience, 12-4317-87), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0550" num="0539">10) centrifuging the mixture at 300 g to remove the supernatant, adding the FACS buffer and resuspending the cells; and 11) repeating step 10) twice, adding the FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102) (the results are shown in <figref idref="DRAWINGS">FIG. <b>9</b></figref>).</p><p id="p-0551" num="0540"><figref idref="DRAWINGS">FIG. <b>9</b></figref> shows that the humanized antibodies (i.e., NB22D-21-huVH1 and NB22D-21-huVH2) have comparable blocking activity against PD-1 protein binding to PD-L1 compared to that of the parent antibody (i.e., NB22D-21) and the positive control KN035.</p><heading id="h-0026" level="1">Example 16 Affinity Maturation of the Humanized Antibodies</heading><p id="p-0552" num="0541">In order to improve the affinity and blocking activity of antibody molecules in binding to a human PD-L1 antigen, the present inventors perform affinity maturation to the humanized candidate.</p><p id="p-0553" num="0542">Affinity maturation is performed by using methods such as single-site saturation mutagenesis, multi-points combinatorial mutagenesis and strand displacement; a Trim primer technique is used to directionally design primers for the CDR regions, thereby constructing an affinity-matured antibody library; and a phage display technique is used to screen the affinity-matured library. The VHH lysates are prepared after monoclones are obtained, and FACS is used to detect the affinity and blocking activity of the clones. By means of screening, we obtain 4 clones that may be superior to the parental, namely SY01-201, SY01-208, SY01-NB-004 and SY01-NB-027-M, respectively.</p><p id="p-0554" num="0543">The specific experimental results are shown in <figref idref="DRAWINGS">FIG. <b>10</b></figref> and <figref idref="DRAWINGS">FIG. <b>11</b></figref>. From the qualitative/semi-quantitative results of the monoclonal cell lysates, it indicates that the four molecules SY01-201, SY01-208, SY01-NB-004 and SY01-NB-027-M have similar binding activity and blocking activity to that of the parental antibody NB22D-21.</p><heading id="h-0027" level="1">Example 17 Engineering of the Post-Translational Modification of the Humanized Antibodies</heading><p id="p-0555" num="0544">In order to optimize the developability of the humanized antibody and avoid the influence of potential post-translational modification sites on protein folding, activity and functions, the present inventors perform antibody engineering design on the humanized antibody NB22D-21-huVH2.</p><p id="p-0556" num="0545">Antibody engineering is performed by using point mutagenesis; random mutagenesis is performed on the potential post-translational modification sites, thereby constructing a derisked antibody library; and a phage display technique is used to screen the library. The VHH lysates are prepared after monoclones are obtained, and FACS is performed to detect the blocking activity of the clones with PD-L1-CHO cells.</p><p id="p-0557" num="0546">By means of preliminary screening, the present inventors obtain 10 derisked candidate antibodies: SY01-D21-3, SY01-D21-4, SY01-D21-5, SY01-D21-6, SY01-D21-8, SY01-D21-17, SY01-D21-21, SY01-D21-24, SY01-D21-38 and SY01-D21-47 (respectively abbreviated as 3, 4, 5, 6, 8, 17, 21, 24, 38 and 47 in <figref idref="DRAWINGS">FIG. <b>15</b></figref>; the parent molecule being NB22D-21-huVH2, abbreviated as D21-Vh2; and the isotype control being human IgG1), and by means of further screening, the present inventors obtain 5 clones that may be superior to the parental, namely SY01-D21-4, SY01-D21-8, SY01-D21-17, SY01-D21-24 and SY01-D21-47, respectively.</p><p id="p-0558" num="0547">The experimental results are shown in <figref idref="DRAWINGS">FIG. <b>15</b></figref>. From the qualitative/semi-quantitative results of the cell lysates of the candidates, it shows that the 4 modified candidates SY01-D21-4, SY01-D21-8, SY01-D21-17 and SY01-D21-24 have similar blocking activity to that of the parental molecule NB22D-21-huVH2. In addition, since the cell expression level of SY01-D21-47 is not high, this clone is not selected for further validations.</p><heading id="h-0028" level="1">Example 18 Full-Length Construction of the Derisked Candidate Clones and Sample Production Thereof</heading><p id="p-0559" num="0548">The positive VHH candidate antibodies SY01-D21-4, SY01-D21-8, SY01-D21-17 and SY01-D21-24 obtained by screening are fused to the human IgG1 Fc fragments. The C-terminus of the positive VHH gene sequence is linked to the N-terminus of the human IgG1 Fc fragment gene sequence to construct a fusion expression plasmid. The fusion expression plasmid is transformed into ExpiCHO cells to induce expression, thereby obtaining 4 VHH-Fc chimeric antibody proteins (respectively referred to as NB22D-21-4, NB22D-21-8, NB22D-21-17 and NB22D-21-24).</p><p id="p-0560" num="0549">The antibody is expressed by using the ExpiCHO transient transfection and expression system; the culture medium is the Gibco ExpiCHO Expression Medium, A29100-01; and the transfection kit is ExpiFectamine&#x2122; CHO Transfection Kit, A29129. The specific method is as follows: one day prior to transfection, ExpiCHO cells are passaged, and in a 25 ml culture, 25 &#x3bc;g of the constructed plasmids are mixed with a transfection reagent, then added dropwise to 25 ml of ExpiCHO cell cultures, fully mixed and expressed at 37&#xb0; C. for 18-22 hours. Then a feed culture medium is added according to the instruction in the kit, and after feeding, the cells are cultured at 32&#xb0; C. On day 5 after transfection, a second feed culture medium is added, and the cells are cultured at 32&#xb0; C. for 10-12 days. Then the expressed cell suspension is centrifuged at a high speed to obtain a supernatant. The obtained supernatant is filtered through 0.22 &#x3bc;m and then purified by using a Protein A/G affinity purification method. 100 mM glycine salt (pH 3.0) is used to elute the protein of interest followed by neutralization with 1 M Tris-HCl.</p><heading id="h-0029" level="1">Example 19 Verification of Binding Activity of the Derisked Candidate Antibodies to Human PD-L1 and Monkey PD-L1</heading><p id="p-0561" num="0550">In order to evaluate 4 derisked VHH-Fc candidate antibodies, an FACS method is used to detect the binding activities thereof to cell expressed human PD-L1 and monkey PD-L1 proteins. The specific method is as follows:</p><p id="p-0562" num="0551">1) collecting the cultured human and monkey PD-L1-CHO cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0563" num="0552">2) adding the human and monkey PD-L1-CHO cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, respectively, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0564" num="0553">3) adding the gradient-diluted candidate antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0565" num="0554">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0566" num="0555">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0567" num="0556">6) adding a PE-labeled anti-human IgG Fc flow cytometry antibody (Abcam, ab98596), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0568" num="0557">7) centrifuging the mixture at 300 g to remove the supernatant, adding the FACS buffer and resuspending the cells; and</p><p id="p-0569" num="0558">8) repeating step 10) twice, adding the FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102).</p><p id="p-0570" num="0559">As shown in Table 7, the binding activities of 4 candidate molecules to the human and monkey PD-L1-CHO are compared, and the present inventors screen out 2 nanobody candidate molecules NB22D-21-4 and NB22D-21-24 which have relatively high affinities to human PD-L1 and monkey PD-L1.</p><p id="p-0571" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 7</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>EC50 of antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="84pt" align="center"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="77pt" align="center"/><tbody valign="top"><row><entry/><entry>EC50 (&#x3bc;g/mL) </entry><entry>EC50 (&#x3bc;g/mL) </entry></row><row><entry/><entry>of antibody</entry><entry>of antibody</entry></row><row><entry/><entry>binding to human </entry><entry>binding to monkey </entry></row><row><entry>Clone number</entry><entry>PD-L1-CHO</entry><entry>PD-L1-CHO</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>NB22D-21-huVH2</entry><entry>0.72</entry><entry>1.82</entry></row><row><entry>NB22D-21-4</entry><entry>0.21</entry><entry>0.30</entry></row><row><entry>NB22D-21-8</entry><entry>0.26</entry><entry>0.70</entry></row><row><entry>NB22D-21-17</entry><entry>1.73</entry><entry>3.25</entry></row><row><entry>NB22D-21-24</entry><entry>0.14</entry><entry>0.39</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0030" level="1">Example 20 Verification of the Blocking Activity of the Derisked Candidate Antibodies Against PD-1</heading><p id="p-0572" num="0560">In order to evaluate the obtained VHH-Fc candidate antibodies, an FACS method is used to detect the blocking activity thereof against PD-1/PD-L1. The specific method is as follows:</p><p id="p-0573" num="0561">1) collecting the cultured human PD-L1-CHO cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0574" num="0562">2) adding the PD-L1-CHO cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0575" num="0563">3) adding the gradient-diluted candidate antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0576" num="0564">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0577" num="0565">5) repeating step 4) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0578" num="0566">6) adding 100 &#x3bc;L of biotin-labeled PD-1-Fc protein diluent (1 &#x3bc;g/mL) to the corresponding wells, resuspending the cells and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0579" num="0567">7) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L of FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0580" num="0568">8) repeating step 7) twice, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0581" num="0569">9) adding a PE-labeled streptavidin (eBioscience, 12-4317-87), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0582" num="0570">10) centrifuging the mixture at 300 g to remove the supernatant, adding the FACS buffer and resuspending the cells; and 11) repeating step 10) twice, adding the FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX AOO-1-1102).</p><p id="p-0583" num="0571">As shown in Table 8, by the FACS experiment, the present inventors verify that the 2 nanobody candidates with clone numbers NB22D-21-4 and NB22D-21-24 in Example 19 both have high blocking activities, and the blocking activities thereof are higher than that of the parental NB22D-21-huVH2 antibody.</p><p id="p-0584" num="0000"><tables id="TABLE-US-00012" num="00012"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 8</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>IC50 of antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="42pt" align="left"/><colspec colname="1" colwidth="63pt" align="center"/><colspec colname="2" colwidth="112pt" align="center"/><tbody valign="top"><row><entry/><entry>Clone number</entry><entry>IC50 (&#x3bc;g/mL)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>NB22D-21-huVH2</entry><entry>1.00</entry></row><row><entry/><entry>NB22D-21-4</entry><entry>0.30</entry></row><row><entry/><entry>NB22D-21-24</entry><entry>0.20</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0031" level="1">Example 21 Specificity Detection of the Binding of the Derisked Candidate Antibodies to PD-L1</heading><p id="p-0585" num="0572">In order to confirm the binding specificity of the derisked candidates to a PD-L1 protein, an FACS method is used to detect the binding specificity thereof to PD-L1 negative cells. The method is specifically divided into two parts, and the first part of the specific method is as follows:</p><p id="p-0586" num="0573">1) collecting the cultured Jurkat and Raji cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer (buffer ingredients: 1*PBS+5% FBS+2% BSA) and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0587" num="0574">2) adding the Jurkat and Raji cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, respectively, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0588" num="0575">3) adding the gradient-diluted candidate antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0589" num="0576">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0590" num="0577">5) repeating step 4) four times, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0591" num="0578">6) adding a PE-labeled anti-human IgG Fc flow cytometry antibody (Abcam, ab98596), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0592" num="0579">7) centrifuging the mixture at 300 g to remove the supernatant, adding the FACS buffer and resuspending the cells; and</p><p id="p-0593" num="0580">8) repeating step 10) twice, adding the FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102).</p><p id="p-0594" num="0581">As shown in Table 9 below, according to the FACS detection results, the present inventors indicate positive and negative by &#x201c;+&#x201d; (binding) and &#x201c;&#x2212;&#x201d; (no binding), respectively, and Table 9 shows that for the NB22D-21-4 and NB22D-21-24 clones, the former has no non-specific binding on both cells, while the latter has relatively high non-specific binding, and the control antibody does not show non-specific binding.</p><p id="p-0595" num="0000"><tables id="TABLE-US-00013" num="00013"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 9</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Non-specific binding of antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="119pt" align="center"/><colspec colname="2" colwidth="21pt" align="center"/><colspec colname="3" colwidth="77pt" align="center"/><tbody valign="top"><row><entry>Clone/cell</entry><entry>Jurkat</entry><entry>Raji</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>NB22D-21-huVH2</entry><entry>&#x2212;</entry><entry>&#x2212;</entry></row><row><entry>NB22D-21-4</entry><entry>&#x2212;</entry><entry>&#x2212;</entry></row><row><entry>NB22D-21-24</entry><entry>+</entry><entry>+</entry></row><row><entry>KN035 (control)</entry><entry>&#x2212;</entry><entry>&#x2212;</entry></row><row><entry>Atezolizumab (control)</entry><entry>&#x2212;</entry><entry>&#x2212;</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0596" num="0582">In the second part of the experiment, the present inventors use an FACS method to detect the binding specificity of the NB22D-21-4 clone to cell expressed B7 family proteins. The specific method is as follows:</p><p id="p-0597" num="0583">1) collecting the cultured B7-H2, B7-H4 and B7-H5 over-expressing CHO cells, centrifuging the collected cells at 300 g to remove the supernatant, resuspending the cells in a formulated FACS buffer (buffer ingredients: 1*PBS+5% FBS+2% BSA) and counting the cells, and adjusting the density of the cell suspension to 2&#xd7;10<sup>6 </sup>cells/mL;</p><p id="p-0598" num="0584">2) adding the B7-H2, B7-H4 and B7-H5 over-expressing cells to a 96-well round-bottom plate at 100 &#x3bc;L/well, respectively, and centrifuging the cells at 300 g to remove the supernatant;</p><p id="p-0599" num="0585">3) adding the gradient-diluted candidate antibody diluents and the control antibody diluents to the corresponding wells, pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0600" num="0586">4) centrifuging the incubated cell mixed solution at 300 g to remove the supernatant, adding 200 &#x3bc;L FACS buffer to the corresponding wells and resuspending the cells by using a multi-channel pipette;</p><p id="p-0601" num="0587">5) repeating step 4) four times, and centrifuging the cell mixed solution at 300 g to remove the supernatant;</p><p id="p-0602" num="0588">6) adding a PE-labeled anti-human IgG Fc flow cytometry antibody (Abcam, ab98596), pipetting the cells repeatedly with a multi-channel pipette and incubating the cells at 4&#xb0; C. for 30 minutes;</p><p id="p-0603" num="0589">7) centrifuging the mixture at 300 g to remove the supernatant, adding the FACS buffer and resuspending the cells; and</p><p id="p-0604" num="0590">8) repeating step 10) twice, adding the FACS buffer to the wells (200 &#x3bc;L/well), resuspending the cells, and performing detection by a flow cytometer (Beckman, CytoFLEX A00-1-1102).</p><p id="p-0605" num="0591">As shown in Table 10 below, according to the FACS detection results, the present inventors indicate positive and negative by &#x201c;+&#x201d; (binding) and &#x201c;&#x2212;&#x201d; (no binding), respectively, and Table 10 shows that NB22D-21-4 does not have non-specific binding on a variety of cells, and the control antibody does not show non-specific binding.</p><p id="p-0606" num="0000"><tables id="TABLE-US-00014" num="00014"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 10</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Specificity of antibodies to B7 family proteins</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="63pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry/><entry>Clone/cell</entry><entry>B7-H2</entry><entry>B7-H3</entry><entry>B7-H4</entry><entry>B7-H5</entry></row><row><entry/><entry namest="offset" nameend="5" align="center" rowsep="1"/></row><row><entry/><entry>NB22D-21-huVH2</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry></row><row><entry/><entry>NB22D-21-4</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry></row><row><entry/><entry>KN035 (control)</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry><entry>&#x2212;</entry></row><row><entry/><entry namest="offset" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0032" level="1">Example 22 Verification of In Vitro MLR Activity of the NB22D-21-4 Antibody</heading><p id="p-0607" num="0592">In order to confirm the ability of the candidate antibody to stimulate T cell activation in vitro, the present inventors establish a mixed lymphocyte reaction assay in vitro. The specific method is as follows: CD14-positive monocytes and CD4-positive T cells are sorted in vitro by using a</p><p id="p-0608" num="0593">Miltenyibiotec sorting kit (Miltenyibiotec, 130-050-201). The monocytes are induced into dendritic cells (DCs) by in vitro induction culture with 100 ng/mL IL-4 and 100 ng/mL GM-CSF for 7 days. Then the CD4-positive T cells and DCs are mixed at a cell number ratio of 10:1, and the gradient-diluted candidate antibody and the control antibody are added to the cells and cultured in a cell incubator at 37&#xb0; C. for 5 days. After 72 hours of culture, the cell supernatant is taken and diluted with PBS, so as to detect the secretion level of IL-2 in the culture supernatant by using an IL-2 ELISA kit; and after 5 days of culture, the cell supernatant is taken and diluted with PBS, so as to detect the secretion level of IFN-&#x3b3; in the culture supernatant by using an IFN-&#x3b3; ELISA kit.</p><p id="p-0609" num="0594">By detecting the secretion levels of IFN-&#x3b3; and IL-2, the present inventors obtain the verification results of mixed lymphocyte reaction assay of the candidate antibody, which results are shown in <figref idref="DRAWINGS">FIG. <b>16</b></figref>. <figref idref="DRAWINGS">FIG. <b>16</b></figref> shows that the nanobody candidate molecule NB22D-21-4 of the present invention can activate the T cell immune response.</p><heading id="h-0033" level="1">Example 23 Affinity Maturation of the Candidate Antibodies</heading><p id="p-0610" num="0595">In order to further improve the affinity and blocking activity of the candidate antibodies in binding to a mouse PD-L1 antigen, we perform affinity maturation design on humanized candidate antibodies.</p><p id="p-0611" num="0596">This round of affinity maturation is performed by using a single-site saturation mutagenesis method; a Trim primer technique is used to directionally design primers for the CDR regions, thereby constructing an affinity-matured antibody library; and subsequently a phage display technique is used to screen the affinity-matured library. The affinity maturation library is subjected to panning and preliminary screening, respectively by using mouse antigens; monoclones are obtained for the subsequent construction and expression of full-length antibodies; and the candidate clones are tested for affinity, human-mouse cross reactivity and blocking activity by FACS. By means of screening, we obtain 5 clones with better activity than that of the parental, namely NB22D-21-45-106, NB22D-21-123, NB22D-21-154, NB22D-21-94 and NB22D-21-109, respectively.</p><p id="p-0612" num="0597">The specific experimental results are shown in <figref idref="DRAWINGS">FIG. <b>12</b></figref>, <figref idref="DRAWINGS">FIG. <b>13</b></figref> and <figref idref="DRAWINGS">FIG. <b>14</b></figref>. The results showed that the five molecules NB22D-21-45-106, NB22D-21-123, NB22D-21-154, NB22D-21-94 and NB22D-21-109 have the similar or better binding activity and blocking activity to or than that of the control antibody NB22D21-4, and have better mouse cross activity than that of the parental NB22D-21-huVH2. The experimental results of Example 15 and Example 17 showed that the NB22D21-4 molecule has better binding activity and blocking activity than that of the parental antibody NB22D-21, and it can be deduced that the 5 molecules obtained by affinity maturation have highly similar or better binding and blocking activity to or than that of the parental antibody NB22D-21, and have better mouse cross activity than that of the parental antibody NB22D-21 and the control antibody KN035.</p><p id="p-0613" num="0598">A experienced specialist in the field will further appreciate that the present invention may be embodied in other specific forms without departing from the spirit or central features thereof. In that the foregoing description of the present invention discloses only exemplary embodiments thereof, it is to be understood that other variations are contemplated as being within the scope of the present invention. Accordingly, the present invention is not limited to the particular embodiments that have been described in detail herein. Rather, reference should be made to the appended claims as indicative of the scope and content of the invention.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002494A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-chemistry idref="CHEM-US-00001" cdx-file="US20230002494A1-20230105-C00001.CDX" mol-file="US20230002494A1-20230105-C00001.MOL"/><us-chemistry idref="CHEM-US-00002" cdx-file="US20230002494A1-20230105-C00002.CDX" mol-file="US20230002494A1-20230105-C00002.MOL"/><us-chemistry idref="CHEM-US-00003" cdx-file="US20230002494A1-20230105-C00003.CDX" mol-file="US20230002494A1-20230105-C00003.MOL"/><us-chemistry idref="CHEM-US-00004" cdx-file="US20230002494A1-20230105-C00004.CDX" mol-file="US20230002494A1-20230105-C00004.MOL"/><us-chemistry idref="CHEM-US-00005" cdx-file="US20230002494A1-20230105-C00005.CDX" mol-file="US20230002494A1-20230105-C00005.MOL"/><us-chemistry idref="CHEM-US-00006" cdx-file="US20230002494A1-20230105-C00006.CDX" mol-file="US20230002494A1-20230105-C00006.MOL"/><us-chemistry idref="CHEM-US-00007" cdx-file="US20230002494A1-20230105-C00007.CDX" mol-file="US20230002494A1-20230105-C00007.MOL"/><us-chemistry idref="CHEM-US-00008" cdx-file="US20230002494A1-20230105-C00008.CDX" mol-file="US20230002494A1-20230105-C00008.MOL"/><us-chemistry idref="CHEM-US-00009" cdx-file="US20230002494A1-20230105-C00009.CDX" mol-file="US20230002494A1-20230105-C00009.MOL"/><us-chemistry idref="CHEM-US-00010" cdx-file="US20230002494A1-20230105-C00010.CDX" mol-file="US20230002494A1-20230105-C00010.MOL"/><us-chemistry idref="CHEM-US-00011" cdx-file="US20230002494A1-20230105-C00011.CDX" mol-file="US20230002494A1-20230105-C00011.MOL"/><us-chemistry idref="CHEM-US-00012" cdx-file="US20230002494A1-20230105-C00012.CDX" mol-file="US20230002494A1-20230105-C00012.MOL"/><us-chemistry idref="CHEM-US-00013" cdx-file="US20230002494A1-20230105-C00013.CDX" mol-file="US20230002494A1-20230105-C00013.MOL"/><us-chemistry idref="CHEM-US-00014" cdx-file="US20230002494A1-20230105-C00014.CDX" mol-file="US20230002494A1-20230105-C00014.MOL"/><us-chemistry idref="CHEM-US-00015" cdx-file="US20230002494A1-20230105-C00015.CDX" mol-file="US20230002494A1-20230105-C00015.MOL"/><us-chemistry idref="CHEM-US-00016" cdx-file="US20230002494A1-20230105-C00016.CDX" mol-file="US20230002494A1-20230105-C00016.MOL"/><us-chemistry idref="CHEM-US-00017" cdx-file="US20230002494A1-20230105-C00017.CDX" mol-file="US20230002494A1-20230105-C00017.MOL"/><us-chemistry idref="CHEM-US-00018" cdx-file="US20230002494A1-20230105-C00018.CDX" mol-file="US20230002494A1-20230105-C00018.MOL"/><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. An isolated PD-L1 binding molecule, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:<claim-text>(i) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1;</claim-text><claim-text>a CDR1 comprising an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 1; or</claim-text><claim-text>a CDR1 comprising an amino acid sequence which differs from SEQ ID NO: 1 by no more than 2 amino acid additions, deletions and/or substitutions;</claim-text><claim-text>(ii) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2;</claim-text><claim-text>a CDR2 comprising an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 2; or</claim-text><claim-text>a CDR2 comprising an amino acid sequence which differs from SEQ ID NO: 2 by no more than 2 amino acid additions, deletions and/or substitutions;</claim-text><claim-text>and</claim-text><claim-text>(iii) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3 or 12;</claim-text><claim-text>a CDR3 comprising an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO: 3 or 12; or</claim-text><claim-text>a CDR3 comprising an amino acid sequence which differs from SEQ ID NO: 3 or 12 by no more than 2 amino acid additions, deletions and/or substitutions.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The isolated PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the heavy chain variable region comprises:<claim-text>(i) a CDR1 as shown in formula RTDSNIX<sub>1</sub>GMH, wherein X<sub>1 </sub>is H, F or N;</claim-text><claim-text>(ii) a CDR2 as shown in formula TIFIDX<sub>2</sub>NTX<sub>3</sub>, wherein X<sub>2 </sub>is G, L or A, and X<sub>3 </sub>is I or L; and</claim-text><claim-text>(iii) a CDR3 as shown in formula DVSGYGRX<sub>4</sub>, wherein X<sub>4 </sub>is A or Y.</claim-text></claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The isolated PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the heavy chain variable region comprises:<claim-text>(i) a CDR1 comprising or consisting of SEQ ID NO: 1; a CDR2 comprising or consisting of SEQ ID NO: 2; and a CDR3 comprising or consisting of SEQ ID NO: 3; or</claim-text><claim-text>(ii) a CDR1 comprising or consisting of SEQ ID NO: 4; a CDR2 comprising or consisting of SEQ ID NO: 5; and a CDR3 comprising or consisting of SEQ ID NO: 3; or</claim-text><claim-text>(iii) a CDR1 comprising or consisting of SEQ ID NO: 6; a CDR2 comprising or consisting of SEQ ID NO: 7; and a CDR3 comprising or consisting of SEQ ID NO: 3; or</claim-text><claim-text>(iv) a CDR1 comprising or consisting of SEQ ID NO: 1; a CDR2 comprising or consisting of SEQ ID NO: 8; and a CDR3 comprising or consisting of SEQ ID NO: 9; or</claim-text><claim-text>(v) a CDR1 comprising or consisting of SEQ ID NO: 10; a CDR2 comprising or consisting of SEQ ID NO: 11; and a CDR3 comprising or consisting of SEQ ID NO: 12; or</claim-text><claim-text>(vi) a CDR1 comprising or consisting of SEQ ID NO: 13; a CDR2 comprising or consisting of SEQ ID NO: 5; and a CDR3 comprising or consisting of SEQ ID NO: 3; or</claim-text><claim-text>(v) a CDR1 comprising or consisting of SEQ ID NO: 14; a CDR2 comprising or consisting of SEQ ID NO: 15; and a CDR3 comprising or consisting of SEQ ID NO: 3; or</claim-text><claim-text>(vi) a CDR1 comprising or consisting of SEQ ID NO: 16; a CDR2 comprising or consisting of SEQ ID NO: 17; and a CDR3 comprising or consisting of SEQ ID NO: 3; or</claim-text><claim-text>(vii) a CDR1 comprising or consisting of SEQ ID NO: 18; a CDR2 comprising or consisting of SEQ ID NO: 19; and a CDR3 comprising or consisting of SEQ ID NO: 3; or</claim-text><claim-text>(viii) a CDR1 comprising or consisting of SEQ ID NO: 20; a CDR2 comprising or consisting of SEQ ID NO: 5; and a CDR3 comprising or consisting of SEQ ID NO: 3.</claim-text></claim-text></claim><claim id="CLM-04-12" num="04-12"><claim-text><b>4</b>.-<b>12</b>. (canceled)</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. An isolated PD-L1 binding molecule, which specifically binds to PD-L1 and comprises a heavy chain variable region, wherein the heavy chain variable region comprises:<claim-text>(i) a CDR1 comprising or consisting of SEQ ID NO: 21; a CDR2 comprising or consisting of SEQ ID NO: 22; and a CDR3 comprising or consisting of SEQ ID NO: 23; or</claim-text><claim-text>(ii) a CDR1 comprising or consisting of SEQ ID NO: 24; a CDR2 comprising or consisting of SEQ ID NO: 25; and a CDR3 comprising or consisting of SEQ ID NO: 3; or</claim-text><claim-text>(iii) a CDR1 comprising or consisting of SEQ ID NO: 26; a CDR2 comprising or consisting of SEQ ID NO: 27; and a CDR3 comprising or consisting of SEQ ID NO: 23; or</claim-text><claim-text>(iv) a CDR1 comprising or consisting of SEQ ID NO: 28; a CDR2 comprising or consisting of SEQ ID NO: 29; and a CDR3 comprising or consisting of SEQ ID NO: 23 or</claim-text><claim-text>(v) a CDR1 comprising or consisting of SEQ ID NO: 30; a CDR2 comprising or consisting of SEQ ID NO: 31; and a CDR3 comprising or consisting of SEQ ID NO: 23.</claim-text></claim-text></claim><claim id="CLM-14-17" num="14-17"><claim-text><b>14</b>.-<b>17</b>. (canceled)</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The isolated PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the heavy chain variable region further comprises an FR region comprising FR1, FR2, FR3 and FR4, and the FR1, FR2, FR3 and FR4 and CDR1, CDR2 and CDR3 are arranged alternately on the heavy chain variable region to form a structure of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 from N-terminus to C-terminus, wherein<claim-text>(i) the FR region comprises:<claim-text>(a) an FR1 comprising the amino acid sequence of SEQ ID NO: 53;</claim-text><claim-text>an FR1 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 53; or</claim-text><claim-text>an FR1 comprising an amino acid sequence which differs from SEQ ID NO: 53 by no more than 2 amino acid additions, deletions and/or substitutions of amino acids;</claim-text><claim-text>(b) an FR2 comprising the amino acid sequence of SEQ ID NO: 54;</claim-text><claim-text>an FR2 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 54; or</claim-text><claim-text>an FR2 comprising an amino acid sequence which differs from SEQ ID NO: 54 by no more than 2 amino acid additions, deletions and/or substitutions of amino acids;</claim-text><claim-text>(c) an FR3 comprising the amino acid sequence of SEQ ID NO: 55;</claim-text><claim-text>an FR3 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 55; or</claim-text><claim-text>an FR3 comprising an amino acid sequence which differs from SEQ ID NO: 55 by no more than 2 amino acid additions, deletions and/or substitutions of amino acids;</claim-text><claim-text>and</claim-text><claim-text>(d) an FR4 comprising the amino acid sequence of SEQ ID NO: 56;</claim-text><claim-text>an FR4 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 56; or</claim-text><claim-text>an FR4 comprising an amino acid sequence which differs from SEQ ID NO: 56 by no more than 2 amino acid additions, deletions and/or substitutions; or</claim-text></claim-text><claim-text>(ii) the FR region comprises:<claim-text>(a) an FR1 comprising the amino acid sequence of SEQ ID NO: 57;</claim-text><claim-text>an FR1 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 57; or</claim-text><claim-text>an FR1 comprising an amino acid sequence which differs from SEQ ID NO: 57 by no more than 2 amino acid additions, deletions and/or substitutions;</claim-text><claim-text>(b) an FR2 comprising the amino acid sequence of SEQ ID NO: 58;</claim-text><claim-text>an FR2 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 58; or</claim-text><claim-text>an FR2 comprising an amino acid sequence which differs from SEQ ID NO: 58 by no more than 2 amino acid additions, deletions and/or substitutions;</claim-text><claim-text>(c) an FR3 comprising the amino acid sequence of SEQ ID NO: 59;</claim-text><claim-text>an FR3 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 59; or</claim-text><claim-text>an FR3 comprising an amino acid sequence which differs from SEQ ID NO: 59 by no more than 2 amino acid additions, deletions and/or substitutions;</claim-text><claim-text>and</claim-text><claim-text>(d) an FR4 comprising the amino acid sequence of SEQ ID NO: 60;</claim-text><claim-text>an FR4 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 60; or</claim-text><claim-text>an FR4 comprising an amino acid sequence which differs from SEQ ID NO: 60 by no more than 2 amino acid additions, deletions and/or substitutions; or</claim-text></claim-text><claim-text>(iii) the FR region comprises:<claim-text>(a) an FR1 comprising the amino acid sequence of SEQ ID NO: 61;</claim-text><claim-text>an FR1 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 61; or</claim-text><claim-text>an FR1 comprising an amino acid sequence which differs from SEQ ID NO: 61 by no more than 2 amino acid additions, deletions and/or substitutions;</claim-text><claim-text>(b) an FR2 comprising the amino acid sequence of SEQ ID NO: 58;</claim-text><claim-text>an FR2 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 58; or</claim-text><claim-text>an FR2 comprising an amino acid sequence which differs from SEQ ID NO: 58 by no more than 2 amino acid additions, deletions and/or substitutions;</claim-text><claim-text>(c) an FR3 comprising the amino acid sequence of SEQ ID NO: 59;</claim-text><claim-text>an FR3 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 59; or</claim-text><claim-text>an FR3 comprising an amino acid sequence which differs from SEQ ID NO: 59 by no more than 2 amino acid additions, deletions and/or substitutions;</claim-text><claim-text>and</claim-text><claim-text>(d) an FR4 comprising the amino acid sequence of SEQ ID NO: 60;</claim-text><claim-text>an FR4 comprising an amino acid sequence having at least 90%, 95% or 99% identity to SEQ ID NO: 60; or</claim-text><claim-text>an FR4 comprising an amino acid sequence which differs from SEQ ID NO: 60 by no more than 2 amino acid additions, deletions and/or substitutions.</claim-text></claim-text></claim-text></claim><claim id="CLM-19-21" num="19-21"><claim-text><b>19</b>.-<b>21</b>. (canceled)</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The isolated PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the heavy chain variable region comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 36-52.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. The isolated PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the heavy chain variable region comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 99% identity to an amino acid sequence of any one of SEQ ID NOs: 36-52 and retaining the ability to specifically bind to PD-L1 or<claim-text>wherein the heavy chain variable region comprises an amino acid sequence having one or more amino acid additions, deletions and/or substitutions compared to an amino acid sequence of any one of SEQ ID NOs: 36-52 and retaining the ability to specifically bind to PD-L1, wherein the one or more amino acid additions, deletions and/or substitutions are no more than five, preferably no more than three.</claim-text></claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. (canceled)</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. The isolated PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the PD-L1 binding molecule is a camelized antibody, a humanized antibody, an affinity-matured antibody or a druggability-modified molecule.</claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. The isolated PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the PD-L1 binding molecule is a single-domain antibody or an antigen-binding fragment thereof.</claim-text></claim><claim id="CLM-00027" num="00027"><claim-text><b>27</b>. The isolated PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the heavy chain variable region is fused to an additional molecule, and the additional molecule is selected from an Fc domain of an immunoglobulin, an antibody, an antigen-binding fragment of the antibody, an antibody-drug conjugate, an antibody-like molecule, an antigen-binding fragment of the antibody-like molecule or a fluorescent protein.</claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. The isolated PD-L1 binding molecule according to <claim-ref idref="CLM-00027">claim 27</claim-ref>, wherein the heavy chain variable region is fused to an Fc domain of human IgG.</claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. An isolated nucleic acid molecule, comprising a nucleotide sequence encoding the isolated PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. A vector, comprising the nucleic acid molecule according to <claim-ref idref="CLM-00029">claim 29</claim-ref>.</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. A host cell, comprising the vector according to <claim-ref idref="CLM-00030">claim 30</claim-ref>.</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. A pharmaceutical composition, comprising an effective amount of the PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref> and a pharmaceutically acceptable carrier.</claim-text></claim><claim id="CLM-00033" num="00033"><claim-text><b>33</b>. A method for preparing the PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the method comprises the following steps:<claim-text>expressing the nucleotide sequence encoding the PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref> in a host cell to produce the PD-L1 binding molecule; and</claim-text><claim-text>isolating the PD-L1 binding molecule from the host cell.</claim-text></claim-text></claim><claim id="CLM-00034" num="00034"><claim-text><b>34</b>. A method for preventing or treating a disease associated with PD-L1 in a subject, the method comprising administering a therapeutically effective amount of the PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref> to the subject.</claim-text></claim><claim id="CLM-00035" num="00035"><claim-text><b>35</b>. (canceled)</claim-text></claim><claim id="CLM-00036" num="00036"><claim-text><b>36</b>. The method according to <claim-ref idref="CLM-00034">claim 34</claim-ref>, wherein the disease associated with PD-L1 is selected from renal cell carcinoma, non-small cell lung cancer, bladder cancer, urothelial carcinoma, and microsatellite unstable solid tumor.</claim-text></claim><claim id="CLM-00037" num="00037"><claim-text><b>37</b>. A kit for preventing or treating a disease associated with PD-L1 in a subject, comprising a container, wherein the container comprises at least one PD-L1 binding molecule according to <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00038" num="00038"><claim-text><b>38</b>. A pharmaceutical composition, comprising an effective amount of the PD-L1 binding molecule according to <claim-ref idref="CLM-00013">claim 13</claim-ref> and a pharmaceutically acceptable carrier.</claim-text></claim></claims></us-patent-application>